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For decades, the primary focus of cancer research has been the cancer tissue itself. Advances 
in next generation sequencing technologies have enabled identification and characterisation 
of driver mutations, provided insights into the tumour burdens and underlying mutational 
processes, sub-clonal diversification and tumour heterogeneity. 
However, all cancers arise from cells that were once normal. Over time, they acquired certain 
mutations which increased their fitness, giving them a selective advantage over their 
neighbours and allowing uncontrolled growth, clonal expansion and malignant transformation. 
Our understanding of somatic evolution occurring in normal tissues with age and in the early 
stages of tumourigenesis remains relatively poorly understood.  
In this thesis, I aimed to investigate somatic evolution in normal ageing human tissues. Firstly, 
I helped to establish a robust low DNA input whole genome sequencing workflow for laser-
capture micro-dissected cellular material. I then utilised this approach to explore genomic and 
evolutionary landscapes of the normal human endometrium.  
In the first results chapter, I investigate the clonal composition of normal endometrial glands. 
The majority of glands are clonal cell populations that share a common recent ancestor and 
the monoclonality is independent of whether they have a driver mutation.  
In the second results chapter, I investigate the mutational landscape of normal endometrial 
glands. We show that somatic mutations (base substitutions, indels and genome 
rearrangements) accumulate with age in a more-or-less linear manner. A small number of 
ubiquitous mutational processes accounts for the majority of all mutations. A remarkably high 
proportion of normal endometrial glands carry at least one driver mutation (of the type that 
one is used to finding in cancers). Accumulation of drivers is negatively affected by parity. 
Through phylogenetic tree reconstruction of somatic mutations in endometrial glands, we 
show that driver mutations often occur early in life and continue to accumulate with age.  
This work identifies a distinct mutational landscape in normal endometrium that is in keeping 
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 General introduction 
1.1 Introduction 
All cells in the human body are thought to acquire somatic mutations. Most of these 
mutations are harmless and are termed ‘passengers’. However, some of the mutations confer 
increased cellular fitness and selective advantage leading to uncontrolled cellular growth, 
clonal expansion and eventually neoplastic transformation (‘driver mutations’). 
 
1.2 Cancer is a disease of the genome fuelled by somatic mutations 
For decades, the primary focus of cancer research has been the cancer tissue itself. Advances 
in next generation sequencing (NGS) technologies have enabled identification and 
characterisation of driver mutations, provided insights into the tumour burdens and 
underlying mutational processes, sub-clonal diversification and tumour heterogeneity. 
Cancers can now be described in terms of their mutation burden, mutational processes and 
patterns of selection. These are considered below. 
1.1.1 Mutation burden 
Large scale next generation sequencing initiatives (Alexandrov, 2018, Cancer Genome Atlas 
Research et al., 2013, Alexandrov, 2013) have allowed better characterisation of the tumour 
mutation burden. These analyses have shown a huge variation in the rates of somatic 
mutations across different types of cancer with the majority of tumours showing 1000-20,000 





1.1.2 Mutational processes 
Cancer genomes carry thousands of somatic mutations, but only a very small proportion of 
these are “drivers” that are implicated in oncogenesis. The remainder are “passengers”, the 
bystanders of the mutational processes that have been operative in those tissues throughout 
life and the development of cancer (Helleday et al., 2014). These mutations occur 
spontaneously as a result of various processes, termed ‘signatures’ (Alexandrov, 2013). They 
can be of endogenous source, such as reactive oxygen species, defective DNA repair 
mechanisms and infidelity in the DNA replication machinery, or of exogenous source, such as 
ultra-violet light exposure and tobacco smoking (Alexandrov, 2013, Alexandrov et al, 2015). 
 Early work on mutational patterns 
Different mutational processes leave specific patterns of mutations on the cancer genomes, 
which are termed “mutational signatures”. Some of the first efforts to characterise 
mutational patterns were made back in the 90’s (Hollstein et al., 1991, Hollstein et al., 1999). 
In a series of studies, multiple samples of the same cancer type were combined to examine 
patterns of coding mutations in TP53. These analyses yielded two key observations. First, 
ultra-violet light exposure related skin cancers were characterised by frequent C>T 
transversions occurring primarily at dipyrimidines, which was in keeping with the pattern of 
mutation observed in vitro. Second, a strong C>A pattern was seen in tobacco smoking related 
lung cancers, which matched the observation made in vitro of DNA exposure to 
benzo(a)pyrene, a known tobacco carcinogen (Nik-Zainal et al., 2015). While these studies 
provided first insights into mutational patterns, the analyses were primarily focused around 
processes with strong mutagenic activity that would generate most of mutations detected in 
individual cancers. However, more than one mutational process may have been operative in 
a given cancer, but the “signal” from these may not be readily deciphered in the mixture of 
mutations.  
 Next Generation Sequencing studies 
Subsequently, advances in next generation sequencing (NGS) have resulted in large amounts 




mutations were identified in individual cancers, which in turn provided sufficient power to 
apply mathematical algorithms to extract individual mutational signatures. 
Large-scale cancer genome sequencing initiatives not only generated comprehensive lists of 
somatic mutations, but also provided an opportunity to decipher mutational signatures from 
thousands of cancers (Alexandrov et al., 2013, Cancer Genome Atlas Research et al., 2013, 
Alexandrov et al., 2018). Some of these signatures are present in most cancer types, for 
example a signature associated with the APOBEC family of cytidine deaminases, while others 
are unique to specific tumours. It is now also known that while certain mutational processes 
operate continuously, leading to accumulation of somatic mutations at a constant rate over 
decades, in a ‘clock-like’ fashion, others generate these more intermittently (Petljak et al., 
2019). These mutational processes determine the mutation burdens that result in the first 
“driver” mutations leading to neoplastic change and may contribute to other normal and 
diseased biological states including ageing. Furthermore, these mutational processes may 
change in non-cancer disease states in which the metabolic state of the cell is chronically 
altered and thus may provide us with a record in DNA of these metabolic changes. 
As more whole genome sequencing data have become available, a more comprehensive 
characterisation of the signatures has been possible of not only single base substitutions, but 
also of dinucleotide substitutions, small insertions and deletions (indels) and structural 
variants (Alexandrov et al., 2018). 
In addition, in an attempt to better our understanding of the underlying mechanisms of the 
mutational processes, Kucab and colleagues tested 79 known or suspected environmental 
agents and their effect on single base substitutions (Kucab et al., 2019). The study found that 
approximately 50% of the tested mutagens were associated with specific mutational 
processes, several of which matched those previously observed in tumours, including UV-light 
and tobacco-related carcinogens.  
Finally, work by Alexandrov and colleagues made a first attempt at estimating the ‘clock-like’ 
mutation rates in normal cells by interrogating thousands of cancer genomes (Alexandrov et 
al., 2015). The study identified two mutational signatures that were seen in most cancer types 
and accumulated mutations at a constant rate over time, thus confirming the existence of 




1.1.3 Patterns of selection and driver mutations 
The above mentioned large sequencing initiatives have also allowed identification and 
characterisation of cancer-associated mutations. As a result, there are now more than 600 
genes that are thought to be implicated in oncogenesis (COSMIC). Statistical models (dN/dS) 
were subsequently applied to identify genes that are under selection across cancer types 
(Martincorena et al., 2017). These analyses have also highlighted driver burden differences 
between cancers with some types, such as chromophobe renal cell carcinomas and ovarian 
carcinomas, characterised by only a handful of driver genes, and others, such as urothelial 
and endometrial carcinomas showing a much broader range of genes under selection. 
 
 Multi-step clonal tumour evolution and heterogeneity 
The multistep process of tumourigenesis was first proposed in 1958 (Foulds, 1958). Molecular 
events that drive cancer development and progression were further characterised over the 
following 30 years (Farber and Cameron, 1980; Weinberg, 1989). Some of the key analyses 
included work by Fearon and Vogelstein in colon in which they showed the complexity of the 
genetic path in colorectal cancer development (Fearon and Vogelstein, 1990). They examined 
different histopathological states in the colone, from normal epithelium to invasive colorectal 
adenocarcinoma. The work showed that the great majority of early adenomatous polyps 
carried inactivating mutations of the tumour-suppressor gene APC. Approximately half of the 
intermediate-sized lesions carried activating mutations of ras oncogenes and about half of 
the advanced colorectal carcinomas had mutations in the tumour-suppressor gene TP53 







1.3 Current knowledge of somatic evolution in normal tissues 
 Driver mutations and clonal expansion 
Some of the first studies reporting somatic mutations in normal tissues were carried out in 
blood. Gene fusion events that are typically seen in leukaemias and lymphomas, were 
detected in nearly 30% of clinically normal individuals studied (Biernaux et al., 1995, Bose et 
al., 1998). Furthermore, work on cord blood showed that TEL-AML1 and AML1-ETO gene 
fusions associated with leukaemia can occur early in life with such events identified in around 
1% of healthy neonates (Mori et al., 2002). 
In 2014, seminal publications based on whole exome sequencing of large cohorts of patients 
showed that driver mutations, including DNMT3A, TET2 and JAK2 that are implicated in 
myeloid neoplasms, are frequently found in the blood of older but otherwise healthy 
individuals (Jaiswal et al., 2014, Genovese et al., 2014). The observation was termed clonal 
haematopoiesis. Work by Jaiswal and colleagues later showed that the presence of those 
clonal expansions conferred a small but significant risk of leukaemia (0.5%-1% per year) and 
that these clones represent early steps of tumourigenesis (Jaiswal et al., 2014). It was later 
shown that clonal haematopoiesis with cancer-associated mutations can occur at all ages (3% 
in 20-29-year olds; 20% in 60-69-year olds). 
Subsequently, driver mutations identified in blood were also shown to be associated with 
non-malignant diseases: in addition to an increased risk of haematological neoplasms, the 
rates of coronary heart disease and ischaemic stroke were also increased (Jaiswal et al., 2017). 
Detection of somatic mutations in normal solid tissues has been more challenging due to 
biological limitations, including slower proliferation, clonally restrictive tissue architecture, 
more difficult tissue access, and technical issues. A series of studies assessing clonal 
expansions in normal tissues, such as colon, prostate and liver, were carried out using 
mutations in mitochondrial DNA (Fellous et al., 2009a, Fellous et al., 2009b, Blackwood et al., 
2011, Greaves, 2003, Greaves et al., 2006). However, while these analyses provided some 
insights into clonal composition of those tissues, the role of mitochondrial mutations in clonal 




The first ground breaking analysis of somatic mutations in normal solid tissues was carried 
out by Martincorena and colleagues, in which extensive clonal patches bearing mutations in 
cancer genes, including TP53, NOTCH1, NOTCH2, NOTCH3 and FAT1, were identified in normal 
sun-exposed skin of middle-aged to elderly individuals (Martincorena et al., 2015). Later, 
accumulation of somatic mutations, including those in cancer genes, and associated tissue 
remodelling have been shown in normal oesophagus (Martincorena et al., 2018, Yokoyama 
et al., 2019).   
Finally, accumulation of cancer-associated mutations with age is not limited to somatic cells. 
Targeted studies on testicular tissue from healthy men have shown that mutations conferring 
predisposition to cancer could also confer a selective advantage to spermatogonia stem cells 
leading to clonal expansion similar to the process of oncogenesis (Maher et al., 2016). Over 
time,  this clonal expansion leads to the relative enrichment of mutant sperm and in some 
cases, to large clones with driver mutations, such as FGFR3 and HRAS, expanding within the 
testes, and  can be associated with spermatocytic seminoma in older men (Goriely et al., 
2009). 
 
 Mutational processes and burden 
DNA mutations are inevitable, but it is the alterations that occur in the genomes of adult stem 
cells (ASC) that have the greatest impact on the tissue mutational burden and are thought to 
be most significant in terms of cancer risk (Tomasetti and Vogelstein, 2015). Tissues with high 
ASC turnovers show higher cancer incidence in comparison to those with lower ASC turnover 
rates. It is therefore important to assess somatic mutation accumulation in ASCs of different 
tissues. Previous work on clonal organoid cultures derived from liver, small intestine and 
colon has shown that despite significant variation in the cancer incidence in these tissues, 
somatic mutations accumulate at a similar rate of around 40 single base substitutions per 
year (Blokzijl et al., 2016). Although age-associated signatures (Signature 1 and 5) were 
observed in all three tissues, their contribution in the liver was markedly different from that 




signature 5, a signature of an unknown underlying mechanism. Interestingly, there was little 
intra-tissue inter-individual variation in the mutational spectra across ages.  
As mentioned earlier, age-associated accumulation of somatic mutations is not unique to the 
soma, but has also been reported in the germline. Studies on trios have shown that de novo 
mutations accumulate with age in the paternal germline, and that there is a degree of 
variability across individuals. Surprisingly, the underlying mutational processes (mostly 
attributed to signature 5 and to a lesser extend to signature 1) are similar between paternal 
and maternal germlines as well as across individuals from a range of ages (Rahbari et al., 2016, 
Jonsson et al., 2017) . 
 
1.1.4 Methods for studying somatic mutations in normal tissues  
Normal tissues are complex systems comprising different populations of cells with distinct 
morphological and functional properties and specific spatial arrangements. However, this 
cellular heterogeneity implies that normal tissues are composed of many clones that are 
usually too small to provide sufficient amount of DNA that is necessary for standard 
sequencing protocols. In recent years, a number of approaches have been developed with 
the aim to study normal tissues (Table 1.1). Some of these are considered below. 
 
 Single cell genomics 
Ideally, one would like to explore tissue heterogeneity targeting one cell at a time, and single 
cell technologies have the potential to provide new insights into the genomic landscapes of 
tumour and normal tissues. Recently, Casasent and colleagues applied this approach to laser-
capture micro-dissected cells to assess genomic changes, particularly copy number variants, 
and to delineate clonal evolution in early-stage breast cancer (Casasent et al., 2018). 
However, the majority of such work has been performed on single cells in suspension and not 
laser-captured material. Overall, these technologies are still under development and are 




whole genome amplification-induced errors and suboptimal variant calling sensitivity (Gawad 
et al., 2016, Navin, 2015) (Table 1.1).  
 
 Single stem cell derived organoids 
An alternative way to study genomic landscapes of individual cells is through the use of in-
vitro clonal organoid experimental models derived from single adult stem cells (Roerink et al., 
2018, Blokzijl et al., 2016, Fatehullah et al., 2016). These provide sufficient amounts of DNA 
for standard ‘bulk’ sequencing methods while circumventing whole genome amplification and 
associated issues. However, while this approach has substantial utility, these are often 
challenging to derive, are highly laborious to generate in large numbers, may show bias 
towards certain subtypes of cell in a tissue, lack spatial information, may favour cells with 
driver mutations and will introduce additional mutations during cell culture that often include 
additional mutational signatures. 
 
 Error-corrected next generation sequencing (ecNGS)  
Another way to study genomic changes in normal tissues at a cellular level is through removal 
of sequencing errors and identification of variants that are present at very low frequencies 
(Hoang et al., 2016, Kennedy et al., 2014, Schmitt et al., 2012). One of these approaches is 
Duplex sequencing, in which both strands of DNA are tagged and mutations are only 
considered bona fide if they are present in both strands of DNA and are complimentary 
(Schmitt et al., 2012). Subsequently, this approach was applied to detect somatic mutations, 
including those in TP53, at frequency <0.01% in peritoneal fluid samples from women without 
cancer (Krimmel et al., 2016).  
 
Another example of ecNGS method is the bottleneck sequencing system (BotSeqS), which 
aims to reduce the error rate of NGS by utilising the consensus of reads from individual 




achieved by circularisation of the DNA template, the addition of unique molecular identifiers 
(UMIs) to asymmetric (Y-shaped) adapters and utilising the mapping coordinates of reads as 
endogenous barcodes. The theoretical error rate for these approaches is reported to be <1 
artefact per 109 nucleotides sequenced, which is calculated by assuming two independent 
mutational events (one on each strand of the original template molecule) occurring at the 
average substitution rate for high-fidelity DNA polymerases.  
 
Method Advantages Disadvantages 
Single cell 
sequencing 
Allows to examine genomic 
changes in individual cells 
Usually requires prior WGA 
 
WGA can be associated with poor 
genome coverage, allele/locus drop out 
and artifacts 
Organoids Provides sufficient DNA for 
standard library preparation and 
sequencing protocols 
Not available for all tissue and cell types 
 
Does not require prior WGA Additional mutations introduced during 
cell culturing 
Provides information on individual 
adult stem cells 
Takes time to grow and is laborious 
 
Clonal samples, therefore more 
confident variant calling 







Allows to detect mutations at a 
single molecule level 
Incomplete genome coverage 
Can only be used for calling single base 
substitutions and indels but not copy 
number and structural variants 
Final variants represent an ‘average’ 
from a mixture of molecules from a 
relatively large population of cells and 
burden can be affected (increased) by 
cells with higher mutation burdens 





1.4 Thesis aims 
In this thesis, I aimed to investigate somatic evolution in normal ageing human tissues. Firstly, I helped 
to establish a robust low DNA input whole genome sequencing workflow for laser-capture micro-
dissected cellular material. I then utilised this approach to explore genomic and evolutionary 
landscapes of the normal human endometrium.  
In the first results chapter, I describe the clonal composition of laser-capture micro-dissected normal 
endometrial glands with multiple samples derived from 28 pre- and post-menopausal women. I also 
correlate the effect of menstrual phase, menopause status and presence or absence of driver 
mutations on clonality. 
In the second results chapter, I investigate the mutational landscape of normal endometrial 
epithelium, including mutation burdens, signatures and prevalence of driver mutations and how these 
are modulated by age and parity. In addition, through phylogenetic tree reconstruction of somatic 
mutations in endometrial glands, we estimate the age at which the identified driver mutations 
occurred. Finally, I compare mutation burdens and patterns of selection of the normal endometrial 
epithelium and endometrial cancer. 
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 Materials and methods 
2.1 Samples 
2.1.1 Endometrium 
Anonymized snap-frozen endometrial tissue samples were obtained from five different 
cohorts.  
Cohort 1: Samples from individuals PD37605, PD37601, PD37607, PD37613, PD37594, 
PD37595, PD41871, PD41860, PD41857, PD41865, PD41868, PD41859, PD41861 and 
PD41869 (age 29 to 46) were provided by Professor Jan Brosens; these were collected from 
women undergoing hysteroscopy examination at the Tommy’s National Early Miscarriage 
Centre, University Hospitals Coventry and Warwickshire NHS Trust. Informed consent was 
obtained and biopsies collected and stored at the Arden Tissue Bank, University Hospitals 
Coventry and Warwickshire NHS Trust in line with the protocols approved by the NRES 
Committee South Central Southampton B (REC reference 12/SC/0526, 19/04/2013).  
Cohort 2: Samples from individuals PD40535, PD39444, PD39953, PD39952, PD39954, 
PD40107, PD42746 and PD42475 (age 24 to 74) were collected by Mr Kourosh Saeb-Parsy 
from non-uterine transplant organ donors with an informed consent obtained from the 
donor’s family (REC reference: 15/EE/0152 NRES Committee East of England – Cambridge 
South).  
Cohort 3: Individuals PD36804 and PD36805 (age 47 and 49), underwent total abdominal 
hysterectomy for benign non-endometrial pathologies and uterine biopsies were collected, 
snap frozen and stored at the Human Research Tissue Bank, Cambridge University Hospitals 
NHS Foundation Trust by Dr Mercedes Jimenez-Linan. The samples were collected in line with 
the protocols approved by the NRES Committee East of England (REC reference 11/EE/0011, 
11/03/2011). 
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Cohorts 4 and 5: Samples from individuals PD37506, PD38812, PD37507 and PD40659 (age 
19 to 81) were collected at autopsy following death from non-gynaecological causes. The use 
of this material was approved by the London, Surrey Research Ethics Committee (REC 
reference 17/LO/1801, 26/10/2017) and East of Scotland Research Ethics Service (REC 
reference: 17/ES/0102, 27/07/2017).  
 
2.1.2 Pan-body survey 
 Donor 1 
In collaboration with Professor Rebecca Fitzgerald and her research team led by Miss Ayesha 
Noorani, I collected 252 samples from a variety of macroscopically normal tissues during a 
rapid (‘warm’) autopsy. The samples were collected in line with the protocols approved by 
the NRES Committee East of England (NHS National Research Ethics Service reference 
13/EE/0043). The post-mortem sample collection was performed on a 78-year-old male, non-
smoker who died of a metastatic oesophageal carcinoma; he had no other co-morbidities. 
The collection was completed within six hours of the patient’s death to ensure tissue integrity 
for morphology preservation and whole genome sequencing (WGS). Every sampled tissue was 
photographed and biopsy sites carefully documented. As there was an extensive lower 
oesophageal tumour that invaded into the pancreas, I was not able to obtain any normal 
tissue samples from the stomach and pancreas. Once collected, all biopsies were snap frozen 
in liquid nitrogen and subsequently stored at -800C. Summary of all sampled tissues is 
provided in Appendix 1. 
 Donors 2 and 3 
Multiple biopsies from twenty-six different tissues were collected from a 54-year-old female 
and a 47 year old male; both individuals died of non-cancer causes (acute coronary syndrome 
and traumatic injuries respectively).  All samples were obtained within less than five hours of 
death. The use of these tissues was approved by the London, Surrey Research Ethics 
Committee (REC reference 17/LO/1801, 26/10/2017). Summary of all obtained tissues is 
provided in Appendix 2.  
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 Additional limited samples from other donors 
To obtain the most comprehensive catalogue of somatic mutations across as many female 
and male tissues as possible and to further validate some of our observations, we acquired 
additional samples, mostly from one or two organs from additional donors. These included, 
breast, stomach, endometrium, cervix, fallopian tubes, pancreas, testis, colon and others. 
These samples were obtained at autopsy following death from non-cancer causes. The use of 
this material was approved by the London, Surrey Research Ethics Committee (REC reference 




2.2 Laser-capture microscopy   
In this work, we aimed to study somatic mutations in relatively small populations of cells from 
specific morphological or functional units, such as endometrial glands or colonic crypts. These 
units typically contain 200-2000 cells, which would equate to approximately 1.2-12 ng of DNA.  
When I first started my PhD (April 2016), a minimum of 200 ng of input DNA (equivalent to 
around 33,300 cells) was required for a successful library preparation by the standard 
sequencing methods.  
Fortunately, Peter Ellis, who at the time was a Principle Staff Scientist in the Research and 
Development Department, was testing different approaches to decrease the amount of input 
DNA for efficient library construction. I have therefore spent the first 10 months of my PhD 
working together with Peter to build a workflow that would enable robust processing of low 
input LCM derived cellular material. The experimental side of this process involved three 
major components: (a) effective tissue preparation (fixation and morphology), (b) cell lysis 
and (c) DNA isolation and library construction. 
2.2.1 Tissue preparation 
Tissue fixation is an essential step in histology as it preserves morphology for accurate 
microscopic assessment. However, routine histology fixatives, specifically formalin, are 
known to have a detrimental impact on both the quality and quantity of extracted DNA 
(Howat and Wilson, 2014). It was therefore essential to optimize this step and to find an 
alternative fixative. Three non-cross-linking fixatives were tested: acetone (100%), ethanol 
(70%) and methanol (100%). Out of these three, ethanol fixation provided the most optimal 
morphology preservation, followed by methanol and acetone.  
In general, two types of tissue preparation are used for histology assessment: frozen and 
paraffin sections. Protocol for the first method usually involves cutting sections from a frozen 
block, followed by a brief (2-5 minutes) immersion in a fixative (70% ethanol in our protocol), 
followed by staining with haematoxylin and eosin (H&E) or haematoxylin only (H) (Figure 2.1). 
The second approach can take up to two days and includes several hours of fixation (to allow 
fixative to penetrate through the entire tissue block) and embedding in paraffin, followed by 




Figure 2.1 | Summary of the LCM workflow. Tissue morphology can be assessed using 
frozen and paraffin sections. This figure outlines individual steps in both approaches. 
Sections can be stained using haematoxylin and eosin (H&E) or haematoxylin only (H). To 
aid sectioning of frozen tissue blocks, biopsies are embedded in rapidly solidifying optimal 
cutting temperature compound (O.C.T.). Specific morphological structures or tissue-
specific functional units, such as colonic crypts or endometrial glands (typically containing 
200-2,000 cells), are laser-capture micro-dissected into individual wells. The cellular 
material is subjected to our modified protocols for cell-lysis, DNA extraction and library 
preparation for whole genome sequencing. 
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Given the fact that we were working with relatively small amounts of input DNA, we wanted 
to minimise tissue handling and potential DNA degradation. Therefore, we first focused on 
optimisation of our workflow for frozen sections (Appendix 3). However, while this method is 
suitable for some tissues, such as colon and endometrium, for many other tissue types, for 
instance, brain and testis, it results in poor preservation of morphology and inability to 
accurately type cells and structures (Figure 2.2). We therefore also optimized tissue fixation 
and preparation protocols for experiments performed on paraffin embedded material 
(Appendix 4).  
Routine clinical histology sections are around 4-5 micron thick. However, to increase the 
amount of input DNA, while also allowing accurate morphology assessment, the section 
thickness for most tissue types was chosen to be 10 microns. 
 
FROZEN SECTION PARAFFIN SECTION 
  
Figure 2.2 |Comparison of testicular histology using frozen and paraffin sections (H&E, 5x 
magnification, 10 micron thickness). The figure shows an example of the two different 
tissue preparation methods and their effect on preservation of morphology.  
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2.2.2 Cell lysis  
To maximise DNA recovery from micro-dissected cellular material, three different types of 
lysis buffers were tested: alkaline lysis, protease lysis (an in-house version, Appendix 5 or a 
commercially available Arcturus™ PicoPure™ DNA extraction kit) and chaotropic lysis (RLT). 
Fixatives and lysis buffers were tested jointly. Below are the results of some of these tests. 
From these and further experiments on other tissue types, a combination of ethanol (70%) 
and protease lysis buffer was selected (Figure 2.3). 
 
Figure 2.3 | Quantification of libraries for assessment of fixation and lysis conditions. This 
figure shows DNA library yeilds obtained when testing different types of fixatives (70% 
ethanol (EtOH) and methanol (MeOH)) and lysis buffers (proteased based buffer (Prot) and 
chaotropic lysis buffer (RLT). H&E, haematoxylin and eosin; OCT, optimal cutting 
temperature compound. Adapted from Peter Ellis. Different fixation and lysis conditions 
were tested on frozen and paraffin tissue sections. 
 
2.2.3 DNA isolation and library construction  
Traditionally, DNA purification and quantification are separate steps. In our protocol, to 
maximize DNA recovery from the low input samples, we introduced a modified solid phase 
reversible immobilization (SPRI) bead purification step within the library construction 























500 um square, EtOH,
H&E, Prot
500 um square, MeOH,
H&E, Prot
500 um square, EtOH,
H&E, RLT
500 um square, EtOH,
H&E, Prot
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Early tests indicated that genomic DNA recovery at the DNA purification step could be as low 
as 50%, which led us to believe that a large proportion of high molecular weight genomic DNA 
was refractory to elution from the SPRI beads. The entire post-elution sample (including 
beads) was therefore integrated into the library construction workflow to minimize these 
losses. It is likely that a combination of buffer detergent, heat and the action of the 
fragmentation enzymes in the next step promotes the release of all available DNA into 
solution. 
Standard NGS workflows for whole genome sequencing typically use around 200 ng input 
DNA material, often fragmented by acoustic shearing. Fragmented DNA is repaired, dA-tailed, 
ligated to adapter sequences and indexed by PCR amplification for 6 cycles. Additional PCR 
cycles are introduced to ameliorate lower DNA inputs; however, this approach is useful only 
when the predefined minimum number of unique DNA templates are present in the final DNA 
library. For instance, sufficient material can be generated from <1 ng human genomic DNA to 
perform whole exome sequencing. However, our ability to produce sequencing data with a 
meaningful library complexity drops dramatically below 10 ng input DNA material. In contrast, 
we discovered that DNA fragmentation reagents that utilize enzymatic rather than acoustic 
fragmentation, yielded a >10-fold improvement in DNA library yield. This increase in efficiency 
led to a dramatic reduction in PCR duplicate rates that enables the generation of whole exome 
sequencing data from DNA inputs as low as 0.75 ng (Figure 2.4). Comparison to the standard 
DNA pipelines showed that our approach performed consistently better when reducing the 
input DNA (Figures 2.4 and 2.5). Duplicate fractions negatively correlated with the number of 




Figure 2.4 |Comparison of standard and our DNA library preparation methods. This figure 
shows comparison between different low input DNA workflows. Although the decrease in 
the input DNA inevitably leads to the decrease in the DNA library yields, our new protocol 
(NEB Ultra II FS) was consistently superior to the standard DNA library preparation 
protocols (‘Old’ pipeline utilises sonication in the DNA fragmentation step of library 
preparation; NEB Ultra II utilises the original version of the enzymatic DNA fragmentation 
NEB kit). Adapted from Peter Ellis. 
 
  
*Normalised for 12x PCR
’OLD’ PIPELINE
NEB ULTRA II
NEB ULTRA II FS
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Figure 2.5 | Comparison of standard (‘OLD Pipeline’ and ‘NEB ULTRA II’) and our new 
approach (‘NEB ULTRA II FS’) for sequencing library preparation. Duplicate fractions 
increase with the decrease in the amount of input DNA. Although the general trend is the 
same with all three approaches, our new library preparation approach was superior to the 
previously available protocols. Adapted from Peter Ellis. 
 
 
Figure 2.6 | Correlation between cell numbers and duplicate fractions. Duplicate fraction 
increases with the decrease in the amount of input DNA (in this case the number of laser-






















Number of cells 
(estimated on histology)
Correlation between cell numbers and duplicate fraction
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Figure 2.7 | Correlation between post-library DNA concentration and duplicate fractions. 
Duplicate fractions negatively correlated with post-library preparation DNA concentration. 
 
All samples in my PhD were processed using the low-input enzymatic fragmentation-based 
library preparation method(Lee-Six et al., 2019). Briefly, each 20 ul LCM lysate was mixed with 
50 ul Ampure XP beads (Beckman Coulter) and 50 μl TE buffer (Ambion; 10 mM Tris-HCl, 1 
mM EDTA) at room temperature.  Following a 5-minute binding reaction and magnetic bead 
separation, genomic DNA was washed twice with 75% ethanol.  Beads were resuspended in 
26 μl TE buffer and the bead/genomic DNA slurry was processed immediately for DNA library 
construction. Each sample (26 μl) was mixed with 7 μl of 5X Ultra II FS buffer, 2 μl of Ultra II 
FS enzyme (New England BioLabs) and incubated on a thermal cycler for 12 minutes at 37°C 
then 30 minutes at 65°C.  Following DNA fragmentation and A-tailing, each sample was 
incubated for 20 minutes at 20°C with a mixture of 30 μl ligation mix and 1 μl ligation 
enhancer (New England BioLabs), 0.9 μl nuclease-free water (Ambion) and 0.1 μl duplexed 
adapters (100 uM; 5’-ACACTCTTTCCCTACACGACGCTCTTCCGATC*T-3’, 5’-phos-
GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’).  Adapter-ligated libraries were purified 
using Ampure XP beads by addition of 65 μl Ampure XP solution (Beckman Coulter) and 65 μl 
TE buffer (Ambion).  Following elution and bead separation, DNA libraries (21.5 μl) were 
amplified by PCR by addition of 25 μl KAPA HiFi HotStart ReadyMix (KAPA Biosystems), 1 μl 




















post-lib preparation DNA concentration (nM)
Correlation between post library preparation DNA concentration and duplicate fraction
Figure 5. Correlation between final DNA concentration and duplicate fraction in LCM samples.
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TTCCGATC*T-3') and 2.5 μl iPCR-Tag (40 μM; 5’-CAAGCAGAAGACGGCATACGAGATXGAGATCG 
GTCTCGGCATTCCTGCTGAACCGCTCTTCCGATC-3’) where ‘X’ represents one of 96 unique 8-
base indexes. The samples were then mixed and thermal cycled as follows: 98 °C for 5 
minutes, then 12 cycles of 98 °C for 30 s, 65°C for 30 s, 72 °C for 1 minute and finally 72 °C for 
5 minutes. Amplified libraries were purified using a 0.7:1 volumetric ratio of Ampure Beads 
(Beckman Coulter) to PCR product and eluted into 25 μl of nuclease-free water (Ambion).  
DNA libraries were adjusted to 2.4 nM and sequenced on the HiSeq X platform (illumina) 
according to the manufacturer’s instructions with the exception that we used iPCRtagseq (5’-
AAGAGCGGTTCAGCAGGAATGCCGAGACCGATCTC-3’) to read the library index.  
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2.3 Variant calling 
2.3.1 Single nucleotide variants (SNVs) 
Sequencing data were first aligned to the reference human genome (NCBI build 37) using 
Burrow-Wheeler Aligner (BWA-MEM) (Li and Durbin, 2009). Duplicates were marked and 
removed and mapping quality thresholds were set at 30. Single base somatic substitutions 
were called using Cancer Variants through Expectation Maximization (CaVEMan) algorithm 
(major copy number 5, minor copy number 2) (Nik-Zainal et al., 2012). These settings were 
used as they provided the most optimal balance between removing genuine variants and 
allowing artefacts through. 
To exclude germline variants, matched normal samples were collected for each donor and 
used when running variant calling algorithms. For the endometrial study, we collected either 
cervix, myometrium, Fallopian tube or endometrial stroma; the type of tissue depended on 
sample source and availability. For the pan-body study, cerebellum was used as a matched 
normal in all three donors.  
A set of previously described post-processing filters was subsequently applied:  
• to remove common single nucleotide polymorphisms, variants were filtered against a 
panel of 75 unmatched normal samples (Nik-Zainal et al., 2012);  
• to remove mapping artefacts associated with BWA-MEM, median alignment score of 
reads supporting a mutation should be greater than or equal to 140 (Alignment Score 
‘ASMD’>=140) and fewer than half of the reads should be clipped (Clipping Score 
‘CLPM’=0)(Lee-Six et al., 2019);  
• to remove artefacts that are specific to the library preparation for laser capture (LCM) 
samples, two additional filters were used. A fragment-based filter, which is designed 
to remove overlapping reads resulting from relatively shorter insert sizes allowed in 
this protocol that can lead to double counting of variants, and a cruciform filter, which 
removes erroneous variants that can be introduced due to the incorrect processing of 
cruciform DNA. For each variant, the standard deviation (SD) and median absolute 
deviation (MAD) of the variant position within the read was calculated separately for 
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positive and negative strand reads. If a variant was supported by a low number of 
reads for one strand, the filtering was based on the statistics calculated from the reads 
derived from the other strand and it was required that either: (a) ≤ 90% of supporting 
reads report the variant within the first 15% of the read as determined from the 
alignment start, or (b) that the MAD >0 and SD>4. Where both strands were supported 
by sufficient reads, it was required for both strands separately to either: (a) ≤90% of 
supporting reads report the variant within the first 15% of the read as determined 
from the alignment start, (b) that the MAD>2 and SD>2, or (c) that at least one strand 
has fulfilled the criteria MAD>1 and SD>10. 
 
2.3.2 Indels 
Insertions and deletions were called using cgpPindel (Raine et al., 2015, Ye et al., 2009). To 
remove germline variants the algorithm was run with the same matched normal samples that 
were used for calling substitutions. Post-processing filters were applied as previously 
described (Nik-Zainal et al., 2012). In addition, a ‘Qual’ filter (the sum of the mapping qualities 
of the supporting reads) of at least 300 and an average sequencing depth cut-off of ³ 15 reads 
were used.  
 
2.3.3 Copy number and structural variants 
Allele-specific copy number profiles were reconstructed for the endometrial gland samples 
by ASCAT (Van Loo et al., 2010, Raine et al., 2016) using matched samples as described above, 
with a ploidy of 2 and contamination with other cell types of 10%. Only samples with a 
minimum coverage of 15X and above were used. All putative copy number changes were 
visually inspected for copy number profiles on Jbrowse (Buels et al., 2016).  
Structural variants (SVs) in endometrial glands were called using matched samples (as 
described above) with the Breakpoints Via Assembly (BRASS) algorithm and further annotated 
by GRASS (https://github.com/cancerit/BRASS). Potential SVs are detected for the sample of 
interest and read-pairs clusters supporting the SV are used for breakpoint sequence de novo 
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assembly. Absence of supporting evidence in the matched control indicates that the SV was 
acquired in the sample of interest. The isolation of minute amounts of DNA for sequencing in 
combination with the LCM enzymatic fragmentation-based library preparation procedure 
introduces additional artefacts and additonal post-processing filtering was performed in two 
phases.  
 
 Further annotation of SVs with statistics that detect LCM specific 
artefacts 
All SVs detected by BRASS were further annotated by AnnotateBRASS. Each SV is defined by 
two breakpoints and their genomic coordinates.  
(A) The following statistics were determined for each breakpoint separately: 
• The total number of reads supporting the SV. 
• The total number of unique reads supporting the SV, based on alignment position 
and read orientation. 
• The standard deviation of the alignment positions of reads supporting the SV. 
• The number of chromosomes, based on read-pairs not supporting the SV, to which 
one read mapped while the mate-read aligned to the SV breakpoint. 
• The number of reads supporting the SV that had an alternative alignment (XA-tag). 
• The number of reads supporting the SV that had an alternative alignment score 
(XS-tag) similar to the current alignment score. 
• The percentage of read-pairs not supporting the SV with a discordant inferred 
insert size (default: ≥ 1000bp). 
(B) A wider search for read-pairs supporting the SV is initiated and the following statistics 
were calculated for each breakpoint separately: 
• The total number of reads supporting the SV. 
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• The total number of unique reads supporting the SV, based on alignment position and 
read orientation. 
• The standard deviation of the alignment positions of reads supporting the SV. 
• The number of reads supporting the SV that had an alternative alignment. 
• The number of reads supporting the SV that had an alternative alignment score similar 
to the current alignment score. 
(C) Reads spanning the SV breakpoints are often clipped. Clipped sequences of sufficient 
length can be aligned to other positions on the genome (i.e., supplementary 
alignment) and it is expected that these align to the proximity of the other SV 
breakpoint. Based on the clipping positions and supplementary alignments the 
following was determined for each SV: 
• Whether the clipped sequences of read-pairs spanning a SV breakpoint align in the 
proximity of the other SV breakpoint. 
• Whether the clipping within read-pairs supporting the SV occurred at roughly the 
same genomic position (default: all clipping positions occurred within 10 bp of 
each other). 
(D) BRASS uses a single matched control and a panel of normals (PoN, bulk WGS) to 
determine whether a SV is somatic. SVs observed in the sample of interest but not in 
the matched control or PoN are considered somatic. However, due to the difference 
in library preparation and the variance of spatial genomic coverage observed it is not 
always possible to accurately assess the validity of the SV. Two different approaches 
were implemented to determine whether the SV is somatic: 
1. A wider search in the matched control sample was performed to search for read-
pairs that could support the SV. The SV was still considered to be detected in cases 
where the discovered read-pairs were insufficient for breakpoint sequence de 
novo assembly. 
 35 
2. Additional controls can be defined in case multiple samples have been isolated 
for the same individual. Samples from the same individual with little genetic 
relationship, as determined from the SNVs and indels, can be used as controls to 
determine whether te detected SV is germline or a recurrent artifact. 
 
 Post-hoc filtering of SVs based on a combination of the above 
statistics. 
SVs were further filtered based on the described statistics. The optimal set of statistics and 
their most practical thresholds depends on the achieved coverage and stringency of filtering 
desired. At default the following criteria were used for detecting somatic SVs: 
• For each breakpoint there must be ≥ 4 unique reads supporting the SV (A.2). 
• The alignment position standard deviation must be > 0 (A.3). 
• At each breakpoint there are read-pairs not supporting the SV that map to < 5 other 
chromosomes (A.4).  
• The total number of chromosomes mapped to by read-pairs not supporting the SV for 
both breakpoints should be < 7 (A.4). 
• The percentage of reads supporting the SV with alternative alignments or alternative 
alignments with similar alignment scores should be ≤ 50% for both SV breakpoints 
separately (A.5-A.6). 
• The percentage of discordant read-pairs not supporting the SV should be ≤ 7.5% of 
total read-pairs for both SV breakpoints separately (A.7). 
• For the wider search of SV-supporting read-pairs the same thresholds apply as under 
criteria 1-6 (B.1-B.5). 
• There are no read-pairs in the matched control that support the SV (C.1). 
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• The SV is not detected in any of the other control samples, or there were ≤ 2 samples 
carrying the same SV and the proportion of control samples carrying the SV was < 1/3 
of the defined control set (C.2). 
• It was not allowed for read-pairs supporting the SV to have widely divergent clipping 
positions in terms of genomic location for both SV breakpoints separately (D.2). 
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2.3.4 Validation experiments and sensitivity 
To test our approach, we performed a set of validation experiments in different tissue types. 
First, the reproducibility of the workflow was assessed by generating pairs of biological ‘near-
replicate’ samples and processing them independently using the new library construction 
methodology. In these experiments, two separate samples were generated from the same 
tissue structure, such as an appendiceal crypt, and subjected to independent DNA extraction, 
cell lysis, library preparation and WGS (Figure 2.8a-d). Subsequent analysis of the sequencing 
data showed similar variant allele frequency (VAF) distributions (Figure 2.8b), a high degree 
of overlap for single nucleotide variants (SNVs) (Figure 2.8c), and similar single base 
substitution mutational spectra (Figure 2.8d).  
We then compared WGS data generated by our new workflow to LCM lysates processed via 
traditional acoustic shearing methods. Similarly, pairs of biological ‘near-replicate’ samples 
were derived from the same histological structure; this time, one sample was processed with 
our new workflow and the other with acoustic shearing. Again, comparison of the WGS data 
between the two, differently processed, samples showed similar VAF distributions, SNVs and 
mutational spectra (Figure 2.8e-h). 
 38 
 
Figure 2.8 | Validation experiments sequencing ‘near-replicate’ samples. a-d, ‘Near-
replicate’ samples were generated by splitting an appendiceal crypt into two halves, which 
were then processed and sequenced independently. b, VAF of all substitutions in both 
halves show similar clonal distribution with a median VAF around 0.5. c, Venn diagram 
demonstrating SNV identity between both samples. d, Mutational spectra of all 
substitutions are also similar. e-h, ‘Near-replicate’ samples were generated by splitting a 
colonic crypt into two halves, which were subsequently processed with our fragmentase-
based method (COL_5_A3) and sonication-based method (COL_4_A3). Similar clonal VAF 
distributions (f) SNV calls (g) and mutational spectra (h) are observed from the two samples. 
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To calculate sensitivity of our somatic variant calling, for selected endometrial tissue 
donors, pairs of biological ‘near-replicates’ were obtained. For these experiments, we 
collected two samples from the same endometrial gland using a z-stacking approach, 
in which a structure is ‘traced’ on consecutive levels (Figure 2.9). 
 
Figure 2.9| An example of a z-stacking approach to ‘tracing’ and micro-dissecting a 
specific structure. Sincer the majority of endometrial glands are clonal cell populations, 
i.e. share the most common recent ancestor, cells derived from the same glands should 
share most of the somatic mutations. Z-stacking and splitting individual glands into two 
separate samples allows to generate biological ‘near-replicates’ that can be used to 
generate biological ‘near-replicates’ to calculate sensitivity.  
 
Each sample was then processed separately with independent DNA extraction, library 
preparation and whole genome sequencing. As these were obtained from the same 
glands, they should represent derivatives of the same single stem cell and therefore 
the same sensitivity would be expected in both samples of each pair. The maximum 
likelihood estimate for sensitivity (s) was then calculated as follows:   
 
where n1 is the number of variants called only in one of the two LCM samples and n2 
is the number of variants called in both LCM samples in each pair.  
Level 1 Level 2 Level 3 Level 4
Level 3, after dissection
Sample A Sample B
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2.4 Initial application of the low DNA input LCM workflow 
The first part of my PhD was dedicated to exploring somatic mutations across multiple tissues 
from the same individuals. This study is still ongoing with sequencing data pending from two 
additional donors (donor 2 and 3). However, the endometrial study stemmed from those 
initial experiments, and a brief summary is therefore provided below. 
 
2.4.1 Samples 
By November 2017, I micro-dissected over 2,900 individual samples from 13 individuals, 
although the majority of the samples were from one individual (Donor 1) (Figure 2.10). Based 
on the post-library preparation DNA concentration (a cut off of minimum 3-5 ng/ul was 
applied), a total of 421 samples were subjected to whole genome sequencing. Only samples 
with ³15-fold coverage were processed through the variant calling pipeline (n=225, Appendix 
6). 
 
Figure 2.10 | Summary of samples sequenced as part of the initial pan-body survey. A total of 421 
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The clonal architectures of human tissues have been investigated previously by other 
approaches, in particular there has been a series of studies that utilised mitochondrial DNA 
(mtDNA) mutations (Fellous et al., 2009a, Blackwood et al., 2011). These have provided 
evidence for the clonal expansion in colon, small intestine, kidney, pancreas and others. The 
analyses presented here illustrate the potential of DNA sequence-based approaches to 
further elucidate tissue architecture and cell lineages providing systematic comparisons of 
the different clonal architectures of normal human tissues and their microanatomical 
structures. 
Micro-dissected units of cells from different tissues showed markedly different VAF 
distributions (Figures 2.10 and Table 2.1). 34% (77/224) of all the sampled units, including 
individual colorectal, appendiceal, small intestinal, prostatic, endometrial crypts or glands 
showed distributions with peaks between 0.3-0.5 (Figures 2.11). Thus, these cell populations 
are predominantly constituted of the descendants of a single progenitor stem cell (the most 
recent common ancestor cell, MRCA) which existed at some point in the past.  
Similar VAF distributions of 0.4-0.5 were observed in subsets of microdissected patches from 
seminiferous tubules, bile ductules, thyroid follicles and segments of bronchial epithelium 
indicating that these were also predominantly derived from single MRCA cells (Figure 2.10 
and Table 2.1). However, other samples from these tissues showed lower VAF peaks 
indicating the presence of clones derived from multiple MRCA cells. All microdissected 
patches from oesophagus, bladder, adrenal and adipose tissue showed low median VAFs. 
Micro-dissections from cardiac muscle and an arterial vessel yielded very few somatic 
mutations, consistent with these tissues being non-renewing in the adult and/or being 
composed of so many clones that none achieve the level of clonal dominance required for 




Figure 2.11 | Clonality of some of the sampled microscopic units. To study clonal 
composition across various normal tissues, laser-capture microdissection and whole 
genome sequencing were applied in two ways. In some tissues, previously described or 
putative clonal units such as crypts in the colon and small intestine were targeted. In other 
cases, including the ectocervix and adrenal gland cortex, variably sized strips or patches of 
cells were microdissected. Clonal composition of the sampled microscopic units can be 
studied using variant allele fractions (VAF) of all single base substitutions(Keller et al., 2008, 
Blokzijl et al., 2016). Each density line represents an individual sample; individual samples 
are grouped and coloured by tissue type. Samples derived from a clonal population, i.e. 
sharing the most common recent ancestor, will have VAF peaks around 0.5 as the majority 
of somatic mutations are heterozygous (e.g. colonic crypts). However, even with LCM 
approach, there might a contamination with other cells types, such as stromal or 
inflammatory cells, which would result in a left-sided shift in the density plots. If a sample 
was oligoclonal, i.e. derived from a few ancestral clones, this would result in an additional 
VAF peak (e.g. seminiferous tubules in testis). Polyclonal samples are those derived from 
many different ancestral clones (including different cell types); their VAF distribution will 
be generally < 0.25.  
 43 
 
Tissue/structure Fraction of clonal samples (%) 
Appendix, crypt 100 (20/20)  
Colon, crypt 100 (20/20) 
Small intestine, jejunum, crypt 89 (8/9) 
Small intestine, ileum, crypt 100 (7/7) 
Prostate, acini 83 (10/12) 
Testis, seminiferous tubules 50 (7/14) 
Liver, bile ductules 26 (5/19) 
Thyroid, follicle 19 (6/31) 
Adrenal gland, cortex  <1 (1/15) 
Lung, respiratory epithelium <1 (1/13) 
Oesophagus, squamous epithelium <1 (1/15) 
Bladder, urothelium 0 (0/7) 
Kidney, glomerulus 0 (0/4) 
Kidney, proximal tubule 0 (0/4) 
Kidney, distal tubule 0 (0/6) 
Liver, parenchyma 0 (0/3) 
Main bronchus, seromucous glands 0 (0/6) 
Ureter 0 (0/4) 
Visceral fat 0 (0/5) 
Skin, sebaceous glands 0 (0/3) 
Heart 0 (0/6) 
Artery 0 (0/1) 
Table 2.1 | Clonality of some of the sampled microscopic units. Different microscopic units were 
dissected out in different tissues, including individual crypts in the small and large intestines or acini 
in the prostate. Samples were considered clonal if the median variant allele fraction (VAF) was >=0.3 




Although estimation of mutation burden from the data in the initial pan-body experiments is 
complicated by differences in clonality and sequencing coverage between samples, two key 
observations were made. First, the results showed inter-tissue heterogeneity in the mutation 
burden within the same individual (Figure 2.12a); tissues of the same chronological age 
demonstrated different mutation burdens. The findings are likely to be reflective of the 
differences in physiology, function and exposures as well as stem cell dynamics and turnover 
rates. Second, although at this stage we only had sequencing data from a very limited number 
of individuals, there was an age-associated accumulation of somatic mutations in prostate 
and endometrium (Figure 2.12b and c). 
 
Figure 2.12 | Somatic mutation burden (SNVs). (a) This figure shows mutaiton burden (SNVs) across 
different tissues derived from one indvidual (Donor 1). BD, bile ductules, SMG, sero-mucous glands, BE, 
bronchial epithelium. Initial experiments in prostate (b) and endometrium (c) showed age-associated 




Filtered CaVEMan and Pindel variants were intersected against a previously published list of 
369 genes that are under selection in human cancers (Martincorena et al., 2017). All non-
synonymous mutations were annotated to indicate mode of action using the Cancer Gene 
Census (719 genes) and a catalogue of 764 genes (https://www.cancergenomeinterpreter.org). 
Variants were triaged against a curated list of 5601 validated cancer driver variants 
(https://www.cancergenomeinterpreter.org/mutations ). Any variant in the sample data which 
co-presented in this reference list was declared a likely driver. The initial results showed that 
endometrium had the highest prevalence of driver mutations compare to other tissues 
(Figure 2.13). 
 
Figure 2.13 | Driver mutation burden across tissues.  Although the number of samples 
studied in the pilot experiments varied between tissues, our first impression was that the 
endometrium had the highest number of driver variants. This was an unexpected finding 


















































































2.4.5 Summary of the initial experiments 
Preliminary results from the very first pan-body experiments have provided first insights into 
inter-tissue heterogeneity in terms of somatic mutation burden and clonal expansion. One of 
the most striking observations was that the majority of the sampled endometrial glands were 
clonal cell populations and had the highest frequency of driver variants. The latter was 
particularly surprising given that the these events occur at a much lower frequency in other 
normal tissues with gland-like structures, such as colon and prostate, yet the documented 
cancer incidence is greater than reported in the endometrium (CRUK, 2019) that are 
associated with a higher cancer incidence rates. We therefore decided to carry out a more in-
depth analysis of the genomic landscape of normal endometrium to find out how age as well 
as other known endometrial cancer risk factors affect the rate of (driver) mutation 
acquisition. The results of this work are discussed in Chapters 3 and 4. 
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2.5 Construction of phylogenies 
As we obtained multiple samples from the same individuals, we needed to differentiate 
between shared and unique variants to avoid double counting. Phylogenetic trees were 
therefore reconstructed for individual patients. 
 
2.5.1 Single nucleotide variants (SNVs) 
Phylogenies for endometrial glands were reconstructed for twenty five donors. Due to the 
low number of available samples, donor PD38812 was not included in this analysis. We first 
generated trees using substitutions called by CaVEMan; matched normal samples were used 
to exclude germline variants and post-processing filters were applied as above. Final variants 
were recalled in all samples from each donor using an in-house re-genotyping algorithm 
(cgpVAF). Variants with a VAF>0.3 were noted to be present (‘1’), VAF<0.1 absent (‘0’) and 
between 0.1 and 0.3 as ambiguous (‘?’). This approach excludes private sub-clonal variants 
from the tree building. The tree was reconstructed using a maximum parsimony approach 
(Hoang et al., 2018) and branch support was calculated using 1000 bootstrap replicates. 
Nodes with a confidence lower than 50 were collapsed into polytomies and branch lengths of 
the collapsed tree were determined by the number of assigned substitutions.  
 
2.5.2 Small insertions and deletions (indels) 
The constructed phylogenies were validated using indels called by Pindel and filtered as 
above. The same approach was applied for the final indel matrices. Although the lower 
number of indels resulted in more polytomous tree, the overall tree topologies were 
reconcilable with those generated using substitutions (Figure 2.14). 




SNV tree Indel tree 
  
Figure 2.14| Comparison of phylogenetic tree structure using SNVs and indels of  
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2.6 Assessment of clonality  
2.6.1 dpClust 
To formally assess clonal composition of individual endometrial glands, we applied a 
previously described method dpclust v2.2.7 (Nik-Zainal et al., 2012) (analysis was performed 
by Stefan Dentro). This sub-clonal reconstruction caller with default parameters to the SNVs 
in each endometrial gland to assess the clonality of each gland. SNVs that fell within a 
detected copy number alteration were excluded from this analysis. The purity of each gland 
was set to 1, the resulting mutation clusters therefore represent proportions of the overall 
sequenced cells. Analysis yields, for every sample, the number of mutation clusters and 
assigned mutations, and the proportion of overall cells that each cluster represents. 
2.6.2 PyClone 
PyClone is a clustering method that is based on a hierarchical Bayes statistical model (Roth et 
al., 2014). It was developed for deep (1,000x) targeted sequencing data from one or more 
samples from the same tumour. The method assigns mutations to putative clonal clusters 
while also estimating their cellular prevalence and correcting for allelic imbalances, which can 
result from segmental copy number aberrations as well as contamination with normal cells. 
We attempted to use this method as an alternative way to infer clonal composition of 
endometrial glands. 
2.6.3 Lichee 
Another computational method that utilises single nucleotide variants to infer sub-clonal 
composition of samples while allowing simultaneous reconstruction of multi-sample cell 
lineage trees (in our study, per donor lineage) is LICHeE (Lineage Inference for Cancer 
Heterogeneity and Evolution) (Popic et al., 2015). This approach relies on VAFs of deep-
sequenced somatic SNVs. The algorithm was run with default settings: distance between 
clusters was 0.15, minimum VAF for a mutation to be present was 0.15, maximum VAF for a 
cluster was 0.65, and a VAF measurement error of 0.10.  
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2.7 Extraction of mutational signatures  
Mutational signature extraction was performed using mutations assigned to every branch of 
the reconstructed phylogenetic trees and each branch was treated as an individual sample. 
Such approach allows characterisation and differentiation of specific mutational processes 
that were operative at various times in individual glands. Substitutions were first categorised 
into 96 classes following the method used by the Mutational Signature working group of the 
Pan Cancer Analysis of Whole Genomes (PCAWG) (Alexandrov, 2018). SBS signature analysis 
was performed in 3 steps: extraction, deconvolution and re-attribution. SBS signatures were 
extracted using 3 approaches: (i) using the HDP package 
(https://github.com/nicolaroberts/hdp) that utilises hierarchical Bayesian Dirichlet process 
either de novo or (ii) with reference signatures (‘priors’) identified by the Mutational 
Signatures working group of the Pan Cancer Analysis of Whole Genomes (PCAWG) 
(Alexandrov, 2018), and (iii) non-negative matrix factorization (NMF) (Alexandrov, 2018). 
Such extensive mutational signature analysis was performed for two reasons: (1) to validate 
signatures as NMF was originally developed for cancer tissues which usually provide many 
more mutations than normal/non-cancer tissue samples; (2) to ensure we do not miss any 
new mutational signatures that are unique to normal tissues. We chose to perform de novo 
signature extraction as mutational signatures had not been previously described in the 
normal endometrium. Furthermore, the so-called ‘known’ signatures or priors were derived 
using cancer sequencing data. Simply fitting mutations to a cancer derived catalogue of 
signatures could potentially ‘over-fit’ certain signatures. 
 
2.7.1 HDP 
(i) HDP de novo signature extraction revealed 3 components (Components 1, 2 and 0, Figure 
2.14); similarity of the components to the 65 reference signatures was assessed; Component 
2 had a high Cosine Similarity (>0.95) to SBS 18. (ii) HDP signature extraction with all 65 
PCAWG priors yielded the following components: ‘priors’/reference SBS signatures (P1 = 
SBS1, P5 = SBS5, P18 = SBS18, P23 = SBS23, P40 = SBS40); ‘new’ component that did not match 
any of the provided 65 reference signatures/priors (N1) and ‘Component 0’ (Comp 0); all of 
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the components from this extraction were taken to further analysis and deconvolution (Figure 
2.16). Because P1, P5, P18, P23 and P40 showed high Cosine Similarity (>0.95) to the 
respective signatures (SBS1, SBS5, SBS18, SBS23 and SBS40), no further deconvolution of 
these components was required. As component N1 did not show high Cosine Similarity to any 
of the reference signatures, deconvolution was performed using a ‘deconvolution’ catalogue 
comprising all of the extracted signatures (SBS1, SBS5, SBS18, SBS23, SBS40). Final exposures 
were derived and signatures re-attributed to the individual samples (branches). As SBS5 and 
SBS40 are relatively featureless and present particular challenges in estimating their separate 
contributions (as previously outlined (Alexandrov, 2018)), these have therefore been 
combined (but are shown separately in Appendix 7). SBS23 was previously found in a small 
number of liver cancers with high mutation burdens. Given its low mutation burden and small 
contribution in our cohort it is unclear whether this is really. Therefore, this signature and the 
associated mutations were placed in the “unattributed” category (Figure 2.16). 
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Figure 2.15 | Extraction of Single Base Substitution (SBS) mutational signatures. Final 
catalogue of single base substitutions were used to re-construct phylogenetic trees for 27 
donors. SBS signatures were extracted on a per branch basis first using Hierarchical Dirichlet 
Process (HDP) de novo. HDP de novo signature extraction revealed 3 components; similarity 
of the extracted components to the 65 reference signatures was assessed; only Component 
2 had a high Cosine Similarity (>0.95) to a reference signature (SBS 18). Signature extraction 
methods are continuously being developed and modified. We therefore applied different 
approaches. If a tissue is relatively homogenous in terms of type mutational processes, this 
can lead to a weaker signal and some of the components (signatures) not separating. HDP 
conditioning with priors (or the known signatures) can be used to aid the extraction. 
However, such approach can also result in a small number of variants falsly attributed to 
signatures that are not really there (‘over-splitting’). 
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Figure 2.16 | Extraction of Single Base Substitution (SBS) mutational signatures. As P1,  P5, 
P18, P23 and P40 showed high Cosine Similarity (>0.95) to the respective signatures (SBS1, 
SBS5, SBS18, SBS23 and SBS40), no further deconvolution of these components was 
required. Because component N1 did not show high Cosine Similarity to any of the reference 
signatures, deconvolution was performed using a ‘deconvolution’ catalogue comprising all 
of the extracted signatures (SBS1, SBS5, SBS18, SBS23, SBS40). Final exposures were derived 
and signatures re-attributed to the individual samples (branches). As SBS5 and SBS40 are 
relatively featureless and present particular challenges in estimating their separate 
contributions, these have therefore been combined (but are shown separately in 
Supplementary Fig 5). SBS23 was previously found in a small number of liver cancers with 
high mutation burdens. Given its low mutation burden and small contribution in our cohort 
it is unclear whether this is really. Therefore, this signature and the associated mutations 





(iii) NMF signature extraction was performed using SigprofilerExtractor Version 0.0.5.51 
(https://pypi.org/project/sigproextractor/#history), SigprofilerMatrixGenerator Version 
1.0.2 (https://pypi.org/project/SigProfilerMatrixGenerator/#history) and SigprofilerPlotting 
Version 1.0.3 (https://pypi.org/project/sigProfilerPlotting/) on solutions between 1 and 20 
signatures with 3 signatures chosen as the optimal solution running 1000 iterations. The 
extraction yielded 3 signatures, which were further deconvoluted as following: Signature A 
into SBS1 (8.16%), SBS5 (79.88%) and SBS23 (11.96%); Signature B into SBS1 (16.18%), SBS5 
(22.6%) and SBS18 (61.22%); Signature C into SBS1(42.1%) and SBS5(57.9%) (Figure 2.17). 
 
Figure 2.17 | Extraction of Single Base Substitution (SBS) mutational signatures. NMF 
extraction yielded 3 signatures, which were also taken to further analysis and 
deconvolution (c).  Using Sigprofiler Version 1.8 (ref), Signature A was deconvoluted into 
SBS1 (8.16%), SBS5 (79.88%) and SBS23 (11.96%); Signature B into SBS1 (16.18%), SBS5 
(22.6%) and SBS18 (61.22%); Signature C into SBS1 (42.1%) and SBS5 (57.9%). 
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Indels were classified using PCAWG method (Alexandrov, 2018) and composite mutational 
spectra were generated for each donor (Appendix 8). However, given the relatively low 
numbers of indels, no formal signature extraction was performed. 
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2.8 Driver mutations 
Analysis of driver variants in the normal endometrial glands was performed in two parts. First, 
filtered CaVEMan and Pindel variants were intersected against a previously published list of 
369 genes that are under selection in human cancers (Martincorena et al., 2017). All non-
synonymous mutations were annotated to indicate mode of action using the Cancer Gene 
Census (719 genes) and a catalogue of 764 genes 
(https://www.cancergenomeinterpreter.org). Truncating variants (nonsense, frameshift and 
essential splice), which resided in recessive/tumour-suppressor genes (TSG) were declared 
likely drivers. Missense mutations in recessive/TSG and dominant/oncogenes were triaged 
against a database of validated hotspot mutations 
(http://www.cbioportal.org/mutation_mapper). All mutations that were shown to be known 
mutational hotspots or ‘likely oncogenic’ were declared drivers. In addition, identified 
activating mutations in mutational hotspots in RRAS2, involving the RAS/MAPK pathway were 
declared as likely drivers. 
 
2.8.1 dN/dS 
Second, to identify genes that are under positive selection in normal endometrium we used 
the dN/dS (Martincorena et al., 2017) method that is based on the observed:expected ratios 
of non-synonymous:synonymous mutations. The analysis was carried out for the whole 
genome (q<0.01 and q<0.001) and for 369 known cancer genes (Martincorena et al., 2017) 
(RHT, restricted hypothesis testing, q<0.05).  Twelve genes were found to be under positive 
selection in normal endometrial glands. The output of this analysis was also used to assess 
whether missense mutations in genes that are under positive selection in normal and/or 
malignant endometrium (PIK3CA, ERBB2, ERBB3, FBXW7 and CHD4) but are not known 
mutational hotspots, are likely to be drivers. We calculated the fraction of the mutations 
tested that are likely to be drivers (f) using the following equation: f = (w-1)/w, where w is the 
observed missense count (52) divided by the expected count (0.14). If f was ≥ 0.95, then all 





To compare patterns of selection in normal endometrial epithelium and cancer, we 
performed dN/dS analysis on previously published data from the The Cancer Genome Atlas, 
TCGA (Martincorena, 2018).  
 
2.8.2 Timing of cancer driver mutations  
To estimate the time interval in which specific driver mutations occurred, we applied two 
approaches: (a) ‘patient-based’, in which we calculated a patient-specific mutation rate by 
taking the ratio of the patient’s mean mutation burden per endometrial gland and the 
patient’s age; (b) ‘cohort-based’, in which mutation rate for each patient was derived from 
the linear mixed-effect model for total mutation rate that included data from the entire 
cohort (Supplementary Results 5). The mutation number at the start and end of a branch in 
the phylogenetic tree was then converted to a lower and upper age by dividing these numbers 
by the estimated mutation rate. Both approaches rely on the assumption of a constant 
mutation rate for endometrial glands throughout a patient’s life. 
Filtered CaVEMan/Pindel variants
369 genes 
(Martincorena et al, Cell, 2017)
301 variants
Annotated with Cancer Gene Census (719 genes)
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2.9 Mixed-effect model and estimation of mutation burdens 
2.9.1 Estimation of the total somatic mutation rate 
Assuming a constant mutation rate, a linear model can be fitted to estimate the number of 
mutations that occurred due to normal mutational processes, which should correlate with 
patient age. To estimate the mutation rate, we could use a simple linear model or a mixed 
effects linear model. Given the fact that we have multiple samples from the same individuals, 
we chose to apply a linear mixed effects model, which takes into consideration both: (a) 
variation explained by the independent variables of interest (fixed effects), such as age, parity 
and others; and (b) variation not explained by the independent variables of interest (random 
effects), which  would give a structure to the error term ϵ (ref). 
We used a random slope with fixed intercept as most women will start menarche at a similar 
age (~13 years), but to account for the potential differences in the rates at which mutations 
were acquired each year in different individuals due to variation in parity, contraception and 
other factors. 
 
We tested features with a known effect on mutation burden or endometrial cancer risks: 
• Age 
• Read depth & VAF (‘Vafdepth’) 





For these analyses, we excluded the following cases: (a) samples from donors with missing 
meta-data, such as BMI and parity; (b) samples with an adjusted coverage (VAF depth) of <7.5 
(adjusted coverage defined as VAF x sequencing depth). To account for the non-independent 
sampling per patient, we used mixed effects models. In these analyses, we tested features 
either with a known effect on mutation burden or endometrial cancer risk; age, read depth & 
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VAF, BMI, Parity. In addition, we tested whether there was any significant difference between 
different patient cohorts. Finally, we tested whether menstrual phase has an effect on the 
clonality and mutation burdens. All statistical analyses were performed in R and are 
summarised in Appendix 9. 
 
2.9.2 Estimation of the driver mutation burden 
To our best knowledge, there has been no previous work on estimating driver mutation rates 
in normal tissues. 
Similar to the above, in order to describe estimates of the total mutation rates, we applied a 
mixed-effects model. However, given the fact that the data (driver variants) are not normally 
distributed and sparse, we used a generalized linear mixed effects model with Poisson 
distribution. As above, we also use a random slope with fixed intercept as most women will 
start menarche at a similar age (~13 years), but to account for the potential differences in the 
rates at which mutations were acquired in different individuals due to variation in parity, 




  Clonal composition of normal 
endometrial epithelium 
It is unknown whether endometrial epithelial glands are clones of cells deriving from a recent 
single common ancestor or whether they are constituted from multiple clones of cells from 
multiple ancestors. In this chapter I have aimed to use the whole genome sequences to 
characterise the clonality of normal endometrial glands. 
 
3.1 Introduction to the chapter 
Human endometrium is the mucosal lining of the corpus (the body) of the uterus. It is a unique 
highly dynamic tissue that undergoes over 400 cycles of breakdown, rapid repair, growth and 
remodelling in response to the oscillating levels of oestrogen and progesterone over a 
woman’s lifetime (Jabbour et al., 2006, Gargett et al., 2007). Histologically, it is composed of 
two major components: the epithelial compartment in the form of tubular glands that 
produce glycogen-rich secretion and open up on to the luminal surface, and the mesenchymal 
compartment comprising cellular endometrial stroma and specialised hormone-sensitive 
blood vessels (spiral arterioles) (Mills et al., 2012, p.1071). Functionally, it is divided into two 
layers: the functionalis,  the superficial layer that is sensitive to hormones and is shed during 
menses, and the basalis, the deep layer which is retained during menstruation or following 
gestation. The latter represents the germinal compartment of the endometrium containing 
adult progenitor stem cells from which the functionalis regenerates during menstrual cycles 
or after gestation (Chan et al., 2004, Gargett et al., 2008). 
 
3.1.1  Endometrial adenogenesis  
Human uterus differentiates from the Mullerian ducts and doubles in size from the twenty-
eighth week of foetal development to birth. During this time, the initial endometrial 
 61 
adenogenesis, the development of glands, occurs. At this stage, the tissue is composed 
primarily of simple columnar epithelium lining the endometrial surface and from which small 
invaginations, primordial endometrial glands, are formed (Mills et al., 2012, p.1071). At birth, 
although the endometrial tissue architecture resembles that of an adult, it is still significantly 
less developed with only occasional endometrial glands present (Valdes-Dapen, 1973). A 
considerable amount of growth and adenogenesis occurs postnatally and in early childhood; 
at puberty, the tissue architecture reaches maturity with coiled, tubular glands radiating 
through to the myometrium (the underlying smooth muscle layer of the uterus) (Valdes-
Dapen, 1973). Importantly, this pattern of gland development is distinct from the one 
observed in the adult endometrium through menstrual cycles when the glands develop 
adluminally from the basal layer (Okulicz et al., 1997, Huang et al., 2012). 
A number of key genes are thought to be involved in the process of endometrial gland 
development. Amongst these are members of the WNT gene family (WNT4, WNT5a and 
WNT7a), which regulate essential cell behaviours including movement, adhesion, 
differentiation and proliferation, that are pivotal to endometrial adenogenesis (Cunha, 1976, 
Sharpe and Ferguson, 1988). Knock out of beta-catenin (CTNNB1), a critical intracellular 
mediator of Wnt signalling (Jeong et al., 2010), or its downstream target gene, transcription 
factor Lef1 (Shelton et al., 2012), has been shown to disrupt gland formation in neonatal 
uterus. Forkhead box A2 (FOXA2) is a key transcription factor for adenogenesis (Jeong et al., 
2010) with studies in mice showing that its ablation leads to significant reduction in the 
number of endometrial glands. Another important gene is CDH1, with its loss also leading to 
a reduction in the number of endometrial glands (Reardon et al., 2012). Notably, both FOXA1 
and CDH1 genes are also thought to be involved in the Wnt signalling pathway. 
 
3.1.2 Endometrium in reproductive years 
During the female reproductive years, from menarche (the first occurrence of menstruation, 
usually at around 13 years) through to menopause (the cessation of menstruation, usually at 
around 51 years), the endometrium undergoes cyclical changes in response to oscillating 
levels of female hormones. 
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Endometrial function and the menstrual cycle are regulated primarily by steroid hormones 
secreted by the ovary. Following ovulation, the corpus luteum, a structure in the ovary that 
develops after an ovum has been discharged, secretes high levels of progesterone to maintain 
endometrial receptivity to the blastocyst, should fertilisation occur (‘Secretory phase’). If 
pregnancy is not achieved, the corpus luteum regresses leading to a rapid decline in 
progesterone and oestrogen levels. The progesterone withdrawal causes tissue breakdown, 
local inflammatory response and shedding of the endometrium (Jouager et al., 2007). 
Following loss of almost the entire endometrial surface, re-epithelization is completed within 
48 hours after the start of menses (Salamonsen et al., 1999, Ludwig et al., 1991) and the tissue 
undergoes further rapid proliferation and growth reaching a thickness of around 5-10 mm, a 
process that is driven by rising levels of unopposed oestrogen secreted by the ovary 
(‘Proliferative phase’). The cycle then re-starts with the next round of ovulation (Day 14-15) 
(Figure 3.1).  
 
 
Figure 3.1 | Schematic of the human menstrual cycle. The human menstrual cycle is 
regulated by the ovary which secretes oestrogen and progesterone; the cycle is divided into 
three phases: menses, proliferative phase and secretory phase. Adapted from Gargett et 
al., 2008.  
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3.1.3 Endometrial adult stem cells 
Adult stem cells are rare undifferentiated cells that are retained throughout the body after 
the completion of embryonic development (Li and Clevers, 2010, Weissman, 2000). They are 
characterised by the ability to self-renew as well as to produce more differentiated daughter 
cells (Gargett, 2007, Bongso and Richards, 2004) and play a critical role in maintenance of 
organs and tissues, and regeneration after damage. The existence of endometrial stem cells 
was first shown by Chan and colleagues (2004); using purified single cell suspensions obtained 
from hysterectomy tissues, they showed that 0.22±0.07% of endometrial epithelial cells and 
1.25±0.18% of stromal cells formed colonies within 15 days. Both the epithelial and stromal 
cells generated two types of colonies: large and small colonies. Large putative stem cell 
colonies were rare (0.08% of single cell suspensions for epithelial cells and 0.02% for stromal 
cells); they displayed much greater self-renewal capability in comparison to the small colonies 
that showed a limited proliferation potential. The authors suggested that the large colonies 
were derivatives of the putative progenitor stem cells while the small colonies were thought 
to have been derived from transient amplifying (TA) cells.  
Subsequently, Schwab and Gargett performed further functional clonogenicity experiments 
this time including samples not only from two phases of the menstrual cycle (proliferative and 
secretory) but also from inactive (post-menopausal) endometrium (Schwab and Gargett, 
2007). The results showed that there is no variation in the frequency of clonogenic epithelial 
and stromal cells in two phases of the menstrual cycle or in the post-menopausal 
endometrium. Importantly, as inactive endometrium comprises the basalis layer only, the 
findings suggested that the endometrial progenitor stem cells reside in the basalis layer and 
persist beyond the menopause. This suggestion that the endometrial epithelial adult stem 
cells (eeASCs) reside in the basalis is further supported by the ability to induce proliferation 
in post-menopausal women who are treated with hormone replacement therapy as well as 
tissue regeneration and regrowth in patients who undergo extensive endometrial ablation for 
heavy bleeding (Tresserra et al., 1999).  
Since the majority of endometrial cancers are of epithelial origin, the remainder of this section 
will be focused on the eeASCs. Despite the fact that their existence was first shown over a 
decade ago, eeASCs have remained poorly characterised in comparison to their counterparts 
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in other tissues, such as colon and stomach. One of the main reasons for this is the lack of a 
specific marker that would reliably distinguish those cells from their mature progeny. Some 
of the general stem cell markers, for instance bcl-2, c-kit (CD117) and CD34 have been 
identified in the normal endometrium (Cho et al., 2004). However, the number of cells that 
expressed these markers were significantly higher than the number of clonogenic cells that 
had been previously shown in the functional studies (Chan et al., 2004, Schwab and Gargett, 
2007).  
Chan and Gargett carried out further experiments to locate label retaining cells (LRCs) to 
identify somatic progenitor stem cells and characterise their location in the stem cell niche in 
the absence of specific markers (Chan and Gargett, 2006). They studied mouse endometrium 
in which the tissue was pulse labelled with Bromodeoxyuridine (BrdU) and examined after an 
8-week chase to identify endometrial LRCs. The results showed that 3% of the epithelial nuclei 
were BrdU+ and were located in the luminal epithelium. The cells did not express Oestrogen 
Receptor alpha (ERα) through dual labelling immunofluorescence, confirming that luminal 
epithelial progenitor stem cells are responsible for the growth of glands during development 
and in cycling mice. With the use of a mouse model with menstrual breakdown and repair, 
ERα negative glandular epithelial LRCs contributed to the repair of the luminal epithelium 
following menstruation. Endometrial repair occurred in the absence of oestrogen. BrdU+ 
epithelia were rapidly lost in the chase period, leading to the notion that the epithelial 
regeneration may depend on self-duplication of a mature epithelial cell type, or that the LRC 
technique is not sensitive enough to label rare endometrial epithelial cells with an ASC 
phenotype. 
3.1.4 Clonal composition of endometrial glands 
Cancers are caused by the accumulation of somatic mutations in normal cells. These 
mutations allow cells to proliferate uncontrollably, escaping homeostatic controls and 
providing survival advantage over their neighbours with subsequent clonal expansion. To 
better understand ageing and early neoplastic transformation, it is essential to expand our 
knowledge on somatic evolution, selective pressures and remodelling in normal tissues. 
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Colon is one of the most studied highly proliferative tissues, in which individual crypts, its 
functional gland-like units, are known to eventually become clonal cell populations that share 
most common recent ancestors (MCRAs). The monoclonal conversion of individual crypts  is 
thought to occur through neutral drift (Snippert et al., 2010); in mice, it has been shown that 
the initially multi-coloured colonic crypts became monochrome over a period of around 1-6 
months in a pattern that is consistent with neutral dynamics. In humans, the monoclonality 
of colonic crypts was shown using naturally occurring somatic mitochondrial DNA (mtDNA) 
mutations through enzyme-histochemical staining for loss of cytochrome C oxidase (CCO) 
protein (Baker et al., 2014). More recently, Nicholson and colleagues used staining for loss of 
mild Periodic Acid-Schiff (mPAS), which detects loss of O-acetylation of sialomucins and is a 
marker of clonality, and showed that in humans, the process of monoclonal conversion of 
colonic crypts takes several years (13 years for 90% conversion, median 6.3 years) (Nicholson 
et al., 2018). 
However, the above mentioned lack of definitive markers for eeASCs has meant that little is 
known about the stem cell dynamics and clonal composition of normal endometrial glands. 
To my best knowledge, work by Tanaka and colleagues from more than 15 years ago is the 
only study inferring clonal composition of human endometrial glands (Tanaka et al., 2003). 
Using a collagenase-based digestion approach, they isolated individual human and mouse 
glands and assessed their clonality using a polymerase chain reaction-based assay for non-
random X-chromosome inactivation with an X-linked androgen receptor gene. They found 
that most of the studied glands were monoclonal populations and that in some of the clonal 
patches expanded over several adjacent glands. Although this study provided first insights 
into stem cell dynamics in the tissue, the clonal patches and their distributions were defined 
by the events that would have occurred in early embryogenesis, whereas the aim of our study 
was to infer adult stem cell dynamics and associated clonal expansion that occurs throughout 
life. 
3.1.5 Study design and sample selection 
Normal endometrium was one of the first tissues that we included in our pan-body survey of 
somatic mutations (Methods). In July 2017, the results of the initial experiments showed two 
striking observations: the majority of the sampled endometrial glands were clonal cell 
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populations and mutations in cancer genes, such as PIK3CA, KRAS and FBXW7, were frequent. 
Yet, there was no morphological evidence of neoplastic transformation in any of those 
samples. Shortly before we made this observation, a whole exome and targeted sequencing 
study on endometriosis was published (Anglesio et al., 2017). In this analysis, Anglesio and 
colleagues investigated genomic changes in deep infiltrating endometriosis (DIE), a disorder 
in which histologically normal endometrium is found deep in abnormal (ectopic) locations, 
such as the urinary bladder or the bowel. Although ectopic, the endometrium in these lesions 
is ‘functional’ and undergoes cyclical changes similar to those in the eutopic (uterine) tissue; 
the associated repetitive breakdown and regeneration causes local bleeding, inflammatory 
reaction and pain. The study showed that driver mutations can be found in these lesions 
without morphological evidence of cancer. This finding was particularly interesting as unlike 
ovarian endometriosis, DIE is not known to undergo malignant transformation (Wei et al., 
2011). Given their results and our observations in normal endometrial glands from the initial 
experiments, we decided to carry out a larger study.  
As human endometrium is a highly dynamic tissue that adopts various physiological states, to 
obtain a representative view of its somatic mutagenesis and consequences throughout life, 
we collected samples from as wide an age range of women as possible. These included 
biopsies taken from women under investigation for reproductive problems (14), 
hysterectomies for benign non-endometrial pathologies (2), residual tissues from transplant 
organ donors (8) and autopsies after death from non-gynaecological causes (4) (Meta-data is 
summarised in Table 3.2). We also aimed to assess how these are modulated by some of the 
known endometrial cancer risk factors such as BMI and parity. Finally, to confirm normal 
histology, all endometrial biopsies were examined by two histopathologists (Dr Mercedes 







Age BMI Parity No.of high 
coverage 
samples 
Menopause status Menstrual phase 
PD37506 Post-mortem 
(traumatic injury) 
19 U U 10 Pre-menopausal Undetermined 
PD40535 Transplant donor 24 24 3 7 Pre-menopausal Proliferative 
PD41871 Infertility clinic 27 30 0 17 Pre-menopausal Secretory 
PD37605 Infertility clinic 29 27 2 9 Pre-menopausal Secretory 
PD37601 Infertility clinic 31 28 0 10 Pre-menopausal Secretory 
PD41860 Infertility clinic 31 23 0 4 Pre-menopausal Secretory 
PD37607 Infertility clinic 34 24 1 19 Pre-menopausal Secretory 
PD41857 Infertility clinic 34 22 1 14 Pre-menopausal Secretory 
PD39444 Transplant donor 35 24 1 10 Pre-menopausal Proliferative 
PD41865 Infertility clinic 36 31 0 2 Pre-menopausal Secretory 
PD41868 Infertility clinic 36 23 0 6 Pre-menopausal Secretory 
PD39953 Transplant donor 37 18 2 8 Pre-menopausal Secretory 
PD41859 Infertility clinic 38 21 0 1 Pre-menopausal Secretory 
PD37613 Infertility clinic 39 22 0 11 Pre-menopausal Secretory 
PD41861 Infertility clinic 39 21 0 8 Pre-menopausal Secretory 
PD41869 Infertility clinic 40 37 0 13 Pre-menopausal Secretory 
PD37594 Infertility clinic 42 20 1 17 Pre-menopausal Secretory 
PD39952 Transplant donor 44 36 0 11 Pre-menopausal Proliferative 
PD39954 Transplant donor 44 24 1 10 Pre-menopausal Secretory 
PD37595 Infertility clinic 46 19.5 5 9 Pre-menopausal Secretory 
PD36804 TAH for 
leiomyomata 
47 30 3 13 Pre-menopausal Secretory 
PD36805 TAH for benign 
ovarian tumour 
49 27 0 7 Pre-menopausal Secretory 
PD38812 Post-mortem 
(traumatic injury) 
54 U U 2 Post-menopausal Proliferative 
PD37507 Post-mortem 
(peritonitis) 
60 U U 14 Post-menopausal Inactive 
PD42746 Transplant donor 67 34 2 2 Post-menopausal Inactive 
PD40107 Transplant donor 69 24 2 10 Post-menopausal Inactive 
PD42475 Transplant donor 74 27 2 8 Post-menopausal Inactive 
PD40659 Post-mortem 81 22 4 5 Post-menopausal Inactive 
Table 3.2 | Summary of clinico-pathological data for all donors.  




3.2.1 Sample Collection 
I laser-capture microdissected >800 individual endometrial glands. DNA from each gland was 
subjected to our LCM library-making protocol modified to accommodate small amounts of 
input DNA (methods). Wherever possible, biopsies from other tissues, including Fallopian 
tube, cervix and myometrium, were also collected. 
 Paired normal selection 
To exclude germline mutations, somatic mutations in each gland were determined by 
comparison with whole genome sequences from pieces of uterus, cervix or Fallopian tube 
from the same individuals. The type of sample that was used as a normal was determined by 
the nature of the procedure during which the endometrial sample was taken: samples from 
the infertility clinic were taken from live donors during hysteroscopy, which is usually limited 
to the endometrium layer of the uterus and therefore we had to use endometrial stroma as 
a paired normal sample; in the case of the hysterectomy resections, post-mortem and 
transplant donor samples, other  tissues were available such as cervix and myometrium. On 
a selection of samples, we re-ran mutation calling algorithms (CaVEMan and Pindel) using 
matched normal samples from two different tissues; no significant difference was observed 
between the two runs (Table 3.3 and Figure 3.2). 
 
Figure 3.2 | An example of the overlap of variants called in the same sample using two 
different paired normal samples (cervix and myometrium). In this case (sample 





Sample ID Subs called  against cervix 
Subs called 
against myometrium 
PD36804b_EM4_G3_E5 896 875 
PD36804b_EM5_G2_B6 1176 1183 
PD36804b_EM5_G3_C6 1059 1052 
PD36804b_EMD_7_A1 1743 2016 
PD36804b_EMD_7_A5 1420 1418 
PD36804b_EMD_7_A6 1408 1399 
PD36804b_EMD_7_C2 1522 1529 
PD36804b_EMD_7_C3 1621 1615 
PD36804b_EMD_7_C6 1396 1398 
PD36804b_EMD_7_E3 1618 1608 
PD36804b_EMD_7_E4 1390 1387 
PD36804b_EMD_7_G4 1403 1397 
PD36804b_EMD_7_G5 1362 1367 
PD36805b_EM10_G2_A3 1092 1104 
PD36805b_EM10_G3_C3 1644 1647 
PD36805b_EM1_G1_L1_2_A1 1525 1518 
PD36805b_EM7_G2_C8 1575 1577 
PD36805b_EM8_G2_F8 1680 1676 
PD36805b_EM9_G1_A9 1662 1659 
PD36805b_EM9_G4_B3 1832 1748 
Table 3.3 | Comparison of substitution mutation burdens in selected samples using 
different types of tissue as the matched normal. 
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3.2.2 Sample QC 
Based on post-library preparation DNA concentration (a cut-off of ³5 ng/ul was applied), a 
total of 292 glands were selected for whole genome sequencing (30x). The mean sequencing 
coverage was 28-fold (Figure 3.3). Only samples with ³15-fold coverage were processed 
through the variant calling pipeline (n=257, Appendix 10). 
 
 
Figure 3.3| Sequencing coverage across all endometrial gland samples. A total of 292 
normal endometrial glands were subjected to whole genome sequencing. Only samples 
with a ³15-fold coverage (indicated by the dotted line) were used for subsequent analyses. 
 
3.2.3 Variant calling 
Using 18 pairs of biological ‘near-replicates’ (details in methods) we calculated the mean 
sensitivity of our somatic mutation variant calling at >0.86% (range 0.70-0.95%). 
A total of 338,376 single nucleotide variants (SNVs) was found with a median of 1521 (range 




















3.2.4 Clonality of endometrial glands 
There are a number of ways in which we could infer clonal composition of endometrial glands. 
Some of these are discussed below, all analyses used filtered caveman input as outlines in 
methods. 
 
 Distribution of variant allele fractions (VAFs) of all mutations 
In the simplest approach, clonality can be explored through variant allele fractions (VAFs). As 
most somatic mutations are heterozygous, those mutations present in all cells of a population 
derived from a single ancestor will have VAFs of 0.5 whereas mutations in cell populations 
derived from multiple ancestors will have lower VAFs or be undetectable by standard 
mutation calling approaches. Therefore, to assess whether endometrial glands are clonal cell 
populations, the VAFs of all called somatic mutations can be used; 91% (234/257) of 
microdissected endometrial glands showed distributions of base substitution VAFs with peaks 
between 0.3 and 0.5 (Figure 3.4) indicating that each gland consists predominantly of a cell 
population descended from a single epithelial progenitor stem cell. Mutations that are 
present at a lower VAF may represent contamination by other cell types; these potentially 
include endometrial stromal cells, inflammatory cells, epithelial cells from neighbouring 
glands or subclonal diversification within the same gland.  
Assessment of small insertions and deletions (indels) showed similar VAF distributions 
confirming the results from base substitutions (Figure 3.5).  
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Figure 3.4| Clonality of normal endometrial glands. Individual normal endometrial glands 
were laser-capture microdissected and whole genome sequenced. The majority (91%) of 
the sampled glands were clonal cell populations, sharing the most recent common 
ancestor, with a median variant allele fraction (VAF) between 0.3 and 0.5 for all identified 
substitutions across individuals. Each density line represents an individual endometrial 
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Figure 3.5| Clonality of endometrial glands based on VAFs distributions for indels. The 
majority of sampled normal endometrial glands were clonal with a median variant allele 
fraction (VAF) for all identified indels of 0.3 or above. 
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 Two-dimensional clustering algorithms: dpclust 
To formally assess clonal composition of each sampled endometrial gland, we applied a 
previously described sub-clonal reconstruction caller (dpclust v2.2.7) (Nik-Zainal et al., 2012) 
with default parameters to the single nucleotide variants (SNVs) in each endometrial gland to 
assess the clonality of each gland (this work was carried out by Stefan Dentro). The analysis 
yields, for every sample, the number of mutation clusters and assigned mutations, and the 
proportion of overall cells that each cluster represents. 
A gland was determined to be the result of a single progenitor cell if a single mutation cluster 
was obtained or when the proportions of cells in which multiple mutation clusters were 
detected. Akin to the so-called “pigeon-hole” principle (Yates et al., 2015), in such a scenario 
the sum of the estimated proportions of cells of a pair of cellular populations exceeds 1 (100% 
of cells), which means at least some cells must contain the mutations in both clusters. 
Alternatively, if the sum of the estimated proportions does not exceed 1 the populations 
could be the result of a single or of separate ancestors.  
The results of the dpclust analysis concurred with our observations based on the distribution 
of VAFs; 89.9% (231/257) of all endometrial glands had a major clone (defined as those with 
³ 75% of sequenced cells) with clusters containing on average 79.5% of all substitutions (sd = 
24.9%) (Figures 3.6 and 3.7, Appendix 11). 83% (214/257) of glands showed evidence of a 
further, subclonal cell population which, based on the “pigeon-hole” principle (Yates et al., 
2015), is a descendant of the main clonal population. The majority of glands also showed 
minor contamination by cells that do not share somatic mutations with the observed clonal 
expansions, potentially including endometrial stromal cells, inflammatory cells and epithelial 





Figure 3.6 | Assessment of clonal composition of individual endometrial glands using mutation clustering method 
dpclust. Each column contains summary of the clonality analysis for individual donors, showing the fraction of 
samples in which 1, 2 or 3 or more mutation clusters were found (a), the fraction of mutations assigned per cluster 



























































































































































































































































































Number of clusters 1 2 >=3

















































































































































Figure 3.7 | Examples of clusters identified in individual endometrial glands with dpclust. 
The clonality analysis yields a posterior density estimate of what proportion of sequenced 
cells likely represents a mutation cluster. Each plot shows the posterior density in black and 
its corresponding 95% confidence interval coloured. Called clusters are marked with a 
vertical black line. 89.9% of all sampled glands had a major clone which is defined as a 
cluster containing >=75% of all base substitutions. The identified subclonal populations can 
represent either late subclonal diversification occurring in an individual endometrial gland, 
incomplete monoclonal conversion of a gland and contribution of more tham one adult 
stem cell or contamination with another clone from an adjacent gland or even stroma. The 
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 Two-dimensional clustering algorithms: LICHeE 
Another computational method that utilises single nucleotide variants to infer sub-clonal 
composition of samples while allowing simultaneous reconstruction of multi-sample cell 
lineage trees (in our study, per donor lineage) is LICHeE (Lineage Inference for Cancer 
Heterogeneity and Evolution) (Popic et al., 2015). This approach relies on VAFs of deep-
sequenced somatic SNVs. The algorithm was run with default settings: distance between 
clusters was 0.15, minimum VAF for a mutation to be present was 0.15, maximum VAF for a 
cluster was 0.65, and a VAF measurement error of 0.10.  
The results showed that 67/257 (26%) glands had one major clone, 189/257 (74%) glands had 
two clusters and 1/257(<1%) had 3 clusters (Figure 3.8).  
 
Figure 3.8 | An example of clusters identified with LICHeE. This tool relies on variant allele 
fractions (VAFs) of deep sequenced SNV’s and default pre-defined distances between clusters. It is 
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 Methods comparison 
Comparison with clonal clusters identified using dpclust and LICHeE showed a correlation of 
0.40 (Figure 3.9). This method generally proved ineffective due primarily to 2 factors. First, 
using VAF instead of cancer-cell fraction yielded VAF clusters which broke the pigeonhole 
principle due to varying contamination by other cell types, LICHeE is unable to handle such 
trees. Second, the distance between clusters would ideally be dynamically chosen rather than 
a single fixed value across all donors and samples. 
 
 
Figure 3.9 | Comparison of clonal mutations identified by dpclust and LICHeE algorithms. 
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 Two-dimensional clustering algorithms: PyClone  
We also attempted to use the PyClone algorithm, which has been previously applied on whole 
exome sequencing data (Roth et al., 2014) (this analysis was performed with help from 
Raheleh Rahbari). However, the algorithm was built for whole exome sequencing data with 
fewer variants, we were unable to run it on our whole genome sequencing data from all 
glands. Instead, we selected 1000 random substitutions per individual with genotype 
priors. The result of the PyClone analysis with beta-binomial emission densities with total 
copy-number priors showed that the majority of mutations were clonal across all 
individuals. Figure 3.10 illustrates an example of a PyClone density plot for donor PD39952 
with 99% of the 1000 selected mutations clustered together at a variant allele fraction 
(VAF) of 0.5. 
 
Figure 3.10 | Density plot of identified clusters and substitutions assigned in donor 
PD39952. For each donor, 1000 random substitutions were selected from different 







 Clonality and presence of driver mutations 
Subsequent analyses demonstrated that many endometrial glands carry “driver” mutations 
in known cancer genes. Such mutations are known to be advantageous to stem cells – these 
allow uncontrolled proliferation and provide selective advantage over their neighbours 
(Stratton et al., 2009). We therefore examined the effect of the presence or absence of a 
driver mutation on clonality of endometrial glands. The analysis showed that endometrial 
glands exhibit clonality irrespective of the presence of known driver mutations (Figure 3.11a) 
with, for example, somatic mutations in all 10 glands from a 19-year-old individual (PD37506) 
having a median VAF >0.3 but no driver mutations identified (Figure 3.11b). Thus, colonisation 
of endometrial glands by descendants of single endometrial epithelial stem cells is not 
contingent on a growth selective advantage provided by driver mutations and may occur by 
a process analogous to genetic drift, as proposed for other tissues (Lopez-Garcia et al., 2010, 
Snippert et al., 2010).  
Given the highly dynamic nature of the endometrium with cycles of tissue loss, rapid 
regeneration (proliferative phase) and further growth and expansion (secretory phase) during 
reproductive years and the lack of these in post-menopausal women, we examined the 
correlation between the menstrual phase, menopause and clonality of glands. The results 
showed that the observed monoclonality was also independent of the menstrual phase and 







Figure 3.11 | Clonality of endometrial glands and driver mutations. The presence of a 
driver mutation did not have a significant effect on the observed monoclonality of the 
glands (Mann-Whitney two-sided test, p =  0.1) (a). All glands from the 19-year-old donor 





3.3 Summary of results for this chapter  
Endometrium is a relatively less studied tissue in comparison to other glandular type tissues, 
such as colon and stomach. Although endometrial epithelial adult stem cells (eeASCs) were 
first described over a decade ago, they remain relatively poorly characterised in comparison 
to their counterparts in other tissues, such as the small and large intestine. In particular, the 
number of stem cells in individual endometrial glands, their dynamics and clonal expansion 
remain poorly understood, which at least in part, is due to the lack of robust biomarkers 
(Tempest et al., 2018) and animal models given that only a limited number of species undergo 
menstrual cycle with tissue loss and regeneration. Here, we show that irrespective of the 
‘starting’ number of eeASCs, the majority of normal endometrial glands are clonal cell 
populations that share common recent ancestors. The monoclonal conversion occurs early 
(all glands from a 19-year old individual were clonal) and is independent of the presence of 
driver mutations and menstrual phase.  
 83 
  The mutational landscape of 
normal endometrial epithelium 
4.1 Introduction to the chapter 
4.1.1 Somatic mutations in normal endometrium 
 Mutation rates 
In recent years, there has been growing interest in somatic mutations in normal ageing 
tissues. A number of studies, including several from our group, have characterised these 
changes for different epithelial tissues, such as the small and large intestine(Lee-Six et al., 
2019, Blokzijl et al., 2016), liver (Blokzijl et al., 2016, Zhu et al., 2019) and oesophagus 
(Martincorena, 2018, Martincorena et al., 2018, Yokoyama et al., 2019); similar work has also  
been carried out on non-epithelial tissues, for instance, skeletal muscle (Franco et al., 2018) 
and blood (Osorio et al., 2018, Lee-Six et al., 2018b). Recent pan-cancer analyses have 
examined somatic mutation rates across various tumours, including those originating in the 
endometrium; the results have given us first estimates of the ‘clock-like’ mutation rates in 
normal cells based on the fact that cancers arise from cells that were once normal (Alexandrov 
et al., 2015). However, such views are likely to be distorted as the estimates were derived 
from cancer tissues rather than from normal tissues directly. To the best of my knowledge, 
our study was the first to estimate mutation burden and rates in the normal human 
endometrium. 
 
  Genomic changes in normal endometrium 
The first insights into the genomic changes in non-neoplastic endometrium were provided in 
a study by Nair and colleagues, in which they applied ultra-deep, targeted sequencing to 
screen for cancer driver mutations in uterine lavage fluid from women undergoing 
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hysteroscopy for molecular screening and diagnosis of endometrial cancer (Nair et al., 2016). 
They showed that a deep targeted sequencing approach can be used to detect early 
microscopic lesions. In addition, they also found cancer associated mutations in ~49% of all 
examined women without histological evidence of endometrial pathology. Importantly, the 
presence or absence of a neoplasm in this study was based on histological assessment made 
only on a small tissue biopsy that was taken during the hysteroscopy and, undoubtedly, some 
of the negative cases could represent missed lesions rather than truly non-neoplastic 
endometrium. In addition, uterine lavage fluid contains a mixture of endometrial and non-
endometrial cells, including those shed from the epithelial lining of the Fallopian tubes, cervix 
and ovary. It is therefore plausible that some of the detected driver mutations were actually 
representative of genomic changes that occurred in these tissues rather than the 
endometrium. Nevertheless, this study was the first to suggest that cancer driver mutations 
may potentially be found in non-neoplastic endometrium. 
As described earlier in Chapter 3, shortly before our initial experiments on normal 
endometrium, a study by Anglesio and colleagues showed that cancer associated mutations 
can be identified in endometriosis (Anglesio et al., 2017). Known cancer driver mutations in 
genes such as PIK3CA, KRAS and ARID1A were found in 5/24 patients some of whom were in 
their 20s. Subsequently, the same group investigated genomic changes in another type of the 
disorder, iatrogenic endometriosis, which is thought to be associated with previous surgical 
procedures (Lac et al., 2018). Similarly, driver mutations could be detected in these samples, 
yet these lesions virtually never undergo malignant transformation (Wei et al., 2011). 
The aim of our study was: to use whole genome sequencing to provide a comprehensive 
characterisation of the mutational landscape of the normal endometrial epithelium; to 
explore how this landscape is influenced by age, BMI and parity, to estimate the age of driver 
mutations and to investigate the relationship of clonal evolution to glandular architecture. 
4.1.2 Current understanding of endometrial cancer 
Endometrial cancer is the most common gynaecological tumour in the developed world with 
9,314 new cases and 2,360 deaths a year in the UK (CRUK, 2019). While it is not the ‘deadliest’ 
malignancy, its incidence has increased by 57% in the UK between 1993-1995 and 2014-2016 
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(CRUK, 2019). Moreover, the incidence is predicted to rise further, which is at least partially 
related to the worldwide obesity epidemic (Morice et al., 2016, Onstad et al., 2016), thus 
making it an important health care issue and burden in the future. Approximately 75% of 
patients with the disease are diagnosed in the early stages (International Federation of 
Gynaecology and Obstetrics (FIGO) stages I and II) with a 5-year overall survival of 74-91% 
(Siegel et al., 2013, Creasman et al., 2006). For patients with advanced disease (stage III and 
IV), 5-year overall survival is 57-66% and 20-26% respectively (Creasman et al., 2006). 
The majority of endometrial cancers are sporadic, but a small proportion of cancers (2-5%) 
are familial (Le Gallo and Bell, 2014). These include tumours associated with Lynch Syndrome 
(hereditary nonpolyposis colorectal cancer) with underlying germline mutations in mismatch 
repair genes (MLH1, MSH2, MSH6 and PMS2) as well certain germline deletions in EPCAM, 
and cancers in patients with Cowden Syndrome who carry germline mutations in PTEN (Le 
Gallo and Bell, 2014). 
 
 Classification of endometrial cancer 
Historically, endometrial cancers have been classified into two broad groups based primarily 
on their clinical, metabolic and endocrine features (Bokhman, 1983). Type I tumours are 
thought to be linked to unopposed oestrogen exposure and obesity, are hormone-receptor 
positive and are usually well to moderately differentiated neoplasms that carry a relatively 
favourable prognosis (Cancer Genome Atlas Research et al., 2013, Murali et al., 2014). Type 
II cancers are less common, tend to present in older, post-menopausal, non-obese women, 
arise in the absence of endocrine and metabolic disturbances, are poorly differentiated and 
have a less favourable outcome. 
Since this original classification by Bokhman in 1983, endometrial cancers have been further 
characterised and subtyped using histological and more recently, molecular features. These 




 Histological classification of endometrial cancer  
According to the World Health Organisation (WHO) classification, neoplasms of the uterine 
corpus comprise several distinct histological types: epithelial carcinomas (endometrioid, 
serous, clear cell, mucinous, squamous cell, transitional cell, small cell and undifferentiated), 
mixed epithelial and mesenchymal tumours (e.g. carcinosarcomas), or mesenchymal tumours 
(e.g. endometrial stromal sarcomas) and others (Silverberg et al., 2003). However, epithelial 
carcinomas account for the majority of all endometrial neoplasms, including endometrioid 
(87-90%) and serous (5-10%) (Liang et al., 2012), and therefore the rest of the discussion will 
be focused on these tumours. 
 
Endometrioid carcinoma 
Endometrioid carcinomas (ECs) are associated with excess exposure to unopposed oestrogen 
with risk factors including, obesity, early age at menarche (the first occurrence of 
menstruation), late age at menopause and nulliparity (never having completed a pregnancy 
beyond 20 weeks). The tumours are typically preceded by hyperplasia (simple or atypical), 
and endometrial intra-epithelial neoplasia (O'Hara and Bell, 2012). The majority of these 
neoplasms are diagnosed at an early stage and are associated with a favourable prognosis 
(Lewin et al., 2010). 
On a molecular level, ECs are characterized by frequent mutations in PIK3CA, PTEN and 
PIK3R1, which result in inappropriate activation of the PI3K pathway (Risinger et al., 1997, 
Rudd et al., 2011). Other signal transduction pathways that are frequently disrupted in these 
tumours include the RAS-RAF-MEK-ERK pathway with mutations in KRAS seen in 18% of cases. 
Somatic mutations in the FGFR2 receptor tyrosine kinase occur in 12% of cases with mutations 
in FGFR2 and KRAS being mutually exclusive (Byron et al., 2012). ECs also frequently show 
disruption of the canonical WNT signalling pathway with mutations in CTNNB1 gene (19-45%) 
(Byron et al., 2012, Machin et al., 2002). It has been suggested that the mutual exclusivity of 
CTNNB1 and KRAS mutations and functional cross talk between the RAS-RAF-MEK-ERK and 
WNT/TCF signalling pathways may occur in this cell type or that functional redundancy exists 
in the biological consequences of altered RAS-RAF-MEK-ERK and WNT/TCF signalling (Byron 
et al., 2012). Finally, 34- 40% of all ECs show microsatellite instability (MSI) (Byron et al., 2012, 
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Cancer Genome Atlas Research et al., 2013), which is attributed to defective mismatch repair, 
primarily due to hypermethylation of the MLH1 promoters; somatic mutations in MSH6 and 
loss of MSH2 expression have also been observed (Esteller et al., 1999, Simpkins et al., 1999, 
Goodfellow et al., 2003). 
Serous endometrial carcinoma 
Serous endometrial carcinomas are high grade neoplasms that are relatively rare accounting 
for only 5-10% of ECs, but are clinically aggressive and contribute substantially to the 
mortality from endometrial cancer accounting for 39% of deaths from endometrial cancer 
(Hamilton et al., 2006). Older age and smoking are thought to be the main risk factors. Serous 
carcinomas arise from surface endometrial intraepithelial carcinoma (Sherman, 2000) on the 
background of atrophic endometrium in older post-menopausal women. The tumours are 
characterised by a high frequency of mutations in TP53, which are believed to be the initiating 
events in the development of these cancers (Fadare and Zheng, 2012). 
 
 Molecular classification of endometrial cancer 
Advances in next generation sequencing technologies have allowed better characterisation 
of many types of cancers. In 2013, The Cancer Genome Atlas Research Network (TCGA) 
published a comprehensive genomic and transcriptomic analysis of endometrial cancers 
(endometrioid, serous and mixed endometrioid/serous carcinomas) (Cancer Genome Atlas 
Research et al., 2013). Based on mutation spectra, copy-number alterations (CNAs) and 
microsatellite instability status, endometrial cancers were classified into four groups (Figure 
4.1): 
POLE (ultra-mutated) cancers that are characterised by extremely high mutation burdens, 
hotspot mutations in the exonuclease domain of POLE, frequent C>A substitutions, few CNAs 
and recurrent mutations in PTEN, PIK3R1, PIK3CA, FBXWA and KRAS. These were also found 
to be associated with favourable outcome; 
Microsatellite-instable (MSI) (hypermutated) cancers that are characterised by 
microsatellite instability due to MLH1 promoter methylation, relatively high mutation 
burdens, few CNAs and frequent mutations in PTEN, KRAS and RPL22; 
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Copy-number low (endometrioid) cancers which comprise microsatellite stable low grade 
endometrioid cancers with low mutation burden and frequent mutations in PTEN and 
CTNNB1; 
Copy-number high (serous-like) cancers that are characterised by extensive CNAs, low 
mutation burdens and recurrent mutations in TP53 as well as FBXW7 and PPP2R1A, but 
infrequent alterations in PTEN and KRAS.  
 
 




POLE (ultramutated) MSI (hypermutated) Copy-number low (endometrioid) Copy-number high (serous-like)
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 Endometrial cancer risk factors  
The estimated lifetime risk of being diagnosed with endometrial cancer is 1 in 36 (3%) (CRUK, 
2019). The main risk factor for endometrioid carcinomas is exposure to endogenous and 
exogenous oestrogens in association with obesity, early age of menarche, late-onset 
menopause, nulliparity, hormone therapy (e.g. tamoxifen) and diabetes. For serous 
carcinomas tumours, older age (>55 years) and smoking are thought to be the main risk 
factors although work by McCullough and colleagues have also shown that the incidence 
increases with elevation in body mass index (BMI) (McCullough et al., 2008). Since the 
majority of endometrial cancers are endometrioid, some of the key risk factors for the disease 
are considered in more detail below. 
 
Obesity 
Obesity is the second biggest preventable cause of cancer in the UK (CRUK, 2019); it is a well-
recognised risk factor for thirteen different types of malignancies, including those arising in 
the breast, colon, liver, ovary and stomach. In women, obesity has a stronger association with 
the development of endometrial cancer than with any other cancer type (Reeves et al., 2007) 
with 34% in the UK and 57% in the US of all such cases attributable to being overweight and 
obese (Renehan et al., 2008, Calle and Kaaks, 2004). This association is well-documented and 
shows a dose-response relationship with the cancer incidence increasing with an elevation in 
the BMI; for every five units of BMI, there is an increase in the risk of developing the disease 
(relative risk, RR=1.50; CI95% 1.42-1.59) (World Cancer Research). Furthermore, being obese 
has an effect on the endometrial cancer prognosis: the RR of disease-specific mortality is 2.53 
for mildly obese (BMI 30-34.9) and 6.25 for severely obese (BMI >40) patients (Calle et al., 
2003), compared to women with a normal BMI. The underlying mechanistic pathways that 
link obesity and endometrial cancer are briefly discussed below. 
Visceral fat is composed of mature fat cells (adipocytes), less differentiated fat cells 
(preadipocytes), endothelial, stromal and nerve cells along with mesenchymal stem cells 
(MSCs) (Mills et al., 2012, p.1071); it serves as an endocrine organ that is responsible for the 
synthesis and secretion of several hormones amongst multiple other functions (Coelho et al., 
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2013). During reproductive years, ovaries are the primary source of oestrogens; whereas in 
post-menopausal women other tissues, in particular visceral fat, become key sites of 
production and secretion of these hormones (Davis et al., 2015). Adipocytes, preadipocytes 
and MSCs secrete aromatase, an enzyme that is necessary for the conversion of androgens to 
oestrogens (Blakemore and Naftolin, 2016, O'Connor et al., 2009). In addition, an increase in 
adiposity (the state of being fat), leads to a decrease in sex hormone-binding globulin (SHBG) 
levels which in turn results in an increase in the pool of available, bioactive oestrogen (Simo 
et al., 2015). When oestrogen is bound to oestrogen alpha and/or beta-receptor, it directly 
modulates the transcription of a variety of pro-proliferative genes including IGF1R and IGF1 
(Westin et al., 2009).  
Visceral fat is also a rich source of adipokines, which regulate metabolism and modulate 
chronic inflammatory states associated with adiposity. Obesity-associated proinflammatory 
adipokines, including leptin, interleukin-6 and tumour necrosis factor alpha, not only suppress 
normal insulin signalling and contribute to insulin resistance (Onstad et al., 2016, Renehan et 
al., 2015, Mu et al., 2012, Kwon and Pessin, 2013), but also promote endometrial proliferation 
(Onstad et al., 2016). 
Finally, Type 2 diabetes which is closely linked with obesity, is characterized by elevated levels 
of insulin and insulin-like growth factor 1 (IGF1) and hyperglycaemia, both of which have been 
shown to play a role in the pathogenesis of endometrial cancer  (Nead et al., 2015, Poloz and 
Stambolic, 2015). In premenopausal women, oestrogen-induced cyclical changes in IGF1 
expression and signaling modulate endometrial proliferation during normal menstrual cycle 
(McCampbell et al., 2006). The positive association of endometrial cancer with 
hyperinsulinaemia and type 2 diabetes is well documented (Nead et al., 2015, Calle and Kaaks, 
2004, Lees and Leath, 2015). Increased expression of insulin and IGF1 receptors is observed 
in endometrial hyperplasia, which heightens the responsiveness of these cells to insulin and 
IGF1 (McCampbell et al., 2006) and promotes hyperactivity of MAPK and PI3K/AKT/mTOR 
signaling frequently observed in endometrial cancer. Proliferative signaling is further 
amplified by the loss of the PTEN tumor suppressor gene, which acts in opposition to the 
PI3K/AKT/mTOR pathway and is an early event in the pathogenesis of endometrial cancer. 
Finally, hyperglycaemia, which occurs as a consequence of insulin insensitivity, serves to 
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further fuel the growth of metabolically active tissue (Masur et al., 2011), including 
endometrial hyperplasia and cancer.  
 
Parity 
A meta-analysis by Wu and colleagues (Wu et al., 2015) has revealed that there is a significant 
inverse association between parity and risk of endometrial cancer with a RR for parous versus 
nulliparous women of 0.69 (CI95% 0.65-0.74).  In addition, parity number of 1, 2 or 3 versus 
nulliparous showed a significant negative association with the relative risk, RR=0.73 (CI95% 
0.64-0.84), RR = 0.62 (CI95% 0.53–0.74); and RR = 0.68 (CI95% 0.65–0.70) respectively). 
Oestrogens are known to stimulate endometrial proliferation and increase mitotic activity, 
which can lead to tumour development (Henderson and Feigelson, 2000, Akhmedkhanov et 
al., 2001) while progestins reduce cell proliferation and promote differentiation and can 
therefore decrease risk of endometrial cancer (Akhmedkhanov et al., 2001). Wu and 
colleagues suggested that the observed negative correlation between parity and risk of 
endometrial cancers is due to slightly higher levels of progesterone relative to oestrogen 
during pregnancy (Wu et al., 2015). They also proposed that the dose-response relationship 
observed between parity and endometrial cancer risk may be attributable to repeated long-
term anti-oestrogenic endometrial effects of progesterone occurring during pregnancies 
(Preston-Martin et al., 1990), or alternatively, due to ‘mechanical shedding of 
malignant/premalignant endometrial cells’ at parturition (Wu et al., 2015, Lambe et al., 1999). 
 
 Microbiome 
In recent years, there has been an increasing amount of interest in the uterine microbiota 
with several studies reporting its association with various disease states including infertility 
and cancer (Walther-Antonio et al., 2016, Chen et al., 2017, Baker, 2018). Bacterial organisms 
that were previously found to be enriched in endometrial cancer cases are summarised in 
Table 4.1. However, there are limitations associated with such investigations, of which 
contamination is probably one of the most significant (Baker, 2018). The majority of uterine 
sampling in the published work and in some of the cases in our study, would have been 
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performed transcervically, which makes it difficult to avoid cross-contamination by 
microbiota from the lower genital tract. In cases where samples were collected in different 
circumstances, such as the transplant and autopsy donors in our study, contamination with 
organisms from the lower abdominal and pelvic cavities may also occur. The use of uterine 
manipulators, cervical dilators and surgical tools as well as histology tissue processing 
















Table 4.1 | List of bacterial organisms previously shown to be associated with 




The results presented in this chapter are based on the final variants that were called in normal 
endometrial glands from 28 women aged 19 to 81 years. Only samples with ³15-fold coverage 
were processed through the variant calling pipeline (n=257, Appendix 10). Our mutation 
burden and signature analyses are based on the same variants that were used for 
reconstruction of phylogenetic trees, which mitigates double counting and differentiates 
between shared and unique variants, which is crucial for timing driver events. 
 
4.2.1 Mutation burden 
The somatic mutation burden in normal endometrial glands from the 28 individuals ranged 
from 209 to 2833 base substitutions (median 1,521) and 1 to 358 indels (median 180) (Figure 
3.2a, b). In large part this variation was attributable to the ages of the individuals with a linear 
accumulation of ~29 base substitutions per gland per year during adult life (linear mixed-
effect model, CI95% 23-34 , p = 3.02 x 10-11) (Appendix 9). However, the possibilities of lower 
mutation rates pre-menarche and post-menopause cannot be excluded. Positive driver 
mutation status conferred an additional ~110 substitutions (CI95% 43-177, p = 1.34 x 10-3). The 
basis for this correlation is unclear. It is conceivable that an elevated total mutation load 
increases the chances of including, by chance, a driver. It is also plausible, however, that 
drivers engender biological changes, for example elevated cell division rates, that result in 
higher overall mutation loads. There was no obvious correlation between parity and total 
somatic mutation burden. 
In addition, to formally test the effect of “sample cohort” on our observations, we applied a 
mixed-effect model; the analysis showed that “cohort” (i.e. whether the sample was from a 
transplant donor/autopsy or from the infertility clinic) had no significant effect on the 




Figure 4.2 | Mutation burden in normal endometrial glands. (a) Substitutions accumulate 
in the endometrium in a relatively linear fashion. A positive correlation between age and 
accumulation of indels (b), copy number alterations (CNA) and structural variants (SV) (c) 
and mutations attributed to single base substitution (SBS) mutational signatures SBS1 (d), 
SBS5/40 (e) and SBS18 (f) was also observed. The fraction of glands with driver mutations 
(g), mean number of driver mutations in glands with drivers (h) and mean number of unique 
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 Coding/non-coding mutation burden 
To explore whether coding and non-coding mutations accumulate at different rates all 
substitutions were split into the two groups. Our analysis shows that there is an age-
associated accumulation of somatic mutations for both types of mutations (linear regression, 
p = 1.22 x 10-6 for coding mutations and p = 4.73 x 10-10 for non-coding mutations (Figure 
4.3a,b). The median ratio of coding to non-coding mutations was 0.011 (range 0.007 - 0.015) 
(Figure 4.3c); there was no association with age (r = -0.024; linear regression p = 0.904). 
 
 
Figure 4.3 | Age-associated accumulation of coding and non-coding mutations in normal 
endometrial epithelium. For each sample, substitutions were divided into coding and non-
coding. (a), (b) Both types of mutations accumulated with age. (c) The median ratio of 
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4.2.2 Endometrium and other normal tissues 
Tissues across the body differ in their physiology, turnover, exposure to mutagens and 
architecture with specific stem cell arrangements and dynamics. All of these are likely to be 
reflected in their mutational landscapes, including mutation burdens. We therefore 
compared mutation burden of endometrial epithelium to that of other normal tissues. 
 In-house LCM experiments: endocervix  
In addition to endometrial glands, nearby normal endocervical glands were micro-dissected 
from one individual (PD37506). In this analysis, for each cell type, only the samples with a 
median VAF of ³0.4 were used. There was a ~2-fold lower somatic mutation burden in 
endocervical than endometrial glands (Figure 4.4). The finding may reflect the absence, in 





Figure 4.4 | Comparison between normal endometrial and endocervical glands. (a) An 
overview histology image of an ~2cm3 tissue biopsy sample from a 19-year-old donor 
(PD37506). The image shows normal endometrial and adjacent endocervical glands, which 
were subsequently micro-dissected. (b) Endometrial and endocervical glands with a similar 
median variant allele frequency (VAF) of substitutions were compared. (c) There was a ~2-
fold difference in the mutation burden between the two types of glands. 
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 Previously published data (non-LCM experiments) 
Using previously published results, we compared mutation rates between normal 
endometrial epithelial and other types of cells. The results showed that endometrial cells 
exhibit lower mutation rates than normal skin epidermal (Martincorena et al., 2015), 
colorectal (Lee-Six et al., 2019, Blokzijl et al., 2016), small intestinal (Lee-Six et al., 2019, 
Blokzijl et al., 2016) and liver cells (Blokzijl et al., 2016), similar burdens to oesophageal cells 
(Martincorena, 2018) and higher rates than skeletal muscle cells (Franco et al., 2018) (Figure 
4.5). Of the mutational signatures found in endometrial cells, SBS1 and SBS5 are found in all 
other cell types (Alexandrov et al., 2015). However, the SBS1 mutation rate is higher in 
colorectal and small intestinal epithelial cells whereas the SBS5 mutation rate is higher in liver 




Figure 4.5 | Comparison of mutation rates between endometrial epithelium and other 
cell types. The barplot shows a comparison of estimated mutilation rates (substitutions) 
for normal endometrial epithelial and other cell types from previously published studies 
(liver, colon and small intestine (Blokzijl et al., 2016), oesophagus (Martincorena et al., 




















4.2.3 Normal endometrium and cancer 
Acquisition of driver mutations enables uncontrolled proliferation, cancer clone expansion 
and increased accumulation of somatic mutations. We therefore compared mutation burdens 
between normal endometrial glands and endometrial cancer. We performed the following 
analyses: 
1. Raw mutation burden comparison between normal endometrial glands and 
tumour using endometrial cancer samples from the Pan-Cancer Analysis of 
Whole Genomes (PCAWG) set. We compared the mutation loads of normal cells 
observed here with those recently released by the Pan Cancer Analysis of Whole 
Genomes Project2. Endometrial cancers exhibited higher mutation loads than 
normal endometrial cells, for base substitutions (~5-fold, medians of 1346 and 
7330 substitutions observed in normal endometrium and endometrial cancer 
respectively (Mann-Whitney test, P = 7.63 x 10-6) (Fig. 4.6a) and indels (Figure 4.6b) 
and these differences also pertain to normal endometrial cells with driver 
mutations. In most endometrial cancers these differences are attributable to 
higher mutation burdens of the ubiquitous base substitution and indel mutational 
signatures. In addition, however, the very high mutation loads of the subsets of 
endometrial cancers with DNA mismatch repair deficiency and polymerase 
epsilon/delta mutations were not seen in normal endometrial cells. Differences 
between endometrial cancers and normal cells were even more marked for 
structural variants and copy number changes (median number zero in normal 
endometrial cells and ~23 in endometrial cancers) and this again pertained to 
normal endometrial cells with drivers. 
 
2. Tumour (Pan Cancer Analysis of Whole Genomes (PCAWG)) and normal 
mutation burden comparison using subsampled sequencing data: These analyses 
were performed with the help of Tim Coorens and Stefan Dentro. We selected five 
tumour (PCAWG) and five normal endometrial gland samples with a similar clonal 
composition (clonal composition was inferred with dpclust (Nik-Zainal et al., 2012) 
and only samples that had a clonal fraction of mutations of ³0.8 were included in 
this analysis). Binary Alignment Map (BAM) files were subsampled at regular 
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fractions (0.1) of the original coverage to assess the sensitivity of mutation calling 
across comparable levels of coverage in both cancer and normal samples; when a 
mutation called in the original BAM file was present in a subsampled BAM file in 
four or more reads, it was taken to be present in the subsampled BAM file. The 
results showed that ³90% of substitutions detected at the original coverage were 
recovered at a median coverage of 22.1x for tumour (range 21.4-43.4x) and 20.1x 
for normal endometrial glands (range 18.6-24.2x) (Figure 4.7a). Comparison of the 
mutation burden between normal and tumour samples at the sequencing 
coverage of 25-30x, showed an ~4-fold difference (Mann-Whitney test, p = 
0.00794, Figure 4.7b), therefore it is highly unlikely that such a marked difference 




Figure 4.6 | Comparison between normal endometrial epithelium and endometrial 
cancer. (a,b) Normal endometrial glands show lower total mutation burden in comparison 
to endometrial cancer (Pan Cancer Analysis of Whole Genomes Project2). (d,e) Genes that 
are under significant positive selection (dN/dS > 1) in normal endometrial epithelium and 
endometrial cancer. RHT, restricted hypothesis testing of known cancer genes. ERBB2 and 
ERBB3 are under selection in normal endometrial epithelium, but are not in endometrial 
cancer. (f) Identified driver mutations and their distribution in normal endometrial glands and 
the two major types of endometrial cancer (endometroid and serous carcinomas). 
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Figure 4.7 | Comparison of mutation burden in subsampled tumour and normal 
endometrial samples. Five tumour and five normal samples with a clonal fraction of 
mutations of ³0.8 were selected, bam files subsampled at a regular interval of the original 
coverage. (a) ³90% of the mutations called at the original coverage were recovered at a 
median coverage of 22.1x for tumour (range 21.4-43.4x) and 20.1x for normal endometrial 
gland samples (range 18.6-24.2x). (b) Comparison of the mutation burden between normal 
and tumour samples at the sequencing coverage of 25-30x, showed an ~4-fold difference. 
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3. Tumour (PCAWG) and normal comparison using clonal mutations only: In 
addition to the original analysis of the total substitution burden in the normal and 
tumour (PCAWG) cases (Figure 4.8a), we made this comparison using ‘clonal’ 
mutations only (clonal composition of each sample was inferred with dpclust (Nik-
Zainal et al., 2012) by Stefan Dentro) (Figure 4.8b). Given that the majority of the 
endometrial cancer samples are from women aged 60 to 80 years, we also 
performed an age-restricted comparison using cases from the two decades (Figure 
4.8c); the results show a significant difference in the clonal substitution burden 
between normal and cancer samples (Wilcoxon rank sum test, p = 4.02 x 10-14). 
 
4. Tumour (TCGA) and normal mutation burden comparison:  Given the above-
mentioned differences in pathogenesis, molecular changes and clinical outcomes 
between the two types of endometrial cancer, we also compared mutation burden 
of normal endometrial glands and the two classes cancer. Ideally, we would have 
liked to have performed both comparisons using whole genome sequencing (WGS) 
data from the same PCAWG data set. Unfortunately, no histology information was 
available for this cohort and so the cancer cases could not be subtyped in the total 
mutation burden comparison. Instead, we compared coding mutations in normal 
endometrial glands and endometrial cancer samples from TCGA. There was a 6-
fold and 5-fold difference in the mutation burden comparing to endometrioid and 




Figure 4.8 | Mutation burden comparison in normal endometrium and endometrial 
cancer. (a) Scatter plot showing all substitutions identified in normal endometrial glands 
and endometrial cancer cases (Pan Cancer Analysis of Whole Genomes (Alexandrov, 2018)); 
(b) comparison of clonal mutations (clonal substitutions are those that were assigned to 
the major clone using dpclust method (Nik-Zainal et al., 2012)); (c) boxplot showing clonal 
substitution burden in tumour and normal endometrium restricted to donors aged 60 to 
80 years (Wilcoxon rank test, p = 4 x 10-14).  In (a) and (b), median mutational burden is 
calculated for each donor; in (c), all samples are included for each of normal tissue donor 
and ‘hypermutator’ cancer cases (defined as those above the 75 percentile (>5,631 




Figure 4.9 | Coding mutation burden comparison in normal endometrium and 
endometrial cancer (TCGA cohort). (a) Scatter plot showing mutation burden for tumour 
and normal samples. For cancer cases, each data point represents an individual donor; for 
normal endometrial samples, each data point represents a median burden for an individual 
donor. (b) Somatic mutation burden in normal endometrium is 6-fold and 5-fold lower than 










































4.2.4 Mutational signatures 
To explore the underlying processes of somatic mutagenesis operative in normal endometrial 
epithelial cells mutational signatures were analysed. Five previously described single base 
substitution (SBS) mutational signatures were identified in endometrial glands (Figure 4.10 
and Appendices 8 and 9): SBS1, predominantly characterised by NCG>NTG mutations and 
likely due to spontaneous deamination of 5-methylcytosine; SBS5 and SBS40, two relatively 
featureless, ‘flat’ signatures of uncertain cause; SBS18, predominantly characterised by C>A 
substitutions and possibly due to reactive oxygen species (Rouhani et al., 2016); and SBS23, a 
signature predominantly composed of C>T mutations and of unknown aetiology. Because 
SBS5 and SBS40 are relatively featureless they present particular challenges in estimating 
their separate contributions (as previously outlined (Alexandrov, 2018)) and have therefore 
been combined (but shown separately in Appendices 8 and 9). SBS23 was previously found in 
a small number of liver cancers at high mutation burdens. Given its low mutation burden and 
small contribution here it is unclear whether this is really the same signature and we have 
therefore included it in the “unattributable” category. The mean signature exposures were 
0.23 for SBS1, 0.58 for SBS5/40 and 0.12 for SBS18. A positive linear correlation with age for 
the mutation burdens attributable to SBS1, combined SBS5/40 and SBS18 signatures was 
observed (Figure 4.2). 
Interestingly, glands from one donor with a history of recurrent missed miscarriage (RMM) 
showed much higher mean SBS18 exposure (0.35) compared to the rest of the cohort. As 
SBS18 has been shown to be associated with base excision repair (BER) deficiency we 
searched for truncating (somatic and germline) mutations in all samples from the 31-year-old 
donor (PD37601). In this analysis we used a panel of twenty five genes associated with BER 




Figure 4.10 | Composite mutational spectra for selected fourteen donors.  Composite 
mutational spectra for twenty seven donors were first generated using single base 
substitutions identified in all glands from each individual. 
 
  












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.2 | Panel of twenty five genes that were used to screen for base excision repair 
deficiency. 
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We currently do not know whether different signatures operate at different times of life. 
Therefore, to ascertain the periods during which different mutational processes operate, 
phylogenetic trees of endometrial glands were constructed for each individual using somatic 
mutations (Figures 4.11, 4.12 and 4.13). These revealed that the mutational processes 
underlying the three signatures are active throughout life.  
With respect to small indels, composite mutational spectra for each donor were generated. 
These were similar across ages and showed that single T insertions at runs of T bases were 
the most common mutation type observed. However, due to the relative sparsity of indels in 




Figure 4.11 | Histology images and reconstructed phylogenetic trees for two individuals in whom every 
normal endometrial gland contained at least one driver mutation: 34 year old (a,b) and 60 year old (c,d). 
(a,b) Haematoxylin and eosin (H&E) images of endometrial glands were taken after laser-capture 
microdissection (20x magnification). (c,d) Phylogenetic trees were reconstructed using single base 
substitutions; the length of each branch is proportional to the number of variants; a stacked barplot of 
attributed single base substitution (SBS) mutational signatures that contributed to each branch is then 
superimposed onto every branch; signature extraction was not performed on branches with less than 100 
substitutions. The ordering of signatures within each branch is for visualization purposes only as it is not 
possible to time different signatures within individual branches. Glands sharing over 100 variants were 
considered part of the same clade (indicated by the colour of the sample ID label). Glands that did not belong 
to any clades are in white. SBS signatures are colour-coded; substitutions that were not attributed to the 
reference signatures and those attributed to SBS23 are shown as ‘Unattributable’. 
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Figure 4.12 | Phylogenetic trees of endometrial glands for donors aged 19-40 years. Phylogenetic trees for 
the other twelve donors were reconstructed also using single base substitutions with  branch length 
proportional to the number of variants; the stacked bar plots represent attributed SBS mutational signatures 
that contributed to each branch. Signature extraction was not performed on branches with less than 100 
substitutions. The ordering of signatures within each branch is for visualization purposes only as it is not 
possible to time different signatures within individual branches. 
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Figure 4.13 | Phylogenetic trees of endometrial glands for donors aged 42 to 81 years. Phylogenetic trees 
for twelve donors aged 42 to 81 years were also reconstructed as described above. Every single gland from 
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4.2.5 Copy Number and Structural Variants  
Serous endometrial carcinomas are characterised by relatively low mutation rates, but 
extensive CNAs (Cancer Genome Atlas Research et al., 2013). In our cohort, somatic CNAs and 
structural variants (genome rearrangements) were found in only 27 out of 182 (15%) normal 
endometrial glands (Figure 4.2, 4.14 and Appendix 13). These included copy number neutral 
loss of heterozygosity (cnn-LOH) in six glands, whole chromosome copy number increases in 
one and structural variants in eighteen (12 large deletions, six tandem duplications and nine 
translocations). The rates are similar to those observed in normal colon with CNAs and/or 
structural variants seen in ~18% of normal colonic crypts(Lee-Six et al., 2019). 
 
Figure 4.14 | An example of copy-number neutral loss of heterozygosity (cnn-LOH) in a 
normal endometrial gland. (a) biallelic truncating mutation is seen in ZFHX3 (p.R715*) with 





The majority of glands showed no change; of those with CNAs/SVs, showed a single change. 
However, one of two glands carrying a TP53 mutation (see below) exhibited nine structural 
variants, indicating that genomic instability caused by defective DNA maintenance occurs in 
normal cells. Although the observation is only seen in one donor, there are two reasons why 
we believe this notion: 
1. R175H mutation in TP53 has a dominant negative effect: We have identified three 
missense mutations in TP53: R175H (81-year-old donor, VAF = 0.52), R158H (69 year 
old donor, VAF = 0.5) and G187D (39 year old donor, VAF = 0.29). One of these 
mutations, R175H, is known to have a dominant negative effect through inactivation 
of the function of wild-type p53 and is implicated in tumour development (Willis et 
al., 2004, Aubrey et al., 2018, Boettcher et al., 2019). It is this very mutation that is 
present in the sample containing 9 structural variants were identified; no structural 
variants were seen in the two other samples with the other two TP53 mutations. 
2. Many endometrial cancer cases have heterozygous TP53 mutations and structural 
variants: 25 out of the 44 endometrial cancer cases (PCAWG) had at least one TP53 
mutation of which 21 had no evidence of loss of heterozygosity, LOH (LOH was 
assumed if VAF was above 0.6 or if there was more than one mutation in TP53). 
Structural variants were detected in all of the studied endometrial cancer cases, 
however the burden was higher in samples with TP53 mutations (median = 251, range 
8-450) than those without (median = 77, range 8-316) (Wilcoxon rank sum test, p = 
0.019) (Figure 4.15).  
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Figure 4.15 | Structural variant burden of endometrial cancer samples with and 
without TP53 mutations. 
 
4.2.6 Cancer driver mutations in normal endometrial glands 
To identify genes under positive selection a statistical method based on the 
observed:expected ratios of non-synonymous:synonymous mutations was used 
(Martincorena et al., 2017). Twelve genes showed evidence of positive selection in the 257 
normal endometrial glands; PIK3CA, PIK3R1, ARHGAP35, FBXW7, ZFHX3, FOXA2, ERBB2, 
CHD4, KRAS, SPOP, PPP2R1A and ERBB3 (Figure 4.6c-e, Appendix 14). All were present in a 
set of 369 genes previously shown to be under positive selection in human cancer 
(Martincorena et al., 2017). In addition, four different truncating mutations (and no other 
mutations) were observed in the progesterone receptor gene (PGR). Although these did not 





























endometrium as an antagonist of oestrogen driven proliferation raises the possibility that 
these inactivating mutations confer growth advantage. 
To comprehensively identify drivers in the 257 endometrial glands, mutations with the 
characteristics of drivers in each of the 369 genes were sought (Methods). 209 driver 
mutations were found in normal endometrial glands from 25/28 women (Appendix 15). The 
youngest carrier was a 24-year-old (PD40535) with a KRAS G12D mutation in 1/7 glands 
sampled. 57% (147/257) of endometrial glands carried at least one driver mutation, 16% 
(42/257) carried at least two and 2% (5/257) carried at least four drivers. Remarkably, in four 
women, aged 34 (19 glands), 44 (11 glands), 60 (14 glands) and 81 (5 glands), all glands 
analysed carried driver mutations suggesting that the whole endometrium had been 
colonised by genomically microneoplastic clones (Figure 4.11 and 4.12). The fraction of 
endometrial glands carrying a driver (Figure 4.2g), the mean number of drivers per gland 
(Figure 4.2h) and the number of different drivers in each individual (corrected for number of 
glands sampled) (Figure 4.2i) all positively correlated with age of the individual. However, 
there were sufficient outliers from this age correlation to suggest that other factors influence 
colonisation of the endometrium by driver carrying clones. 
Driver mutations in both recessive (tumour suppressor genes) and dominant cancer genes 
were found, similar to recent publications (Suda et al., 2018, Lac et al., 2019, Anglesio et al., 
2017). PIK3CA was the most frequently mutated cancer gene, with at least one missense 
mutation in 54% (15/28) of women and five different mutations found in two women (Figure 
4.11 and Figure 4.13). Most truncating driver mutations in recessive cancer genes (including 
in ZFHX3, ARGHAP35 and FOXA2 which showed formal evidence of selection in normal 
endometrial glands, see above) were heterozygous without evidence of a mutation 
inactivating the second, wild type allele. Therefore, haploinsufficiency of these genes appears 
sufficient to confer growth advantage in normal cells. Nevertheless, further inactivating 
mutations, including copy number neutral LOH of the wild type allele and truncating 
mutations, in the same genes in other glands indicate that additional advantage is conferred 
by complete abolition of their activity (notably for ZFHX3 in the 60 year old, Figure 4.12 and 
4.15). Driver mutations were found in genes encoding growth factor receptors (ERBB2, ERBB3 
and FGFR2), components of signal transduction pathways (HRAS, KRAS, BRAF, PIK3CA, PIK3R1, 
ARHGAP35, RRAS2, NF1, PP2R1A and PTEN), pathways mediating steroid hormone responses 
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(ZFHX3, FOXA2, ARHGAP35), proteins involved in chromatin function (KMT2D and ARID5B) 
and protein-mediated degradation pathways (FBXW7) that target oncoproteins such as mTOR 




Figure 4.16 | Oncoplot of all driver mutations and their distribution across individual 
endometrial gland samples and donors. Each cell represents an individual endometrial 
gland sample and is colour-coded to represent the total number of detected driver 
mutations (0-3). PIK3CA was the most frequently mutated gene with at least one mutation 
detected in 54% (15/28) of women. In some glands, these co-occurred with mutations in 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Rate of driver mutations and mixed-effect model 
The fraction of endometrial glands carrying a driver (Figure 4.2g), the mean number of drivers 
per gland (Figure 4.2h) and the number of different drivers in each individual (corrected for 
number of glands sampled) Figure 4.2i) all positively correlated with age of the individual. 
However, there were sufficient outliers from this age correlation to suggest that other factors 
influence colonisation of the endometrium by driver carrying clones. Indeed, use of a 
generalised linear mixed effect model showed that age has a positive association with 
accumulation of driver mutations (0.035 driver mutation per year, CI95% 0.01-0.06, p = 3.31 x 
10-4) while parity has a negative association (-0.253 per life birth, CI95% -0.46 to -0.05, p = 1.33 
x 10-2) (Appendix 16); no correlation was observed with menstrual phase (Appendix 17). 
 
 Timing of driver mutations 
Constructing phylogenetic trees based on whole genome sequences of individual endometrial 
glands enabled characterisation of the mode of expansion of normal cell clones with drivers 
and timing of their initiation. Phylogenetically closely related glands were often in close 
physical proximity within the endometrium (Figure 4.11). In phylogenetic clusters for which 
the mutation catalogues were almost identical, this may simply reflect multiple sampling of a 
single tortuous gland weaving in and out of the plane of section, rather than distinct glands 
with their own stem cell populations (e.g. glands C5 and E5, Figure 4.11a, c). For other 
phylogenetic clusters, the different branches within the clade have diverged substantially, 
sometimes acquiring different driver mutations, and therefore are likely derived from 
different stem cell populations. In such instances phylogenetically related glands can range 
over distances of hundreds of microns suggesting that their clonal evolution has entailed 
capture and colonisation of extensive zones of endometrial lining (e.g. glands C1, A2, B1, H2, 
A3, B3, Figure 4.11b, d). Conversely, many glands in close physical proximity are 
phylogenetically distant (e.g. glands E1 and G2, Figure 4.11a, c), indicating that their cell 
populations have remained isolated from each other. 
Driver mutations were positioned on the phylogenetic trees of somatic mutations 
constructed for each individual and their times of occurrence were estimated by assuming 
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constant somatic mutation rates during life (Figure 4.18, 4.18and 4.20). This assumption is 
unlikely to be completely correct. However, the results indicate that mutations in normal 
endometrial cells (and particularly those attributable to SBS1 and SBS5/40) are acquired in 
more-or-less linear fashions throughout life and that potential modifying factors, including 
acquisition of a driver, make only modest differences to mutation rates. Furthermore, our 
approach is, overall, likely to overestimate the ages before which driver mutations have 
occurred because it does not account for the time taken by a single endometrial stem cell to 
colonise an individual gland, which in colorectal crypts is estimated at several years (Nicholson 
et al., 2018). The results indicate, therefore, that at least some driver mutations occur early 
in life. These included a KRAS G12D mutation in three glands from a 35 year old and a PIK3CA 
mutation in two glands from a 34 year old, which are both likely to have arisen during the first 
decade (Figures 4.11, 4.12, 4.13 and 4.18). A pair of drivers in ZFHX3 and PIK3CA, co-occurring 
in six glands from a 60 year old, were also acquired during the first decade indicating that 
driver associated clonal evolution also begins early in life (Figures 4.11 and 4.19). Indeed, it is 
possible that many more clones with drivers were initiated during the first decade, but their 
phylogenetic trees are not informative in this regard (Figures 4.19 and 4.20). Three normal 
cell clones (from 3 individuals) with a driver mutation were demonstrably initiated after age 
20 (Figure 4.19). There was evidence, however, for continuing acquisition and clonal 
expansion of driver mutations into the third and fourth decades and further accumulation 




Figure 4.18 | Timing of driver mutations in normal endometrial glands. To time driver mutations, phylogenetic 
trees were reconstructed for 25 out of the 28 donors using single nucleotide variants (SNVs). To estimate the time 
interval in which specific mutations occurred, we calculated a patient-specific mutation rate by taking the ratio 
of the patient’s mean mutation burden per endometrial gland and the patient’s age. The mutation number at 
the start and end of a branch in the phylogenetic tree was then converted to a lower and upper age by dividing 
these numbers by the estimated mutation rate. This approach relies on the assumption of a constant mutation 
rate for endometrial glands throughout a patient’s life. The same approach was used for timing indels. We timed 
driver mutations that occurred in the ‘trunks’ and branches. Here, we display driver variants that occurred in the 
‘trunks’ of the individual trees only. We show that many driver variants occur decades before the reported peak 
incidence of endometrial cancer (variants with an interval of <1 year between the upper age and the age at 
sampling were excluded from this plot for illustration purposes). Based on our calculations, four driver variants 
(KRAS G12D, PIK3CA G118D, PIK3CA E542K and ZFHX3 R715*) from three different women occurred before the 
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Figure 4.19 | Timing of all driver mutations. To time driver mutations, we used the reconstructed SNV based 
phylogenetic trees for 25 out of the 28 donors. Here, to estimate the time interval in which specific mutations 
occurred, we calculated a patient-specific mutation rate by taking the ratio of the patient’s mean mutation 
burden per endometrial gland and the patient’s age. The mutation number at the start and end of a branch 
in the phylogenetic tree was then converted to a lower and upper age by dividing these numbers by the 
estimated mutation rate. This approach relies on the assumption of a constant mutation rate for endometrial 
glands throughout a patient’s life. The same approach was used for timing indels. We timed driver mutations 
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Figure 4.20 | Timing of driver mutations using patient-based and cohort-based estimates of mutation 
rates. To estimate the time interval in which specific mutations occurred, we applied two approaches: (a) 
‘patient-based’, in which we calculated a patient-specific mutation rate by taking the ratio of the patient’s 
mean mutation burden per endometrial gland and the patient’s age; (b) ‘cohort-based’, in which mutation 
rate for each patient was derived from the linear mixed-effect model for total mutation rate that included 
data from the entire cohort. The mutation number at the start and end of a branch in the phylogenetic tree 
was then converted to a lower and upper age by dividing these numbers by the estimated mutation rate. 
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 Microbiome 
The microbiome content of the endometrium has become a hot topic in recent years. We 
examined whether there were any correlations of the microbiome and patient age, BMI and 
somatic mutations. To detect bacterial DNA sequences in the available whole-genome 
sequencing data from normal endometrial glands, read-pairs which had one or both reads 
unmapped were identified and bases with Phred quality score < 10 were removed. The 
remaining sequence was split into non-overlapping 30 bp fragments. Terminal fragments 
were processed without further splitting (30-59 bp). The obtained fragments were aligned to 
the viral GOTTCHA database (Freitas et al., 2015) at the taxonomic levels of phylum, class, 
order, family, genus, species and strain using BWA (Li and Durbin, 2010). For each endometrial 
gland sample, we also calculated unmapped and mapped read ratios which were included in 
the mixed-effect model. 
First, we looked for the presence of bacterial organisms that have been previously associated 
with endometrial cancer (Walther-Antonio et al., 2016) (Table 4.1) at a species level. 
Porphyromonas asaccharolytica was identified in two glands from two patients 
(PD37507b_EMD2_G7_A2 and PD39952b_EMD_15_G1) at a relative abundance of 0.0357 
and 0.0229 respectively. Although the species has been previously associated with 
endometrial cancer, given the fact that the two calls are only identified in one sample from 
each donor and at a relative abundance <0.05, we are hesitant to make firm conclusions 
based on these limited observations. No other endometrial cancer associated bacterial 
organisms were identified in the WGS data from the normal endometrial glands. 
Second, we examined the relative abundance of all identified bacterial genomes at the 
phylum and order levels (Figure 4.21) for each donor. Interestingly, the top three phyla 
detected in the normal endometrial glands were Proteobacteria, Actinobacteria and 
Firmicutes, all of which are known to be the most prevalent phyla in normal/”healthy” uterine 
microbiota (Baker, 2018).  
Next, to test whether there is any correlation between the relative abundance of the 
identified bacteria and the total somatic mutation burden in normal endometrium, we 
applied a linear mixed-effect model. At the phylum level, relative abundance of Firmicutes 
has a negative effect on the acquisition of somatic mutations in normal endometrium (-172 
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substitutions, p = 2 x 10-2). At the order level, there is a negative correlation between the 
relative abundance of Lactobacillales and the rate of total mutation burden (-309 
substitutions, p = 2.1 x 10-2).  This is an interesting observation and it is not yet clear what the 
underlying mechanism might be between the somatic mutation acquisition and the relative 
abundance of Lactobacillales. It may well be that this association is related to other factors 
such BMI, age and parity. Further work to explore the endometrial microbiome and its 
association with somatic mutation burden fully on a larger study with a microbiome-specific 
hypothesis and methodology, in particularly in relation to the sample collection, and strict 




Figure 4.21| Heatmap of bacterial organisms identified in normal endometrial glands. The figure 
shows summary of the identified bacterial genomes and their relative abundance in normal 




4.2.7 Summary of results in this chapter  
Using a combination of laser-capture microdissection and whole genome sequencing of 
individual endometrial glands, we show that the ‘driver’ mutations in normal cell clones are 
not only abundant in this tissue, but occur in the early decades of life, accumulate with age 
and in some women appear to colonise the entire endometrium without morphological 
evidence of neoplastic transformation. We show that parity has a ‘protective’ effect on the 
rate at which driver events occur in this tissue. Importantly, although we report a high 
prevalence of driver mutations in this tissue, genomic changes in key cancer genes, such as 
PTEN and TP53, that are usually seen in both types of endometrial cancer, are relatively 
infrequent in the normal endometrium with only five such mutations identified in the entire 
cohort. Interestingly, other types of genomic alterations (CNAs and structural variants) were 
also uncommon. Furthermore, unlike cancer, normal endometrial glands are characterised by 
relatively homogenous mutational processes with the majority of the samples showing 
primarily SBS1, SBS5 and SBS18 signatures. Together, these observations support the notion 
that cancer is a complex multi-step process and that single events, such as single base 
substitutions in cancer genes, alone do not necessarily lead to neoplastic transformation. 
A series of studies are being conducted in our group, and elsewhere, in multiple different 
normal tissues, and we are already seeing that the observed mutation patterns across sites 
are not the same. Here, we showed that the landscape of somatic mutations is different 
between endometrium and other normal tissues, such as colon. The epithelial component in 
both colon and endometrium comprises glandular structures, each containing a pool of stem 
cells within the basal compartments. Although the incidence of cancer and the rate at which 
somatic mutations occur is higher in the colon, surprisingly driver mutations have been found 
in only ~1% of crypts. PIK3CA, the second most commonly mutated gene in endometrial 
cancer, and is also the most frequently mutated cancer gene in normal endometrium and yet, 
no detectable morphological changes were seen. These findings also highlight that other 
factors, such as cell context and microenvironment, play role in the development of cancer. 
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 General discussion 
5.1 Summary of findings 
This, and other, studies of normal endometrial epithelium, together with recent studies of 
other normal cell types (Blokzijl et al., 2016, Martincorena, 2018, Martincorena et al., 2015, 
Lee-Six et al., 2018a, Lee-Six et al., 2018b, Genovese et al., 2014, Jaiswal et al., 2014, Suda et 
al., 2018, Lee-Six et al., 2019), is revealing the landscape of somatic mutations in normal 
human cells. Somatic mutations are predominantly generated by a limited repertoire of 
ubiquitous mutational processes generating base substitutions, small indels, genome 
rearrangements and whole chromosome copy number changes which exhibit more-or-less 
constant mutation rates during the course of a lifetime. Additional mutational signatures 
which are present only in some cells, only in some cell types and/or are intermittent also 
operate in some normal cells, although apparently not the endometrial epithelium, 
supplementing the mutation load contributed by ubiquitous signatures. The latter include 
exposures such as ultraviolet light in skin (Martincorena et al., 2015), APOBEC mutagenesis in 
occasional colon crypts and other signatures of unknown cause in normal colon 
epithelium(Lee-Six et al., 2019). 
 
A small subset of mutations generated by these mutational processes have the properties of 
driver mutations. Numerous cell clones with one or more drivers colonise much of the normal 
endometrial epithelium (Suda et al., 2018, Lac et al., 2019), in contrast to the colon where 
just 1% of normal crypts in middle-aged individuals carry a driver(Lee-Six et al., 2019, Suda et 
al., 2018). This marked difference in driver mutation landscape seems unlikely to be due to 
any relatively modest difference in total somatic mutation rate between endometrial and 
colonic epithelial stem cells (Blokzijl et al., 2016, Lee-Six et al., 2019, Roerink et al., 2018). 
However, it may be attributable to intrinsic differences in physiology between endometrium 
and colon. In the endometrium, the cyclical process of tissue breakdown, shedding and 
remodelling iteratively opens up denuded terrains for pioneering clones of endometrial 
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epithelial cells with drivers to preferentially colonise compared to wild type cells. By contrast, 
in the colon the selective advantage of a clone with a driver is usually confined to the small 
siloed population of a single crypt, with only occasional opportunities for further expansion. 
Thus, the endometrium, in some respects, resembles more the squamous epithelia of skin 
and oesophagus in which cell clones derived from basal cells (with or without driver 
mutations) directly compete against each other for occupancy of the squamous sheet and in 
which substantial proportions of such sheets become colonised over a lifetime by normal cell 
clones carrying driver mutations (Martincorena et al., 2015, Martincorena et al., 2018). 
Although this rampant colonisation by driver clones in endometrium progresses with age, it 
is already well advanced in some young women, and parity apparently has an inhibitory effect 
on it, indicating that multiple factors influence its progression. The effect of parity is of 
particular interest since increased parity also reduces endometrial cancer risk and it is 
plausible that this is mediated by a suppressive effect of parity on driver clone expansion (Wu 
et al., 2015). More extensive studies of the mutational landscape in normal endometrium are 
required to better assess how pregnancy, the premenarchical and postmenopausal states, 
hormonal contraceptive use and hormone replacement therapies influence it and also the 
potential impact it has on pregnancy and fertility. 
 
The burdens of all mutation classes are lower in normal endometrial cells, including those 
with drivers, than in endometrial cancers. However, these differences are most marked for 
structural variants/copy number changes and for the extreme base substitution/indel 
hypermutator phenotypes due to DNA mismatch repair deficiency and polymerase 
delta/epsilon mutations which were not found in normal endometrium. The results therefore 
indicate that in endometrial epithelium, and in other tissues thus far studied including colon, 
oesophagus and skin, normal mutation rates are sufficient to generate large numbers of 
clones with driver mutations behaving as normal cells, but that acquisition of an elevated 
mutation rate and burden is associated with further evolution to invasive cancer (Lee-Six et 
al., 2019, Martincorena et al., 2015, Martincorena, 2018). Given that the endometrial 
epithelium is extensively colonised by clones of normal cells with driver mutations in middle-
aged and older women and that the lifetime risk of endometrial cancer is only 3% (CRUK), this 
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conversion from normal cell clone with drivers to symptomatic malignancy appears to be 
extremely rare.  
 
The frequent colonisation of normal endometrial epithelium by normal cell clones with driver 
mutations provides a particular opportunity to time the onset of drivers during the lifetime 
of an individual by construction of phylogenetic trees of cell lineages based on whole genome 
sequences. The results show that the first drivers in these clones often arise relatively early 
in life, indicate that some occur within the first decade and do not exclude many more doing 
so. The modal period of diagnosis of endometrial cancer is 75-80 years. Therefore, if normal 
cell clones with drivers are progenitors of endometrial cancers, which is plausible given the 
similar repertoires of cancer genes in which the driver mutations are found, then it is 
conceivable that some neoplastic clones ultimately manifesting as cancer were initiated 
during childhood and that evolution to malignancy has taken place over much of the 
individual’s lifetime. This perspective on the long duration of neoplastic evolution of invasive 
endometrial cancer has resonance with previous observations on leukaemia (Greaves, 2005, 
Greaves, 2003) and, more recently, other solid malignancies (Mitchell et al., 2018, Anderson 
et al., 2018, Maura et al., 2018, Gerstung et al., 2018) and may therefore be a common feature 




5.2.1 Method limitations 
The low DNA input LCM workflow has been particularly impactful for when we are able to 
identify and capture clonal units, such as colonic crypts or endometrial glands in mitotically 
active tissue. Conversely, in mitotically relatively in-active tissues (brain, heart and skeletal 
muscle) or highly polyclonal tissues (liver and lung), this approach is less informative and 
requires greater read depth. These tissues would benefit from error-corrected WGS 
techniques which are currently under development and have the potential to differentiate 
between sequencing artefacts and genuine variants residing within small clones within a 
polyclonal sample. 
5.2.2 Study limitations 
Within the endometrial study, the main issue is the fact that we were restricted by the 
availability of eligible samples, which impacted our case ascertainment, specifically the age 
spectrum. In addition, the availability of the associated metadata, such as BMI and parity, was 
suboptimal reducing the power of our analyses when accounting for these variables. In our 
comparison of the mutation rate in the endometrium to other tissues, some of the possible 
limitations include differences in experimental approaches (organoid cultures and LCM-
derived material) and additional mutations that could’ve been acquired during the cell 
culture, sequencing depth and clonality and purity of the samples. 
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5.3 Work in context  
5.3.1 Relevant work published during my PhD 
During the course of our work, a study by Anglesio and colleagues showed that cancer 
associated mutations can be identified in morphologically normal, but in abnormally located 
(ectopic) endometrium. Specifically, they studied deep infiltrating endometriosis, a condition 
that almost never undergoes malignant transformation (Anglesio et al., 2017). Known cancer 
driver mutations in genes such as PIK3CA, KRAS and ARID1A were found in 5/24 patients, 
including those in their late 20s. Later, the same group studied another type of endometriosis, 
iatrogenic endometriosis, which is thought to be associated with previous surgical procedures 
(Lac et al., 2018). The results showed driver mutations in 11/40 such cases and yet these 
lesions virtually never undergo malignant transformation.  
Finally, Suda and colleagues applied targeted and whole exome sequencing approach to study 
ovarian endometriosis and concurrent normal endometrium from the same patients; they 
showed that cancer driver mutations are not only abundant in the endometriotic lesions, but 
can also be detected in the eutopic (uterine) normal endometrium without morphological 
evidence of malignancy (Suda et al., 2018).  
 
5.3.2 Early detection  
In recent years, significant efforts have been made to improve early cancer diagnosis through 
the development of techniques to screen blood and other bodily fluids for early cancer driver 
events. In this work, I show that the ‘driver’ mutations in normal endometrial epithelium are 
not only abundant, but occur in the early decades of life, accumulate with age and in some 
women appear to colonise the entire endometrium without morphological evidence of 
malignant transformation. These observations along with the recent work in other normal 
tissues, such as skin and oesophagus, have implications on our understanding of ageing and 
what constitutes ‘normal’ and force us to reconsider the rather simplistic binary distinction 
between ‘drivers’ and ‘passengers’. The findings also highlight that caution should be taken 
in the development and utilization of mutation-based early detection tools in endometrial 
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and other cancer types and  that a multi-dimensional (‘multi-omics’) approach, which would 
also incorporate methylation and transcriptomics data, should be considered to avoid false 
positive results and unnecessary diagnostic tests, overtreatment and distress. 
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5.4 Future work 
5.4.1 Endometrium expansion  
Based on our initial observation in relation to somatic mutation accumulation, I plan to study 
more endometrial glands from healthy women expanding across the age range, particularly 
at the extremes and around perimenopause.  
The expanded dataset will allow us to:  
1. Model more accurately mutational burden as a function of age and to determine 
whether the accumulation of mutations is truly linear or whether there are oestrogen-
related rate changes, for instance at puberty and menopause.  
2. Use better characterise driver landscape of peri- and post-menopausal women to 
better understand what constitutes ‘normal’ ageing and endometrial tumourigenesis. 
3. Model with greater power the effect of known epidemiological cancer risk factors, 
such as BMI, parity and hormonal therapy. 
5.4.2 Panbody completion 
The preliminary pan-body analyses on a single male donor (78 year old), which included 224 
samples across twenty five tissues have already provided first insights into the clonal 
architecture, mutational signatures and mutation burden. We have expanded this work to 
two further donors: one male (47 year old) and one female (54 year old). The additional data 
will not only validate some of our initial observations in terms of burden and signatures, but 




These preliminary normal tissue analyses have already provided an initial survey of clonal 
architecture, mutational signatures and mutation burden. More extensive studies of each 
tissue are required to investigate whether additional mutational signatures occur 
sporadically, to characterise the accumulation of mutations from each signature with age, to 
provide more comprehensive estimates of mutation burden and to extend to post-mitotic cell 
types, such as myocytes and neurones, which are not easily studied our low DNA input LCM 
approach here. The survey also indicates that small clones of cells carrying driver mutations 
are present and, given the relatively modest number of samples analysed, relatively common 
in many normal tissues. This phenomenon similarly requires more in-depth characterisation 
of the differences between tissues in the proportions of normal cells carrying drivers, the 
accumulation of driver clones in each tissue with age, and the extent to which driver 
mutations alter the parameters of clonal expansion. The results of such studies will 
collectively establish a basis for subsequent exploration of how mutational processes in vivo 
are influenced by inherited genetic background, by lifestyle, occupational and environmental 
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List of abbreviations and acronyms 
ASC  adult stem cells 
CCO   cytochrome C oxydase 
eeASCs endometrial epithelial adult stem cells 
HDP  Hierarchical Dirichlet Process 
LCM  Laser-capture microscopy 
LRCs  Label retaining cells 
NGS  next generation sequencing 
SNV  single nucleotide variant 
SV  structural variant 
TA  Transient amplifying 
TAH  total abdominal hysterectomy 
VAF  variant allele fraction 




Tissue_type Biopsy_site Structure SampleID Seq_depth 
Appendix Appendix_tip Crypt PD28690bv_APP1_F2 55.6 
Appendix Appendix_tip Crypt PD28690bv_APP1_G3 40.5 
Appendix Appendix_tip Crypt PD28690bv_APP_4_A7 35.5 
Appendix Appendix_tip Crypt PD28690bv_APP_4_A8 33.9 
Appendix Appendix_tip Crypt PD28690bv_APP_4_C7 25.2 
Appendix Appendix_mid Crypt PD28690bw_APP_3_A1 26.7 
Appendix Appendix_mid Crypt PD28690bw_APP_3_B2 25.2 
Appendix Appendix_mid Crypt PD28690bw_APP_3_C4 31.8 
Appendix Appendix_mid Crypt PD28690bw_APP_3_D1 27.6 
Appendix Appendix_mid Crypt PD28690bw_APP_3_D2 28.1 
Appendix Appendix_mid Crypt PD28690bw_APP_3_D4 32.1 
Appendix Appendix_mid Crypt PD28690bw_APP_3_D5 27.1 
Appendix Appendix_mid Crypt PD28690bw_APP_3_F2 35.2 
Appendix Appendix_mid Crypt PD28690bw_APP_3_F3 23.8 
Appendix Appendix_mid Crypt PD28690bw_APP_3_F4 26.8 
Appendix Appendix_mid Crypt PD28690bw_APP_3_G3 23.7 
Appendix Appendix_mid Crypt PD28690bw_APP_3_G4 30.3 
Appendix Appendix_mid Crypt PD28690bw_APP_3_H3 24.8 
Appendix Appendix_mid Crypt PD28690bw_APP_3_H4 27.2 
Colon Colon_transverse Crypt PD28690cc_COL_1_B11 20.9 
Colon Colon_transverse Crypt PD28690cc_COL_1_B12 15.4 
Colon Colon_transverse Crypt PD28690cc_COL_1_C11 18.9 
Colon Colon_transverse Crypt PD28690cc_COL_1_C12 15.3 
Colon Colon_transverse Crypt PD28690cc_COL_2_B8 29.9 
Colon Colon_transverse Crypt PD28690cc_COL_2_F9 24.2 
Colon Colon_transverse Crypt PD28690cc_COL_2_G8 33.1 
Colon Colon_transverse Crypt PD28690cc_COL_2_G9 25.9 
Colon Colon_transverse Crypt PD28690cc_COL_2_H8 27.5 
Colon Colon_transverse Crypt PD28690cc_COL_5_A3 51.9 
Small_intestine Jejunum Crypt PD28690bp_SB1_A9 19.3 
Small_intestine Jejunum Crypt PD28690bp_SB1_B8 38.4 
Small_intestine Jejunum Crypt PD28690bp_SB1_B9 26.6 
Small_intestine Jejunum Crypt PD28690bp_SB1_D8 27.2 
Small_intestine Jejunum Crypt PD28690bp_SB1_E9 26.9 
Small_intestine Jejunum Crypt PD28690bp_SB1_G8 17.8 
Small_intestine Jejunum Crypt PD28690bp_SB1_G9 29.0 
Small_intestine Jejunum Crypt PD28690bp_SB1_H8 15.5 
Small_intestine Jejunum Crypt PD28690bp_SB1_H9 50.6 
Small_intestine Ileum Crypt PD28690bt_SB2_A11 21.4 
Small_intestine Ileum Crypt PD28690bt_SB2_F10 23.8 
Small_intestine Ileum Crypt PD28690bt_SB2_F11 24.0 
Small_intestine Ileum Crypt PD28690bt_SB2_G10 17.5 
Small_intestine Ileum Crypt PD28690bt_SB2_H10 17.2 
Small_intestine Ileum Crypt PD28690bt_SB3_B5 19.2 
Small_intestine Ileum Crypt PD28690bt_SB3_F5 22.3 
Liver_bile_duct Liver_left_lobe Bile_duct PD28690cr_BD_3_A8 21.8 
Liver_bile_duct Liver_left_lobe Bile_duct PD28690cr_BD_3_A9 15.3 
Liver_bile_duct Liver_left_lobe Bile_duct PD28690cr_BD_3_C7 16.9 
Liver_bile_duct Liver_left_lobe Bile_duct PD28690cr_BD_3_C8 25.2 
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Liver_bile_duct Liver_right_lobe Bile_duct PD28690cx_BD_2_C1 24.9 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690da_BD_5_A1 30.3 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690da_BD_5_C1 30.2 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690da_BD_5_E1 31.1 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690db_BD_6_A2 26.2 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690db_BD_7_A3 26.1 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690db_BD_7_C3 30.3 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690di_BD_1_B2 16.1 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690dj_BD_8_C4 27.7 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690dr_BD_4_A10 31.9 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690dr_BD_4_C10 30.1 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690dr_BD_4_E10 32.7 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690dw_BD_10_A6 30.0 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690dw_BD_9_A5 33.5 
Liver_bile_duct Liver_right_lobe Bile_duct PD28690dw_BD_9_G5 30.6 
Liver_parenchyma Liver_right_lobe Liver_parenchyma PD28690di_HEP1_Z2 23.9 
Liver_parenchyma Liver_right_lobe Liver_parenchyma PD28690di_HEP2_Z1 26.2 
Liver_parenchyma Liver_right_lobe Liver_parenchyma PD28690di_HEP2_Z2 30.1 
Ureter Urothelium Urothelium PD28690ip_U_1_C5 35.0 
Ureter Urothelium Urothelium PD28690ip_U_1_A5 31.6 
Ureter Urothelium Urothelium PD28690ip_U_1_B5 30.3 
Ureter Urothelium Urothelium PD28690ip_U_1_D5 29.9 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L1_B1 26.4 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L1_B3 28.1 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L1_C2 26.8 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L1_D2 26.9 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L1_F2 28.7 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L1_G2 28.7 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L2_C3 30.6 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L2_C4 29.0 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L2_F3 31.7 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L4_B6 24.4 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L4_C6 26.5 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L4_E6 15.9 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L4_F5 28.6 
Testis Left_testis Seminiferous_tubule PD28690id_T3_L4_H5 25.2 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES1_CU1 22.9 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES1_CU2 22.7 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES2_CU1 43.1 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES2_CU2 45.6 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU1 33.9 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU2 24.2 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU3 28.0 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU4 32.7 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU5 20.5 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU6 31.7 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU7 32.9 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU8 35.4 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES4_CU1 40.4 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES4_CU2 30.1 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES4_CU3 35.9 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES4_CU5 45.4 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES4_CU6 41.3 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES5_CU3 33.1 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES5_CU4 31.8 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES5_CU5 30.1 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES5_CU7 27.5 
Oesophagus Oesophagus_upper_third Squamous_epithelium PD28690bl_OES5_CU8 34.2 
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Prostate Prostate_right_lobe Acinus PD28690fd_PA_1_A1 26.4 
Prostate Prostate_left_lobe Acinus PD28690fd_PA_1_A10 26.0 
Prostate Prostate_right_lobe Acinus PD28690fd_PA_1_A2 26.8 
Prostate Prostate_left_lobe Acinus PD28690fd_PA_1_A3 27.2 
Prostate Prostate_left_lobe Acinus PD28690fd_PA_1_A6 29.8 
Prostate Prostate_left_lobe Acinus PD28690fd_PA_1_A8 21.8 
Prostate Prostate_right_lobe Acinus PD28690fd_PA_1_C2 19.8 
Prostate Prostate_left_lobe Acinus PD28690fd_PA_1_C3 25.3 
Prostate Prostate_left_lobe Acinus PD28690fd_PA_1_C5 26.1 
Prostate Prostate_left_lobe Acinus PD28690fd_PA_1_C6 26.4 
Prostate Prostate_left_lobe Acinus PD28690fd_PA_1_E10 28.0 
Prostate Prostate_left_lobe Acinus PD28690fd_PA_1_E12 29.8 
Bronchus_epithelium Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L1_A2 35.6 
Bronchus_epithelium Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L1_C2 34.0 
Bronchus_epithelium Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L1_E1 44.2 
Bronchus_epithelium Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L1_E2 39.0 
Bronchus_epithelium Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L1_G1 31.0 
Bronchus_epithelium Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L2_A3 36.7 
Bronchus_epithelium Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L2_C3 42.7 
Bronchus_epithelium Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_A7 31.7 
Bronchus_epithelium Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_A8 36.6 
Bronchus_epithelium Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_B8 34.9 
Bronchus_epithelium Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_D9 35.0 
Bronchus_epithelium Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_G9 37.8 
Bronchus_epithelium Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_H7 41.4 
Bronchus_sero_mucous_glands Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L1_SMG1A 37.3 
Bronchus_sero_mucous_glands Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L2_SMG1D 32.9 
Bronchus_sero_mucous_glands Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L1_SMG1D 31.7 
Bronchus_sero_mucous_glands Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L1_SMG2B 30.3 
Bronchus_sero_mucous_glands Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L2_SMG1B 29.1 
Bronchus_sero_mucous_glands Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L2_SMG2A 29.0 
Bronchus_sero_mucous_glands Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L1_SMG2A 28.0 
Bronchus_sero_mucous_glands Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L2_SMG2B 17.0 
Bronchus_sero_mucous_glands Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L1_SMG1C 15.5 
Adrenal_gland_cortex Zona_fasciculata Zona_fasciculata PD28690gu_AG1_ZF_L1 40.1 
Adrenal_gland_cortex Zona_fasciculata Zona_fasciculata PD28690gu_AG1_ZF_L2 40.4 
Adrenal_gland_cortex Zona_fasciculata Zona_fasciculata PD28690gu_AG1_ZF_L3 39.5 
Adrenal_gland_cortex Zona_fasciculata Zona_fasciculata PD28690gu_AG1_ZF_L4 36.1 
Adrenal_gland_cortex Zona_fasciculata Zona_fasciculata PD28690gu_AG1_ZF_L5 39.1 
Adrenal_gland_cortex Zona_glomerulosa Zona_glomerulosa PD28690gu_AG1_ZG_L1 25.2 
Adrenal_gland_cortex Zona_glomerulosa Zona_glomerulosa PD28690gu_AG1_ZG_L2 40.4 
Adrenal_gland_cortex Zona_glomerulosa Zona_glomerulosa PD28690gu_AG1_ZG_L3 30.8 
Adrenal_gland_cortex Zona_glomerulosa Zona_glomerulosa PD28690gu_AG1_ZG_L4 36.4 
Adrenal_gland_cortex Zona_glomerulosa Zona_glomerulosa PD28690gu_AG1_ZG_L5 27.7 
Adrenal_gland_cortex Zona_reticularis Zona_reticularis PD28690gu_AG1_ZR_L1 20.7 
Adrenal_gland_cortex Zona_reticularis Zona_reticularis PD28690gu_AG1_ZR_L2 34.0 
Adrenal_gland_cortex Zona_reticularis Zona_reticularis PD28690gu_AG1_ZR_L3 35.1 
Adrenal_gland_cortex Zona_reticularis Zona_reticularis PD28690gu_AG1_ZR_L4 34.6 
Adrenal_gland_cortex Zona_reticularis Zona_reticularis PD28690gu_AG1_ZR_L5 34.6 
Periadrenal_visceral_fat Visceral_fat Visceral_fat PD28690gu_AG1_AT_L1 23.5 
Periadrenal_visceral_fat Visceral_fat Visceral_fat PD28690gu_AG1_AT_L2 27.5 
Periadrenal_visceral_fat Visceral_fat Visceral_fat PD28690gu_AG1_AT_L3 24.4 
Periadrenal_visceral_fat Visceral_fat Visceral_fat PD28690gu_AG1_AT_L4 43.4 
Periadrenal_visceral_fat Visceral_fat Visceral_fat PD28690gu_AG1_AT_L5 24.6 
Skin_sebaceous_gland Skin_lower_abdomen Skin_sebaceous_gland PD28690bf_SKN2_C2 24.2 
Skin_sebaceous_gland Skin_lower_abdomen Skin_sebaceous_gland PD28690bf_SKN2_E1 36.2 
Skin_sebaceous_gland Skin_lower_abdomen Skin_sebaceous_gland PD28690bf_SKN2_H1 33.1 
Kidney Right_kidney_superior Distal_tubule PD28690hk_KD_3_E3 26.9 
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Kidney Right_kidney_superior Glomerulus PD28690hk_KD_3_A3 26.4 
Kidney Right_kidney_superior Glomerulus PD28690hk_KD_5_G2 24.9 
Kidney Right_kidney_superior Glomerulus PD28690hk_KD_1_D1 23.8 
Kidney Right_kidney_superior Proximal_tubule PD28690hk_KD_6_A2 22.7 
Kidney Right_kidney_superior Glomerulus PD28690hk_KD_6_A4 22.7 
Kidney Right_kidney_superior Proximal_tubule PD28690hk_KD_5_H2 21.5 
Kidney Right_kidney_superior Proximal_tubule PD28690hk_KD_4_D4 21.0 
Kidney Right_kidney_superior Distal_tubule PD28690hk_KD_4_A4 18.9 
Kidney Right_kidney_superior Distal_tubule PD28690hk_KD_5_E2 18.4 
Kidney Right_kidney_superior Distal_tubule PD28690hk_KD_4_C4 18.2 
Kidney Right_kidney_superior Distal_tubule PD28690hk_KD_1_A1 18.1 
Kidney Right_kidney_superior Proximal_tubule PD28690hk_KD_1_E1 15.9 
Kidney Right_kidney_superior Distal_tubule PD28690hk_KD_6_G3 15.2 
Thyroid Thyroid_left_inferior_lobe Follicle PD28690fl_F1_2_A12 31.1 
Thyroid Thyroid_left_inferior_lobe Follicle PD28690fl_F2_2_B12 27.5 
Thyroid Thyroid_left_inferior_lobe Follicle PD28690fl_F3_2_C12 28.8 
Thyroid Thyroid_left_inferior_lobe Follicle PD28690fl_F4_2_D12 31.7 
Thyroid Thyroid_left_inferior_lobe Follicle PD28690fl_F5_2_E12 20.2 
Thyroid Thyroid_left_inferior_lobe Follicle PD28690fl_F6_2_F12 19.8 
Thyroid Thyroid_left_superior_lobe Follicle PD28690fm_F1_1_A1 61.2 
Thyroid Thyroid_left_superior_lobe Follicle PD28690fm_F1_1_A11 26.3 
Thyroid Thyroid_left_superior_lobe Follicle PD28690fm_F1_1_B1 50.7 
Thyroid Thyroid_left_superior_lobe Follicle PD28690fm_F2_1_B11 34.0 
Thyroid Thyroid_left_superior_lobe Follicle PD28690fm_F2_2_B2 32.9 
Thyroid Thyroid_left_superior_lobe Follicle PD28690fm_F3_1_C11 27.1 
Thyroid Thyroid_left_superior_lobe Follicle PD28690fm_F4_1_D11 28.7 
Thyroid Thyroid_left_superior_lobe Follicle PD28690fm_F5_1_E11 29.8 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_EW_CT_A2 31.9 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_EW_CT_D3 36.3 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_F1_1_A1 57.0 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_F1_3_E1 56.2 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_F1_4_G1 46.7 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_F1_6_G2 60.8 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_F2_3_F1 42.4 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_F2_6_H2 57.1 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_F3_1_C1 29.5 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_F3_5_F2 54.0 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_F4_1_E1 30.1 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_F5_1_A3 45.8 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_L1_CL2_C3 15.3 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_L1_CL4_G3 25.0 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_L2_CL2_C7 24.0 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_L5_CL2_G5 25.8 
Thyroid Thyroid_right_superior_lobe Follicle PD28690fq_L5_CL3_A7 19.7 
Heart Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_C10 22.0 
Heart Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_C9 27.5 
Heart Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_E10 16.6 
Heart Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_E9 29.1 
Heart Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_G10 19.1 
Heart Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_G9 29.8 
Bladder Bladder_left_wall Urothelium PD28690ch_BL2_CU1_L3_4_D11 34.7 
Bladder Bladder_left_wall Urothelium PD28690ch_BL2_CU2_L3_4_E11 34.4 
Bladder Bladder_left_wall Urothelium PD28690ch_BL2_CU3_L3_4_F11 28.9 
Bladder Bladder_right_wall Urothelium PD28690cm_BL1_CU1_L1_2_A10 39.6 
Bladder Bladder_right_wall Urothelium PD28690cm_BL1_CU2_L1_2_B10 42.4 
Bladder Bladder_right_wall Urothelium PD28690cm_BL1_CU3_L3_4_G10 31.0 
Bladder Bladder_right_wall Urothelium PD28690cm_BL1_CU4_L3_4_H10 37.2 





Sex Female Sex Male 
Age 54 Age 47 
Donor ID 11-S11 Donor ID 11-S7  
Tissue Adrenal gland Tissue Adrenal gland 
Tissue Bladder (urinary) Tissue Bladder (urinary) 
Tissue Brain, Cerebellum Tissue Brain, Cerebellum 
Tissue Breast Tissue Cecum 
Tissue Cecum Tissue Colon, ascending 
Tissue Colon Tissue Colon, descending 
Tissue Duodenum Tissue Colon, sigmoid 
Tissue Fallopian tube Tissue Colon,transversal 
Tissue Gallbladder Tissue Duodenum 
Tissue Gl Tract Tissue Esophagus 
Tissue Ileum Tissue Gallbladder 
Tissue Jejunum Tissue Ileum 
Tissue Kidney Tissue Jejunum 
Tissue Kidney, cortex Tissue Kidney 
Tissue Kidney, medulla Tissue Kidney, medulla 
Tissue Liver Tissue Liver 
Tissue Lung Tissue Lung 
Tissue Ovary Tissue Pancreas 
Tissue Pancreas Tissue Prostate 
Tissue Rectum Tissue Rectum 
Tissue Skin Tissue Salivary gland 
Tissue Stomach (fundus) Tissue Skin 
Tissue Thyroid Tissue Stomach (fundus) 
Tissue Uterus, cervix Tissue Testis 





Fixation of Frozen Tissue Sections for LCM 
Ethanol 
Add 100 ul of 70% ethanol to a single slide with unfixed frozen sections for 2-3 minutes 
Wash 2-3x with PBS (10 sec) 
Place slides into a petri dish/coplin jar with PBS until ready for staining 
Phosphate-buffered paraformaldehyde 4% 
Add 100 ul 4% phosphate-buffered paraformaldehyde (PFA) to a single slide with unfixed 
frozen sections for 5 minutes 
Wash 3x with PBS 
Place slides into a petri dish/coplin jar with PBS before staining 
Phosphate-buffered paraformaldehyde 1% 
Add 100 ul 1% phosphate-buffered paraformaldehyde (PFA) to a single slide with unfixed 
frozen sections for 5 minutes 
Wash 3x with PBS 
Place slides into a petri dish/ coplin jar with PBS before staining 
Methanol 
Add 100 ul of ice-cold methanol to a single slide with unfixed frozen sections for 2-3 minutes 
Wash 3x with PBS 
Place slides into a petri dish/coplin jar with PBS before staining 
Acetone 
Add 100 ul of ice-cold acetone to a single slide with unfixed frozen sections for 2 minutes 
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Wash 3x with PBS 
Place slides into a petri dish/coplin jar with PBS before staining 
 
Staining frozen sections with haematoxylin 
Staining should be done in a fume hood (CGP Containment level 1 lab) 
Ensure stains and alcohols have been recently changed 
Place fixed unstained tissue slides into haematoxylin for 10 seconds 
Rinse 2x with tap water 
Place the slides into 70% ethanol 2x for approximately 5 seconds 
Place the slides into 100% ethanol 2x for approximately 5 seconds 
Place the slides into xylene 1x for 5 seconds 
 
Staining frozen sections with haematoxylin and eosin 
Staining should be done in a fume hood (CGP Containment level 1 lab) 
Ensure stains and alcohols have been recently changed 
Place fixed unstained tissue slides into haematoxylin for 10 seconds 
Rinse with tap water 2x 
Place slides into eosin for 5 seconds 
Rinse with tap water 1x 
Place the slides into 70% ethanol for 5-10 seconds 
Place the slides into 100% ethanol 2x for 5-10 seconds 
Place the slides into xylene (or Neo-clear xylene substitute) for 5 seconds  
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Appendix 4 
H&E staining for LCM paraffin sections 
Staining should be done in a fume hood (CGP Containment level 1 lab) 
Remove paraffin/dewax by sequential immersion in the following: 
   Xylene – 2 min 
   Xylene – 2 min 
   Ethanol 100% – 1 min 
   Ethanol 100% – 1 min 
   Ethanol 70%   -  1 min 
   Deion – 1 min 
 Stain with Haematoxylin (Gills) and eosin 
Haematoxylin – 10-20 sec 
Tap water – 20 sec wash  
Tap water – 20 sec wash 
Eosin – 5-10 sec 
Tap water – 10-20 sec wash 
Ethanol 70% - 10-20 sec 
Ethanol 70% - 10-20 sec 
Ethanol 100% -10-20 sec 
Ethanol 100% -10-20 sec 




General Information on PAXgene 
PAXgene Tissue FIX rapidly penetrates and fixes tissue, with a fixation rate of approximately 
1 mm/30 minutes. The reagent preserves morphology and biomolecules without the 
destructive cross-linking and degradation associated with formalin fixation.  
The process includes two steps:  
1. Tissue fixation – Immersion of tissue in PAXgene Tissue FIX 
2. Tissue stabilisation and storage - PAXgene Tissue STABILIZER. Tissue samples can be 
stored in PAXgene Tissue STABILIZER for 7 days at room temperature, up to 4 weeks 
at 2-8°C and indefinitely at -20°C or -80°C. 
 
Equipment needed 
PAXgene Tissue Fix Container 
PAXgene Tissue STABILIZER  
Tissue Cassettes (for smaller biopsies) 
 
Use one of the following protocols: 
Protocol A: for storing multiple small biopsies in a Single PAXgene Tissue FIX Container.  
Protocol B: for storing a single biopsy (20 x 20 x 20 mm) in a PAXgene Tissue FIX Container. 
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Protocol A - For multiple small samples 
 
1 - Resect and cut tissue into max. 4 x 15 x 15 mm sections.  
2 - Place each section into a tissue cassette. 
3 - Place up to 4 tissue cassettes into a single PAXgene Tissue FIX Container. 
4 – Fixation at room temperature for 2 – 24 hours, depending on tissue type and size, 
assuming a fixation rate of approximately 1mm in 30 minutes. Recommended standard 
fixation time of 24 hours.  
5 – After fixation step is complete pour off the PAXgene Tissue FIX solution from the Tissue 
FIX Container and fill the container with PAXgene Tissue STABILIZER. 
7 – Transfer to -20°C or -80°C for long-term storage. 
 
Protocol B – For a single, larger tissue sample 
 
1 – Tissue sample can have max. dimensions 20 x 20 x 20 mm.  
2 - Place tissue directly into a PAXgene Tissue FIX Container. 
3 – Fixation at room temperature for 6 – 48 hours, depending on tissue type and size, 
assuming a fixation rate of approximately 1mm in 30 minutes. Recommended standard 
fixation time of 48 hours.  
4 – After fixation step is complete pour off the PAXgene Tissue FIX solution from the Tissue 
FIX Container and fill the container with PAXgene Tissue STABILIZER. 




Biopsy_site Structure SampleID Seq_depth 
Appendix_tip Crypt PD28690bv_APP1_C3 54.0 
Appendix_tip Crypt PD28690bv_APP1_F2 55.6 
Appendix_tip Crypt PD28690bv_APP1_G3 40.5 
Appendix_tip Crypt PD28690bv_APP_4_A7 35.5 
Appendix_tip Crypt PD28690bv_APP_4_A8 33.9 
Appendix_tip Crypt PD28690bv_APP_4_C7 25.2 
Appendix_mid Crypt PD28690bw_APP_3_A1 26.7 
Appendix_mid Crypt PD28690bw_APP_3_B2 25.2 
Appendix_mid Crypt PD28690bw_APP_3_C4 31.8 
Appendix_mid Crypt PD28690bw_APP_3_D1 27.6 
Appendix_mid Crypt PD28690bw_APP_3_D2 28.1 
Appendix_mid Crypt PD28690bw_APP_3_D4 32.1 
Appendix_mid Crypt PD28690bw_APP_3_D5 27.1 
Appendix_mid Crypt PD28690bw_APP_3_F2 35.2 
Appendix_mid Crypt PD28690bw_APP_3_F3 23.8 
Appendix_mid Crypt PD28690bw_APP_3_F4 26.8 
Appendix_mid Crypt PD28690bw_APP_3_G3 23.7 
Appendix_mid Crypt PD28690bw_APP_3_G4 30.3 
Appendix_mid Crypt PD28690bw_APP_3_H3 24.8 
Appendix_mid Crypt PD28690bw_APP_3_H4 27.2 
Colon_transverse Crypt PD28690cc_COL_1_B11 20.9 
Colon_transverse Crypt PD28690cc_COL_1_B12 15.4 
Colon_transverse Crypt PD28690cc_COL_1_C11 18.9 
Colon_transverse Crypt PD28690cc_COL_1_C12 15.3 
Colon_transverse Crypt PD28690cc_COL_2_B8 29.9 
Colon_transverse Crypt PD28690cc_COL_2_F9 24.2 
Colon_transverse Crypt PD28690cc_COL_2_G8 33.1 
Colon_transverse Crypt PD28690cc_COL_2_G9 25.9 
Colon_transverse Crypt PD28690cc_COL_2_H8 27.5 
Colon_transverse Crypt PD28690cc_COL_5_A3 51.9 
Jejunum Crypt PD28690bp_SB1_A9 19.3 
Jejunum Crypt PD28690bp_SB1_B8 38.4 
Jejunum Crypt PD28690bp_SB1_B9 26.6 
Jejunum Crypt PD28690bp_SB1_D8 27.2 
Jejunum Crypt PD28690bp_SB1_E9 26.9 
Jejunum Crypt PD28690bp_SB1_G8 17.8 
Jejunum Crypt PD28690bp_SB1_G9 29.0 
Jejunum Crypt PD28690bp_SB1_H8 15.5 
Jejunum Crypt PD28690bp_SB1_H9 50.6 
Ileum Crypt PD28690bt_SB2_A11 21.4 
Ileum Crypt PD28690bt_SB2_F10 23.8 
Ileum Crypt PD28690bt_SB2_F11 24.0 
Ileum Crypt PD28690bt_SB2_G10 17.5 
Ileum Crypt PD28690bt_SB2_H10 17.2 
Ileum Crypt PD28690bt_SB3_B5 19.2 
Ileum Crypt PD28690bt_SB3_F5 22.3 
Liver_left_lobe Bile_duct PD28690cr_BD_3_A8 21.8 
Liver_left_lobe Bile_duct PD28690cr_BD_3_A9 15.3 
Liver_left_lobe Bile_duct PD28690cr_BD_3_C7 16.9 
Liver_left_lobe Bile_duct PD28690cr_BD_3_C8 25.2 
Liver_right_lobe Bile_duct PD28690cx_BD_2_C1 24.9 
Liver_right_lobe Bile_duct PD28690da_BD_5_A1 30.3 
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Liver_right_lobe Bile_duct PD28690da_BD_5_C1 30.2 
Liver_right_lobe Bile_duct PD28690da_BD_5_E1 31.1 
Liver_right_lobe Bile_duct PD28690db_BD_6_A2 26.2 
Liver_right_lobe Bile_duct PD28690db_BD_7_A3 26.1 
Liver_right_lobe Bile_duct PD28690db_BD_7_C3 30.3 
Liver_right_lobe Bile_duct PD28690di_BD_1_B2 16.1 
Liver_right_lobe Bile_duct PD28690dj_BD_8_C4 27.7 
Liver_right_lobe Bile_duct PD28690dr_BD_4_A10 31.9 
Liver_right_lobe Bile_duct PD28690dr_BD_4_C10 30.1 
Liver_right_lobe Bile_duct PD28690dr_BD_4_E10 32.7 
Liver_right_lobe Bile_duct PD28690dw_BD_10_A6 30.0 
Liver_right_lobe Bile_duct PD28690dw_BD_9_A5 33.5 
Liver_right_lobe Bile_duct PD28690dw_BD_9_G5 30.6 
Liver_right_lobe Liver_parenchyma PD28690di_HEP1_Z2 23.9 
Liver_right_lobe Liver_parenchyma PD28690di_HEP2_Z1 26.2 
Liver_right_lobe Liver_parenchyma PD28690di_HEP2_Z2 30.1 
Urothelium Urothelium PD28690ip_U_1_C5 35.0 
Urothelium Urothelium PD28690ip_U_1_A5 31.6 
Urothelium Urothelium PD28690ip_U_1_B5 30.3 
Urothelium Urothelium PD28690ip_U_1_D5 29.9 
Left_testis Seminiferous_tubule PD28690id_T3_L1_B1 26.4 
Left_testis Seminiferous_tubule PD28690id_T3_L1_B3 28.1 
Left_testis Seminiferous_tubule PD28690id_T3_L1_C2 26.8 
Left_testis Seminiferous_tubule PD28690id_T3_L1_D2 26.9 
Left_testis Seminiferous_tubule PD28690id_T3_L1_F2 28.7 
Left_testis Seminiferous_tubule PD28690id_T3_L1_G2 28.7 
Left_testis Seminiferous_tubule PD28690id_T3_L2_C3 30.6 
Left_testis Seminiferous_tubule PD28690id_T3_L2_C4 29.0 
Left_testis Seminiferous_tubule PD28690id_T3_L2_F3 31.7 
Left_testis Seminiferous_tubule PD28690id_T3_L4_B6 24.4 
Left_testis Seminiferous_tubule PD28690id_T3_L4_C6 26.5 
Left_testis Seminiferous_tubule PD28690id_T3_L4_E6 15.9 
Left_testis Seminiferous_tubule PD28690id_T3_L4_F5 28.6 
Left_testis Seminiferous_tubule PD28690id_T3_L4_H5 25.2 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES1_CU1 22.9 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES1_CU2 22.7 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES2_CU1 43.1 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES2_CU2 45.6 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU1 33.9 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU2 24.2 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU3 28.0 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU4 32.7 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU5 20.5 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU6 31.7 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU7 32.9 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES3_CU8 35.4 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES4_CU1 40.4 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES4_CU2 30.1 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES4_CU3 35.9 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES4_CU5 45.4 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES4_CU6 41.3 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES5_CU3 33.1 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES5_CU4 31.8 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES5_CU5 30.1 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES5_CU7 27.5 
Oesophagus_upper_third Squamous_epithelium PD28690bl_OES5_CU8 34.2 
Prostate_right_lobe Acinus PD28690fd_PA_1_A1 26.4 
Prostate_left_lobe Acinus PD28690fd_PA_1_A10 26.0 
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Prostate_right_lobe Acinus PD28690fd_PA_1_A2 26.8 
Prostate_left_lobe Acinus PD28690fd_PA_1_A3 27.2 
Prostate_left_lobe Acinus PD28690fd_PA_1_A6 29.8 
Prostate_left_lobe Acinus PD28690fd_PA_1_A8 21.8 
Prostate_right_lobe Acinus PD28690fd_PA_1_C2 19.8 
Prostate_left_lobe Acinus PD28690fd_PA_1_C3 25.3 
Prostate_left_lobe Acinus PD28690fd_PA_1_C5 26.1 
Prostate_left_lobe Acinus PD28690fd_PA_1_C6 26.4 
Prostate_left_lobe Acinus PD28690fd_PA_1_E10 28.0 
Prostate_left_lobe Acinus PD28690fd_PA_1_E12 29.8 
Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L1_A2 35.6 
Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L1_C2 34.0 
Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L1_E1 44.2 
Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L1_E2 39.0 
Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L1_G1 31.0 
Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L2_A3 36.7 
Left_distal_bronchus Bronchial_epithelium PD28690ef_BR4_L2_C3 42.7 
Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_A7 31.7 
Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_A8 36.6 
Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_B8 34.9 
Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_D9 35.0 
Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_G9 37.8 
Right_distal_bronchus Bronchial_epithelium PD28690eh_BR5_L2_H7 41.4 
Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L1_SMG1A 37.3 
Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L2_SMG1D 32.9 
Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L1_SMG1D 31.7 
Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L1_SMG2B 30.3 
Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L2_SMG1B 29.1 
Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L2_SMG2A 29.0 
Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L1_SMG2A 28.0 
Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L2_SMG2B 17.0 
Left_distal_bronchus Sero_mucous_gland PD28690ef_BR4_L1_SMG1C 15.5 
Zona_fasciculata Zona_fasciculata PD28690gu_AG1_ZF_L1 40.1 
Zona_fasciculata Zona_fasciculata PD28690gu_AG1_ZF_L2 40.4 
Zona_fasciculata Zona_fasciculata PD28690gu_AG1_ZF_L3 39.5 
Zona_fasciculata Zona_fasciculata PD28690gu_AG1_ZF_L4 36.1 
Zona_fasciculata Zona_fasciculata PD28690gu_AG1_ZF_L5 39.1 
Zona_glomerulosa Zona_glomerulosa PD28690gu_AG1_ZG_L1 25.2 
Zona_glomerulosa Zona_glomerulosa PD28690gu_AG1_ZG_L2 40.4 
Zona_glomerulosa Zona_glomerulosa PD28690gu_AG1_ZG_L3 30.8 
Zona_glomerulosa Zona_glomerulosa PD28690gu_AG1_ZG_L4 36.4 
Zona_glomerulosa Zona_glomerulosa PD28690gu_AG1_ZG_L5 27.7 
Zona_reticularis Zona_reticularis PD28690gu_AG1_ZR_L1 20.7 
Zona_reticularis Zona_reticularis PD28690gu_AG1_ZR_L2 34.0 
Zona_reticularis Zona_reticularis PD28690gu_AG1_ZR_L3 35.1 
Zona_reticularis Zona_reticularis PD28690gu_AG1_ZR_L4 34.6 
Zona_reticularis Zona_reticularis PD28690gu_AG1_ZR_L5 34.6 
Visceral_fat Visceral_fat PD28690gu_AG1_AT_L1 23.5 
Visceral_fat Visceral_fat PD28690gu_AG1_AT_L2 27.5 
Visceral_fat Visceral_fat PD28690gu_AG1_AT_L3 24.4 
Visceral_fat Visceral_fat PD28690gu_AG1_AT_L4 43.4 
Visceral_fat Visceral_fat PD28690gu_AG1_AT_L5 24.6 
Skin_lower_abdomen Skin_sebaceous_gland PD28690bf_SKN2_C2 24.2 
Skin_lower_abdomen Skin_sebaceous_gland PD28690bf_SKN2_E1 36.2 
Skin_lower_abdomen Skin_sebaceous_gland PD28690bf_SKN2_H1 33.1 
Right_kidney_superior Distal_tubule PD28690hk_KD_3_E3 26.9 
Right_kidney_superior Glomerulus PD28690hk_KD_3_A3 26.4 
Right_kidney_superior Glomerulus PD28690hk_KD_5_G2 24.9 
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Right_kidney_superior Glomerulus PD28690hk_KD_1_D1 23.8 
Right_kidney_superior Proximal_tubule PD28690hk_KD_6_A2 22.7 
Right_kidney_superior Glomerulus PD28690hk_KD_6_A4 22.7 
Right_kidney_superior Proximal_tubule PD28690hk_KD_5_H2 21.5 
Right_kidney_superior Proximal_tubule PD28690hk_KD_4_D4 21.0 
Right_kidney_superior Distal_tubule PD28690hk_KD_4_A4 18.9 
Right_kidney_superior Distal_tubule PD28690hk_KD_5_E2 18.4 
Right_kidney_superior Distal_tubule PD28690hk_KD_4_C4 18.2 
Right_kidney_superior Distal_tubule PD28690hk_KD_1_A1 18.1 
Right_kidney_superior Proximal_tubule PD28690hk_KD_1_E1 15.9 
Right_kidney_superior Distal_tubule PD28690hk_KD_6_G3 15.2 
Thyroid_left_inferior_lobe Follicle PD28690fl_F1_2_A12 31.1 
Thyroid_left_inferior_lobe Follicle PD28690fl_F2_2_B12 27.5 
Thyroid_left_inferior_lobe Follicle PD28690fl_F3_2_C12 28.8 
Thyroid_left_inferior_lobe Follicle PD28690fl_F4_2_D12 31.7 
Thyroid_left_inferior_lobe Follicle PD28690fl_F5_2_E12 20.2 
Thyroid_left_inferior_lobe Follicle PD28690fl_F6_2_F12 19.8 
Thyroid_left_superior_lobe Follicle PD28690fm_F1_1_A1 61.2 
Thyroid_left_superior_lobe Follicle PD28690fm_F1_1_A11 26.3 
Thyroid_left_superior_lobe Follicle PD28690fm_F1_1_B1 50.7 
Thyroid_left_superior_lobe Follicle PD28690fm_F2_1_B11 34.0 
Thyroid_left_superior_lobe Follicle PD28690fm_F2_2_B2 32.9 
Thyroid_left_superior_lobe Follicle PD28690fm_F3_1_C11 27.1 
Thyroid_left_superior_lobe Follicle PD28690fm_F4_1_D11 28.7 
Thyroid_left_superior_lobe Follicle PD28690fm_F5_1_E11 29.8 
Thyroid_right_superior_lobe Follicle PD28690fq_EW_CT_A2 31.9 
Thyroid_right_superior_lobe Follicle PD28690fq_EW_CT_D3 36.3 
Thyroid_right_superior_lobe Follicle PD28690fq_F1_1_A1 57.0 
Thyroid_right_superior_lobe Follicle PD28690fq_F1_3_E1 56.2 
Thyroid_right_superior_lobe Follicle PD28690fq_F1_4_G1 46.7 
Thyroid_right_superior_lobe Follicle PD28690fq_F1_6_G2 60.8 
Thyroid_right_superior_lobe Follicle PD28690fq_F2_3_F1 42.4 
Thyroid_right_superior_lobe Follicle PD28690fq_F2_6_H2 57.1 
Thyroid_right_superior_lobe Follicle PD28690fq_F3_1_C1 29.5 
Thyroid_right_superior_lobe Follicle PD28690fq_F3_5_F2 54.0 
Thyroid_right_superior_lobe Follicle PD28690fq_F4_1_E1 30.1 
Thyroid_right_superior_lobe Follicle PD28690fq_F5_1_A3 45.8 
Thyroid_right_superior_lobe Follicle PD28690fq_L1_CL2_C3 15.3 
Thyroid_right_superior_lobe Follicle PD28690fq_L1_CL4_G3 25.0 
Thyroid_right_superior_lobe Follicle PD28690fq_L2_CL2_C7 24.0 
Thyroid_right_superior_lobe Follicle PD28690fq_L5_CL2_G5 25.8 
Thyroid_right_superior_lobe Follicle PD28690fq_L5_CL3_A7 19.7 
Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_C10 22.0 
Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_C9 27.5 
Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_E10 16.6 
Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_E9 29.1 
Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_G10 19.1 
Heart_left_ventricle Cardiac_myocytes PD28690gd_HEART_2_G9 29.8 
Bladder_left_wall Urothelium PD28690ch_BL2_CU1_L3_4_D11 34.7 
Bladder_left_wall Urothelium PD28690ch_BL2_CU2_L3_4_E11 34.4 
Bladder_left_wall Urothelium PD28690ch_BL2_CU3_L3_4_F11 28.9 
Bladder_right_wall Urothelium PD28690cm_BL1_CU1_L1_2_A10 39.6 
Bladder_right_wall Urothelium PD28690cm_BL1_CU2_L1_2_B10 42.4 
Bladder_right_wall Urothelium PD28690cm_BL1_CU3_L3_4_G10 31.0 
Bladder_right_wall Urothelium PD28690cm_BL1_CU4_L3_4_H10 37.2 





Comparison of SBS signatures using two different approaches: HDP with 65 PCAWG priors 
and NMF with Sigprofiler attribution. Final signatures from HDP with 65 priors and NMF 
extraction and attribution for selected individuals. 
NMF/SigprofilerHDP with 65 PCAWG priors 
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Composite mutational spectra of all small insertions and deletions (indels) for each 
donor. Indels were classified and composite mutational spectra for each individual were 
generated; due to the relative sparsity of indels detected, no formal signature extraction 
was performed. 
  










Modelling total mutation burden in normal
endometrium












Load in sample level data for 28 donors with associated meta-data on age, body mass index (BMI) and parity.
endom_burden <- read.csv("~/Desktop/Endometrium_for_model_26062019.csv") 
 
# Samples per patient 
endom_burden %>% group_by(PatientID) %>%  count(PatientID) %>%  rename(`Sample count` = n)
 %>% arrange(desc(`Sample count`)) %>%  kable() %>%  kable_styling(bootstrap_options = c("s




































# Look at raw data 
endom_burden %>% ggplot(aes(Age, Subs_tree, colour = PatientID)) + 
  geom_jitter(width = 0.2) + 
  theme(plot.title = element_text(size = 8)) + 
  ggtitle("Age-associated accumulation of somatic mutations in normal endometrium (substitu
tions only)") + 
  theme(plot.title = element_text(size = 14)) + theme_bw() +theme(plot.title = element_text






Fit linear mixed effects models and estimate
mutation rate per year
To account for the non-independent sampling per patient we use a linear mixed-effects model as the observed
frequencies of all substitutions approximates a normal distribution. We also use a random slope with fixed intercept
as most women will start menarche at a similar age (~13 years), but to account for the potential differences in the
rates at which mutations were acquired in different individuals due to variation in parity, contraception and other
factors.
We test features with a known affect on mutation burden or endometrial cancer risks:
Age





We use backwards elimination to define the final model






# Combine read depth and median sample depth as Vafdepth 
  endom_burden %<>%  mutate(Vafdepth = Seq_X*SampleMedianVAF) 
 
# Make BMI and Parity numeric 
  endom_burden %<>%  mutate(BMI.QC = as.numeric(BMI)) 
  endom_burden %<>%  mutate(Parity.QC = as.numeric(Parity)) 
 
# Exclude cases without Parity data 
  endom_burden.qc <- endom_burden %>% filter(!is.na(Parity.QC))   
 
# Build the full model 
 
  full_lmer_model = lmer(Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + Parity.QC +
 Cohort + (Age - 1|PatientID),  data=endom_burden, REML=F) 
   
  print(full_lmer_model)
## Linear mixed model fit by maximum likelihood  ['lmerModLmerTest'] 
## Formula:  
## Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + Parity.QC +   
##     Cohort + (Age - 1 | PatientID) 
##    Data: endom_burden 
##       AIC       BIC    logLik  deviance  df.resid  
##  3566.797  3605.836 -1772.398  3544.797       246  
## Random effects: 
##  Groups    Name Std.Dev. 
##  PatientID Age    3.651  
##  Residual       219.661  
## Number of obs: 257, groups:  PatientID, 28 
## Fixed Effects: 
##            (Intercept)                     Age                Vafdepth   
##               -280.880                  29.666                  27.855   
##          Driver_status                  BMI.QC               Parity.QC   
##                110.348                   7.572                 -16.138   
##      CohortPost-mortem               CohortTAH  CohortTransplant donor   
##                 30.250                 -56.199                 -97.972
# Drop each fixed effect 
  lme4:::drop1.merMod(full_lmer_model, test = "Chisq")
## Single term deletions 
##  
## Model: 
## Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + Parity.QC +  
##     Cohort + (Age - 1 | PatientID) 
##               Df    AIC    LRT   Pr(Chi)     
## <none>           3566.8                      
## Age            1 3611.0 46.170 1.084e-11 *** 
## Vafdepth       1 3590.9 26.116 3.215e-07 *** 
## Driver_status  1 3575.2 10.362  0.001286 **  
## BMI.QC         1 3565.2  0.436  0.509086     
## Parity.QC      1 3565.1  0.299  0.584717     
## Cohort         3 3562.8  1.979  0.576675     
## --- 






Remove feature with largest P > 0.05 to make reduced model 1
# Remove Parity from full model 
  reduced1_glmer_model <- update(full_lmer_model, ~ . -Parity.QC ) 
  anova(full_lmer_model,reduced1_glmer_model)
## Data: endom_burden 
## Models: 
## reduced1_glmer_model: Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + Cohort +  
## reduced1_glmer_model:     (Age - 1 | PatientID) 
## full_lmer_model: Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + Parity.QC +  
## full_lmer_model:     Cohort + (Age - 1 | PatientID) 
##                      Df    AIC    BIC  logLik deviance  Chisq Chi Df 
## reduced1_glmer_model 10 3565.1 3600.6 -1772.5   3545.1               
## full_lmer_model      11 3566.8 3605.8 -1772.4   3544.8 0.2987      1 
##                      Pr(>Chisq) 
## reduced1_glmer_model            
## full_lmer_model          0.5847
  print(reduced1_glmer_model)
## Linear mixed model fit by maximum likelihood  ['lmerModLmerTest'] 
## Formula: Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + Cohort +   
##     (Age - 1 | PatientID) 
##    Data: endom_burden 
##       AIC       BIC    logLik  deviance  df.resid  
##  3565.095  3600.586 -1772.548  3545.095       247  
## Random effects: 
##  Groups    Name Std.Dev. 
##  PatientID Age    3.654  
##  Residual       219.783  
## Number of obs: 257, groups:  PatientID, 28 
## Fixed Effects: 
##            (Intercept)                     Age                Vafdepth   
##               -327.209                  29.847                  28.011   
##          Driver_status                  BMI.QC       CohortPost-mortem   
##                111.647                   9.277                 -64.864   
##              CohortTAH  CohortTransplant donor   
##                -77.080                -115.590






## Single term deletions 
##  
## Model: 
## Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + Cohort +  
##     (Age - 1 | PatientID) 
##               Df    AIC    LRT   Pr(Chi)     
## <none>           3565.1                      
## Age            1 3610.2 47.111 6.707e-12 *** 
## Vafdepth       1 3589.5 26.442 2.716e-07 *** 
## Driver_status  1 3573.7 10.629  0.001113 **  
## BMI.QC         1 3563.8  0.705  0.401140     
## Cohort         3 3561.5  2.387  0.496036     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
Remove next feature with largest P > 0.05 to make reduced
model 2
# Remove Cohort from reduced model 1 
reduced2_glmer_model <- update(reduced1_glmer_model, ~ . -Cohort) 
anova(reduced1_glmer_model,reduced2_glmer_model)
## Data: endom_burden 
## Models: 
## reduced2_glmer_model: Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + (Age -  
## reduced2_glmer_model:     1 | PatientID) 
## reduced1_glmer_model: Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + Cohort +  
## reduced1_glmer_model:     (Age - 1 | PatientID) 
##                      Df    AIC    BIC  logLik deviance  Chisq Chi Df 
## reduced2_glmer_model  7 3561.5 3586.3 -1773.7   3547.5               
## reduced1_glmer_model 10 3565.1 3600.6 -1772.5   3545.1 2.3871      3 
##                      Pr(>Chisq) 
## reduced2_glmer_model            
## reduced1_glmer_model      0.496
print(reduced2_glmer_model)
## Linear mixed model fit by maximum likelihood  ['lmerModLmerTest'] 
## Formula: Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + (Age -   
##     1 | PatientID) 
##    Data: endom_burden 
##       AIC       BIC    logLik  deviance  df.resid  
##  3561.482  3586.326 -1773.741  3547.482       250  
## Random effects: 
##  Groups    Name Std.Dev. 
##  PatientID Age    3.771  
##  Residual       220.280  
## Number of obs: 257, groups:  PatientID, 28 
## Fixed Effects: 
##   (Intercept)            Age       Vafdepth  Driver_status         BMI.QC   






lme4:::drop1.merMod(reduced2_glmer_model, test = "Chisq")
## Single term deletions 
##  
## Model: 
## Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + (Age -  
##     1 | PatientID) 
##               Df    AIC    LRT   Pr(Chi)     
## <none>           3561.5                      
## Age            1 3605.6 46.093 1.128e-11 *** 
## Vafdepth       1 3587.3 27.855 1.308e-07 *** 
## Driver_status  1 3569.9 10.413  0.001251 **  
## BMI.QC         1 3560.1  0.593  0.441211     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
Remove next feature with largest P > 0.05 to make reduced
model 3
# Remove BMI information from reduced model 2 
reduced3_glmer_model <- update(reduced2_glmer_model, ~ . -BMI.QC) 
anova(reduced2_glmer_model,reduced3_glmer_model)
## Data: endom_burden 
## Models: 
## reduced3_glmer_model: Subs_tree ~ Age + Vafdepth + Driver_status + (Age - 1 | PatientID) 
## reduced2_glmer_model: Subs_tree ~ Age + Vafdepth + Driver_status + BMI.QC + (Age -  
## reduced2_glmer_model:     1 | PatientID) 
##                      Df    AIC    BIC  logLik deviance  Chisq Chi Df 
## reduced3_glmer_model  6 3560.1 3581.4 -1774.0   3548.1               
## reduced2_glmer_model  7 3561.5 3586.3 -1773.7   3547.5 0.5931      1 
##                      Pr(>Chisq) 
## reduced3_glmer_model            
## reduced2_glmer_model     0.4412
Define the final model
# Define final model keeping all features that are significant with P < 0.05 
  final_glmer_model <- reduced3_glmer_model 
 







## Linear mixed model fit by maximum likelihood . t-tests use 
##   Satterthwaite's method [lmerModLmerTest] 
## Formula:  
## Subs_tree ~ Age + Vafdepth + Driver_status + (Age - 1 | PatientID) 
##    Data: endom_burden 
##  
##      AIC      BIC   logLik deviance df.resid  
##   3560.1   3581.4  -1774.0   3548.1      251  
##  
## Scaled residuals:  
##     Min      1Q  Median      3Q     Max  
## -5.0371 -0.4099  0.0067  0.4361  3.9936  
##  
## Random effects: 
##  Groups    Name Variance Std.Dev. 
##  PatientID Age     14.78   3.845  
##  Residual       48474.42 220.169  
## Number of obs: 257, groups:  PatientID, 28 
##  
## Fixed effects: 
##               Estimate Std. Error       df t value Pr(>|t|)     
## (Intercept)   -267.398    120.757   57.039  -2.214  0.03082 *   
## Age             28.620      2.732   28.290  10.477 3.02e-11 *** 
## Vafdepth        29.028      5.266  255.958   5.513 8.61e-08 *** 
## Driver_status  109.881     33.881  249.039   3.243  0.00134 **  
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##             (Intr) Age    Vfdpth 
## Age         -0.829               
## Vafdepth    -0.543  0.081        
## Driver_stts  0.131 -0.220 -0.161
# Estimate confidence intervals using "likelihood profile" method 
  # confint.merMod(final_glmer_model, method = "profile") 
  confint.merMod(final_glmer_model, method = "Wald")
##                    2.5 %    97.5 % 
## .sig01                NA        NA 
## .sigma                NA        NA 
## (Intercept)   -504.07833 -30.71845 
## Age             23.26647  33.97419 
## Vafdepth        18.70793  39.34852 
## Driver_status   43.47519 176.28725
# Calculate mutation rates for each donor from this model













PD37506 Post-mortem  
(traumatic injury) 
19 U U 10 Pre-menopausal Undetermined 
PD40535 Transplant donor 24 24 3 7 Pre-menopausal Proliferative 
PD41871 Infertility clinic 27 30 0 17 Pre-menopausal Secretory 
PD37605 Infertility clinic 29 27 2 9 Pre-menopausal Secretory 
PD37601 Infertility clinic 31 28 0 10 Pre-menopausal Secretory 
PD41860 Infertility clinic 31 23 0 4 Pre-menopausal Secretory 
PD37607 Infertility clinic 34 24 1 19 Pre-menopausal Secretory 
PD41857 Infertility clinic 34 22 1 14 Pre-menopausal Secretory 
PD39444 Transplant donor 35 24 1 10 Pre-menopausal Proliferative 
PD41865 Infertility clinic 36 31 0 2 Pre-menopausal Secretory 
PD41868 Infertility clinic 36 23 0 6 Pre-menopausal Secretory 
PD39953 Transplant donor 37 18 2 8 Pre-menopausal Secretory 
PD41859 Infertility clinic 38 21 0 1 Pre-menopausal Secretory 
PD37613 Infertility clinic 39 22 0 11 Pre-menopausal Secretory 
PD41861 Infertility clinic 39 21 0 8 Pre-menopausal Secretory 
PD41869 Infertility clinic 40 37 0 13 Pre-menopausal Secretory 
PD37594 Infertility clinic 42 20 1 17 Pre-menopausal Secretory 
PD39952 Transplant donor 44 36 0 11 Pre-menopausal Proliferative 
PD39954 Transplant donor 44 24 1 10 Pre-menopausal Secretory 
PD37595 Infertility clinic 46 19.5 5 9 Pre-menopausal Secretory 
PD36804 Hysterectomy for 
leiomyomata 
47 30 3 13 Pre-menopausal Secretory 
PD36805 Hysterectomy for 
benign ovarian tumour 
49 27 0 7 Pre-menopausal Secretory 
PD38812 Post-mortem 
(traumatic injury) 
54 U U 2 Post-
menopausal 
Proliferative 
PD37507 Post-mortem  
(peritonitis) 
60 U U 14 Post-
menopausal 
Inactive 
PD42746 Transplant donor 67 34 2 2 Post-
menopausal 
Inactive 
PD40107 Transplant donor 69 24 2 10 Post-
menopausal 
Inactive 
PD42475 Transplant donor 74 27 2 8 Post-
menopausal 
Inactive 

































































Modelling the effect of menstrual phase on total
mutation burden and clonality












Load in sample level data for all 28 donors, but exclude post-menopausal women and women with undetermined
menstrual phase.
  endom_burden <- read.csv("Endometrium_for_model_26062019.csv", stringsAsFactors = F, na.s
trings = c("", "NA", "Unknown", "Uncertain")) 
  dim(endom_burden)
## [1] 257  25
# Make BMI and Parity numeric 
  endom_burden %<>%  mutate(BMI.QC = as.numeric(BMI)) 
  endom_burden %<>%  mutate(Parity.QC = as.numeric(Parity)) 
   
# Exclude post-menopausal women  
  endom_burden.qc <- endom_burden %>% filter(Menopause_status_num == 0)  
  dim(endom_burden.qc)
## [1] 218  27
# Exclude cases with undetermined menstrual phase 
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## [1] 208  27
 # Samples per patient 
endom_burden.qc %>% group_by(PatientID) %>%  count(PatientID) %>%  rename(`Sample count` =
 n) %>% arrange(desc(`Sample count`)) %>%  kable() %>%  kable_styling(bootstrap_options = c
























# Plot data 
endom_burden.qc %>% ggplot(aes(Age, Subs_tree, colour = PatientID)) + 
  geom_jitter(width = 0.2) + 
  theme(plot.title = element_text(size = 3)) + 
  ggtitle("Accumulation of substitutions in endometrium (pre-menopausal women only)") + 
  theme(plot.title = element_text(size = 3)) + theme_bw() +theme(plot.title = element_text
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Does menstrual phase have an effect on the total mutation burden?
To test the effect of menstrual phase on the total mutation burden we apply the final mixed-effect model with
features that have been shown to be significant in the full cohort of patients.
These significant features are:
Age
Read depth & VAF (‘Vafdepth’)
Driver mutations
# Combine read depth and median sample depth as 'Vafdepth' 
  endom_burden.qc %<>%  mutate(Vafdepth = Seq_X*SampleMedianVAF) 
 
# Total mutation burden 
  full_lmer_model1 = lmer(Subs_tree ~ Age + Vafdepth + Driver_status + Menstrual_phase_num
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## Linear mixed model fit by maximum likelihood . t-tests use 
##   Satterthwaite's method [lmerModLmerTest] 
## Formula:  
## Subs_tree ~ Age + Vafdepth + Driver_status + (Age - 1 | PatientID) 
##    Data: endom_burden.qc 
##  
##      AIC      BIC   logLik deviance df.resid  
##   2853.6   2873.6  -1420.8   2841.6      202  
##  
## Scaled residuals:  
##     Min      1Q  Median      3Q     Max  
## -3.5372 -0.4404  0.0263  0.4820  4.0069  
##  
## Random effects: 
##  Groups    Name Variance Std.Dev. 
##  PatientID Age     14.5    3.807  
##  Residual       42357.8  205.810  
## Number of obs: 208, groups:  PatientID, 22 
##  
## Fixed effects: 
##               Estimate Std. Error       df t value Pr(>|t|)     
## (Intercept)   -474.721    184.103   30.774  -2.579   0.0149 *   
## Age             36.876      4.798   23.455   7.685 7.43e-08 *** 
## Vafdepth        21.747      5.419  207.876   4.013 8.36e-05 *** 
## Driver_status  132.336     32.969  201.308   4.014 8.42e-05 *** 
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##             (Intr) Age    Vfdpth 
## Age         -0.925               
## Vafdepth    -0.338  0.018        
## Driver_stts  0.083 -0.113 -0.190
  anova(full_lmer_model1,reduced_lmer_model1)
## Data: endom_burden.qc 
## Models: 
## reduced_lmer_model1: Subs_tree ~ Age + Vafdepth + Driver_status + (Age - 1 | PatientID) 
## full_lmer_model1: Subs_tree ~ Age + Vafdepth + Driver_status + Menstrual_phase_num +  
## full_lmer_model1:     (Age - 1 | PatientID) 
##                     Df    AIC    BIC  logLik deviance  Chisq Chi Df 
## reduced_lmer_model1  6 2853.6 2873.6 -1420.8   2841.6               
## full_lmer_model1     7 2854.9 2878.2 -1420.4   2840.9 0.7026      1 
##                     Pr(>Chisq) 
## reduced_lmer_model1            
## full_lmer_model1        0.4019
Does menstrual phase have an effect on clonality?
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## Linear mixed model fit by maximum likelihood . t-tests use 
##   Satterthwaite's method [lmerModLmerTest] 
## Formula:  
## Subs_tree ~ Age + Vafdepth + Driver_status + (Age - 1 | PatientID) 
##    Data: endom_burden.qc 
##  
##      AIC      BIC   logLik deviance df.resid  
##   2853.6   2873.6  -1420.8   2841.6      202  
##  
## Scaled residuals:  
##     Min      1Q  Median      3Q     Max  
## -3.5372 -0.4404  0.0263  0.4820  4.0069  
##  
## Random effects: 
##  Groups    Name Variance Std.Dev. 
##  PatientID Age     14.5    3.807  
##  Residual       42357.8  205.810  
## Number of obs: 208, groups:  PatientID, 22 
##  
## Fixed effects: 
##               Estimate Std. Error       df t value Pr(>|t|)     
## (Intercept)   -474.721    184.103   30.774  -2.579   0.0149 *   
## Age             36.876      4.798   23.455   7.685 7.43e-08 *** 
## Vafdepth        21.747      5.419  207.876   4.013 8.36e-05 *** 
## Driver_status  132.336     32.969  201.308   4.014 8.42e-05 *** 
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##             (Intr) Age    Vfdpth 
## Age         -0.925               
## Vafdepth    -0.338  0.018        
## Driver_stts  0.083 -0.113 -0.190
  anova(full_lmer_model1,reduced_lmer_model1)
## Data: endom_burden.qc 
## Models: 
## reduced_lmer_model1: Subs_tree ~ Age + Vafdepth + Driver_status + (Age - 1 | PatientID) 
## full_lmer_model1: Subs_tree ~ Age + Vafdepth + Driver_status + Menstrual_phase_num +  
## full_lmer_model1:     (Age - 1 | PatientID) 
##                     Df    AIC    BIC  logLik deviance  Chisq Chi Df 
## reduced_lmer_model1  6 2853.6 2873.6 -1420.8   2841.6               
## full_lmer_model1     7 2854.9 2878.2 -1420.4   2840.9 0.7026      1 
##                     Pr(>Chisq) 
## reduced_lmer_model1            
## full_lmer_model1        0.4019
Does menstrual phase have an effect on clonality?
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  full_lmer_model2 = lmer(SampleMedianVAF ~ Age + Vafdepth + Driver_status + Menstrual_phas
e_num + (Age - 1|PatientID),  data=endom_burden.qc, REML=F)
## Warning in checkConv(attr(opt, "derivs"), opt$par, ctrl = control 
## $checkConv, : Model failed to converge with max|grad| = 0.0184371 (tol = 
## 0.002, component 1)
  summary(full_lmer_model2)
## Linear mixed model fit by maximum likelihood . t-tests use 
##   Satterthwaite's method [lmerModLmerTest] 
## Formula:  
## SampleMedianVAF ~ Age + Vafdepth + Driver_status + Menstrual_phase_num +   
##     (Age - 1 | PatientID) 
##    Data: endom_burden.qc 
##  
##      AIC      BIC   logLik deviance df.resid  
##   -584.8   -561.5    299.4   -598.8      201  
##  
## Scaled residuals:  
##      Min       1Q   Median       3Q      Max  
## -2.97712 -0.48971  0.05725  0.56190  2.74962  
##  
## Random effects: 
##  Groups    Name Variance  Std.Dev.  
##  PatientID Age  2.486e-07 0.0004986 
##  Residual       3.055e-03 0.0552702 
## Number of obs: 208, groups:  PatientID, 22 
##  
## Fixed effects: 
##                       Estimate Std. Error         df t value Pr(>|t|)     
## (Intercept)          2.236e-01  4.256e-02  3.449e+01   5.253 7.75e-06 *** 
## Age                  5.753e-04  8.292e-04  1.954e+01   0.694    0.496     
## Vafdepth             1.390e-02  1.365e-03  1.827e+02  10.185  < 2e-16 *** 
## Driver_status       -4.209e-03  8.558e-03  2.072e+02  -0.492    0.623     
## Menstrual_phase_num  2.068e-04  1.540e-02  2.217e+01   0.013    0.989     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##             (Intr) Age    Vfdpth Drvr_s 
## Age         -0.659                      
## Vafdepth    -0.348  0.058               
## Driver_stts  0.037 -0.162 -0.198        
## Mnstrl_phs_ -0.586 -0.083 -0.071  0.077 
## convergence code: 0 
## Model failed to converge with max|grad| = 0.0184371 (tol = 0.002, component 1)
  reduced_lmer_model2 = lmer(SampleMedianVAF ~ Age + Vafdepth + Driver_status + (Age - 1|Pa
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## Warning in checkConv(attr(opt, "derivs"), opt$par, ctrl = control 
## $checkConv, : Model failed to converge with max|grad| = 0.0180755 (tol = 
## 0.002, component 1)
  summary(reduced_lmer_model2)
## Linear mixed model fit by maximum likelihood . t-tests use 
##   Satterthwaite's method [lmerModLmerTest] 
## Formula: SampleMedianVAF ~ Age + Vafdepth + Driver_status + (Age - 1 |   
##     PatientID) 
##    Data: endom_burden.qc 
##  
##      AIC      BIC   logLik deviance df.resid  
##   -586.8   -566.8    299.4   -598.8      202  
##  
## Scaled residuals:  
##      Min       1Q   Median       3Q      Max  
## -2.97672 -0.49076  0.05746  0.56106  2.74980  
##  
## Random effects: 
##  Groups    Name Variance  Std.Dev.  
##  PatientID Age  2.486e-07 0.0004986 
##  Residual       3.055e-03 0.0552703 
## Number of obs: 208, groups:  PatientID, 22 
##  
## Fixed effects: 
##                 Estimate Std. Error         df t value Pr(>|t|)     
## (Intercept)    2.239e-01  3.448e-02  3.567e+01   6.495 1.59e-07 *** 
## Age            5.762e-04  8.264e-04  1.987e+01   0.697    0.494     
## Vafdepth       1.390e-02  1.361e-03  1.836e+02  10.212  < 2e-16 *** 
## Driver_status -4.218e-03  8.532e-03  2.063e+02  -0.494    0.622     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##             (Intr) Age    Vfdpth 
## Age         -0.876               
## Vafdepth    -0.483  0.053        
## Driver_stts  0.102 -0.157 -0.194 
## convergence code: 0 
## Model failed to converge with max|grad| = 0.0180755 (tol = 0.002, component 1)
  anova(full_lmer_model2,reduced_lmer_model2)
23/09/2019 R Notebook
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## Data: endom_burden.qc 
## Models: 
## reduced_lmer_model2: SampleMedianVAF ~ Age + Vafdepth + Driver_status + (Age - 1 |  
## reduced_lmer_model2:     PatientID) 
## full_lmer_model2: SampleMedianVAF ~ Age + Vafdepth + Driver_status + Menstrual_phase_num 
+  
## full_lmer_model2:     (Age - 1 | PatientID) 
##                     Df     AIC     BIC logLik deviance Chisq Chi Df 
## reduced_lmer_model2  6 -586.84 -566.82 299.42  -598.84              
## full_lmer_model2     7 -584.84 -561.48 299.42  -598.84 2e-04      1 
##                     Pr(>Chisq) 
## r duced_l r_model2            




SampleID Chr1 start1 end1 Chr2 start2 end2 strand1 strand2 svclass 
PD40535b_EMD_20_A11 12 120886465 120886466 12 123019772 123019773 + + deletion 
PD37601b_EMD_11_E9 18 22857100 22857101 18 22859098 22859099 - - 
tandem-
duplication 
PD37601b_EMD_11_G10 5 113338567 113338568 5 113488147 113488148 + + deletion 
PD37607b_EMD_6_E2 16 78780536 78780537 16 78824915 78824916 + + deletion 
PD39444b_EMD_14_E9 19 47148553 47148555 19 47241742 47241744 + + deletion 
PD39444b_EMD_14_E9 19 47148554 47148556 20 2795831 2795833 - - translocation 
PD39444b_EMD_14_E9 19 47241742 47241743 20 2795831 2795832 + + translocation 
PD39953b_EMD_17_C9 1 207866091 207866094 1 208150175 208150178 - - 
tandem-
duplication 
PD41861b_EMD_F11 22 29443121 29443122 X 12249093 12249094 - - translocation 
PD37594b_EMD_8_A9 3 153811859 153811860 3 153818239 153818240 - - 
tandem-
duplication 
PD37594b_EMD_8_F12 6 90123273 90123274 6 90124479 90124480 + + deletion 
PD39952b_EMD_15_C2 10 76122556 76122557 10 76164984 76164985 + + deletion 
PD39952b_EMD_15_E3 10 76122556 76122557 10 76164984 76164985 + + deletion 
PD39954b_EMD_16_E3 X 110302620 110302621 X 110304074 110304075 + + deletion 
PD39954b_EMD_16_C2 X 66635162 66635163 X 66738873 66738874 + - inversion 
PD39954b_EMD_16_E2 X 66635165 66635166 X 66738873 66738874 + - inversion 
PD39954b_EMD_16_E3 X 66635165 66635166 X 66738873 66738874 + - inversion 
PD39954b_EMD_16_G3 X 66635164 66635165 X 66738873 66738874 + - inversion 
PD37595b_EMD_9_C1 12 60041293 60041294 12 60046767 60046768 - - 
tandem-
duplication 
PD38812b_EMD_13_C5 14 69063692 69063693 14 69129713 69129714 + + deletion 
PD38812b_EMD_13_C5 7 154208554 154208555 7 154221315 154221316 + + deletion 
PD37507b_EMD_2_B5 14 87635387 87635388 14 87649060 87649061 - - 
tandem-
duplication 
PD37507b_EMD2_G7_A2 4 110760126 110760127 4 110761792 110761793 - - 
tandem-
duplication 
PD40107b_EMD_18_A1 20 22312601 22312602 20 23066262 23066263 + + deletion 
PD40107b_EMD_18_A3 9 11230240 11230242 9 11233177 11233179 + + deletion 
PD40107b_EMD_18_A3 9 11231379 11231380 9 11234244 11234245 - - 
tandem-
duplication 
PD42475b_EMD_A9 5 41940779 41940780 5 41943347 41943348 - - 
tandem-
duplication 
PD40659c_EMD_19_A1 1 15342186 15342187 12 49278653 49278654 + - translocation 
PD40659c_EMD_19_C1 1 109642333 109642334 3 37034595 37034596 + + translocation 
PD40659c_EMD_19_C1 1 109642338 109642339 3 37034579 37034580 - - translocation 
PD40659c_EMD_19_C1 3 41330863 41330865 3 56348950 56348952 + + deletion 
PD40659c_EMD_19_C1 4 24731077 24731078 5 133211928 133211929 - + translocation 
PD40659c_EMD_19_C1 4 24731078 24731079 5 133211919 133211920 + - translocation 
PD40659c_EMD_19_C1 4 54948131 54948132 4 61183815 61183816 + - inversion 
PD40659c_EMD_19_C1 4 54948132 54948133 4 61183813 61183814 - + inversion 
PD40659c_EMD_19_C1 4 135500411 135500412 5 63470404 63470405 - - translocation 
PD40659c_EMD_19_C1 7 73366851 73366852 7 73665165 73665166 + + deletion 












Copy number variants 
Age SampleID Chrom Start End 
Total copy 
number Minor allele copy number 
49 PD36805b_EM7_G2_C8 3 151924874 197908615 2 0 
60 PD37507b_EMD2_G13_A3 16 67451927 90292766 2 0 
60 PD37507b_EMD2_G20_H3 16 67347740 90292766 2 0 
44 PD39952b_EMD_15_A1 11 87268 38612664 2 0 
44 PD39952b_EMD_15_A3 20 61098 29650825 1 0 
44 PD39952b_EMD_15_C1 11 87268 38511931 2 0 
69 PD40107b_EMD_18_G2 17 49346457 81185372 2 0 
69 PD40107b_EMD_18_G4 13 62420270 115108598 4 1 
81 PD40659c_EMD_19_C1 3 41336053 56347925 1 0 
31 PD41860b_EMD_G12 11 85897571 114112013 1 0 
31 PD41860b_EMD_G12 13 19020095 115108598 1 0 
39 PD41861b_EMD_E10 20 61098 21998953 2 0 








gene_name qglobal_cv gene_name qglobal_cv gene_name qglobal_RHT gene_name qglobal_cv gene_name qglobal_cv gene_name qglobal_RHT
PIK3CA 0 PIK3CA 0 PIK3CA 0 PTEN 0 PTEN 0 PTEN 0
ARHGAP35 0 ARHGAP35 0 ARHGAP35 0 TP53 0 TP53 0 TP53 0
PIK3R1 3.64E-07 PIK3R1 3.64E-07 PIK3R1 6.69E-09 PIK3CA 0 PIK3CA 0 PIK3CA 0
FBXW7 3.90E-06 FBXW7 3.90E-06 FBXW7 7.17E-08 CTNNB1 0 CTNNB1 0 CTNNB1 0
FOXA2 0.0002395 FOXA2 0.00023946 FOXA2 4.40E-06 KRAS 0 KRAS 0 KRAS 0
KRAS 0.0013681 KRAS 2.51E-05 CTCF 0 CTCF 0 CTCF 0
PPP2R1A 0.005791 PPP2R1A 0.00010637 ARID1A 0 ARID1A 0 ARID1A 0
ZFHX3 0.0064149 ZFHX3 0.00011782 PIK3R1 0 PIK3R1 0 PIK3R1 0
CHD4 0.0091925 CHD4 0.00016884 FBXW7 4.46E-06 FBXW7 4.46E-06 FBXW7 8.19E-08
ERBB2 0.00584202 ARHGAP35 6.29E-06 ARHGAP35 6.29E-06 ARHGAP35 1.16E-07
SPOP 0.00657231 ARID5B 8.81E-06 ARID5B 8.81E-06 ARID5B 1.62E-07
ERBB3 0.01518232 ZFHX3 9.43E-06 ZFHX3 9.43E-06 ZFHX3 1.73E-07
SPOP 1.07E-05 SPOP 1.07E-05 SPOP 1.97E-07
FOXA2 0.00011264 FOXA2 0.00011264 FOXA2 2.07E-06
PPP2R1A 0.00012485 PPP2R1A 0.00012485 PPP2R1A 2.29E-06
FGFR2 0.0001309 FGFR2 0.0001309 FGFR2 2.40E-06
RNF43 0.00202553 RNF43 3.72E-05
CHD4 0.00326925 CHD4 6.00E-05



















Whole exome, q<0.01 Whole exome, q<0.001 RHT, q<0.05
Normal endometrium
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Modelling driver mutation burden in normal
endometrium










Load in data files
Load in sample level data for the 28 donors with associated meta-data, including Body Mass Index (BMI), Parity and
Cohort (sample source).
endom_burden <- read.csv("Endometrium_for_model_26062019.csv", stringsAsFactors = F, na.str
ings = c("", "NA", "Unknown", "Uncertain")) 
# Samples per patient 
endom_burden %>% group_by(PatientID) %>%  count(PatientID) %>%  rename(`Sample count` = n)
 %>% arrange(desc(`Sample count`)) %>%  kable() %>%  kable_styling(bootstrap_options = c("s




































# Look at the raw data 
  endom_burden %>% ggplot(aes(Age, Total_drivers, colour = PatientID)) + 
  geom_jitter() + 
  theme(plot.title = element_text(size = 8)) + 
  ggtitle("Age-associated accumulation of driver mutations in normal human endometrium") + 
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Fit a mixed-effect model to estimate driver mutation
rates
To account for the non-independent sampling per patient we use a generalized linear mixed effects model with
Poisson distribution. We also use a random slope with fixed intercept as most women will start menarche at a similar
age (~13 years), but to account for the potential differences in the rates at which mutations were acquired in different
individuals due to variation in parity, contraception and other factors.
We test features that can have an effect on mutation burden or are modulate endometrial cancer risk:
Age




We use backwards elimination to define the final model
Define full model and drop each fixed effect in turn
23/09/2019 R Notebook
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# Combine read depth and median sample depth (Seq_X) as 'Vafdepth' 
  endom_burden %<>%  mutate(Vafdepth = Seq_X*SampleMedianVAF) 
 
# Make BMI and Parity numeric 
  endom_burden %<>%  mutate(BMI.QC = as.numeric(BMI)) 
  endom_burden %<>%  mutate(Parity.QC = as.numeric(Parity)) 
   
# Exclude cases without Parity data 
  endom_burden.qc <- endom_burden %>% filter(!is.na(Parity.QC))  
   
# Define the full model containing all features 
  full_glmer_model = glmer(Total_drivers ~ Age + Vafdepth + BMI.QC + Parity.QC + Cohort +(A
ge - 1|PatientID), data=endom_burden.qc, family = poisson(link = "log"), control =   glmerC
ontrol(optimizer="bobyqa", optCtrl = list(maxfun = 100000))) 
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## Generalized linear mixed model fit by maximum likelihood (Laplace 
##   Approximation) [glmerMod] 
##  Family: poisson  ( log ) 
## Formula: Total_drivers ~ Age + Vafdepth + BMI.QC + Parity.QC + Cohort +   
##     (Age - 1 | PatientID) 
##    Data: endom_burden.qc 
## Control:  
## glmerControl(optimizer = "bobyqa", optCtrl = list(maxfun = 1e+05)) 
##  
##      AIC      BIC   logLik deviance df.resid  
##    483.6    514.6   -232.8    465.6      222  
##  
## Scaled residuals:  
##     Min      1Q  Median      3Q     Max  
## -1.2757 -0.7002 -0.1361  0.5323  2.0615  
##  
## Random effects: 
##  Groups    Name Variance  Std.Dev. 
##  PatientID Age  4.832e-05 0.006951 
## Number of obs: 231, groups:  PatientID, 25 
##  
## Fixed effects: 
##                         Estimate Std. Error z value Pr(>|z|)    
## (Intercept)            -1.937221   0.728279  -2.660  0.00781 ** 
## Age                     0.031603   0.011826   2.672  0.00753 ** 
## Vafdepth                0.044643   0.028273   1.579  0.11434    
## BMI.QC                 -0.006626   0.023231  -0.285  0.77547    
## Parity.QC              -0.259493   0.113226  -2.292  0.02192 *  
## CohortPost-mortem       0.242012   0.917639   0.264  0.79199    
## CohortTAH               0.153797   0.424937   0.362  0.71741    
## CohortTransplant donor  0.304985   0.280186   1.089  0.27637    
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##             (Intr) Age    Vfdpth BMI.QC Prt.QC ChrtP- ChrTAH 
## Age         -0.493                                           
## Vafdepth    -0.311  0.087                                    
## BMI.QC      -0.626 -0.136 -0.275                             
## Parity.QC   -0.271 -0.211 -0.003  0.371                      
## ChrtPst-mrt  0.300 -0.502  0.000 -0.013 -0.264               
## CohortTAH    0.243 -0.275  0.115 -0.225 -0.197  0.281        
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# "user" parametric boot function as defined in drop1.merMod help example 
  PBSumFun <- function(object, objectDrop, ...) { 
    pbnames <- c("stat", "p.value") 
    r <- if (missing(objectDrop)) { 
      setNames(rep(NA, length(pbnames)), pbnames) 
    } else { 
      pbtest <- PBmodcomp(object, objectDrop, nsim = nsim, ref = NULL, seed=12345, details
 = 0) 
      unlist(pbtest$test[2, pbnames]) 
    } 
    attr(r, "method") <- c("Parametric bootstrap via pbkrtest package") 
    r 
  } 
# Drop each fixed effect from model and test significance
# Use 1000 samples to form the reference distribution 
nsim <- 1000 
drop1(full_glmer_model, test = "user", sumFun = PBSumFun)
## Single term deletions 
##  
## Model: 
## Total_drivers ~ Age + Vafdepth + BMI.QC + Parity.QC + Cohort +  
##     (Age - 1 | PatientID) 
## Method:  
## Parametric bootstrap via pbkrtest package 
##  
##  
##             stat p.value 
## <none>                   
## Age       6.7178 0.05277 
## Vafdepth  2.4586 0.14317 
## BMI.QC    0.0821 0.83577 
## Parity.QC 5.3143 0.08761 
## Cohort    1.1445 0.85466
Remove feature with the largest P > 0.05 to make reduced model
1
# Remove Cohort from the full model 
  reduced1_glmer_model <- update(full_glmer_model, ~ . -Cohort, control=glmerControl(optimi
zer="bobyqa", optCtrl = list(maxfun = 100000))) 
# Drop each fixed effect from the model and test significance 
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## Single term deletions 
##  
## Model: 
## Total_drivers ~ Age + Vafdepth + BMI.QC + Parity.QC + (Age -  
##     1 | PatientID) 
## Method:  
## Parametric bootstrap via pbkrtest package 
##  
##  
##              stat p.value 
## <none>                    
## Age       10.8137 0.00326 
## Vafdepth   2.3500 0.13436 
## BMI.QC     0.0160 0.91478 
## Parity.QC  4.7712 0.06361
Remove next feature with the largest P > 0.05 to make reduced
model 2
# Remove BMI from the above model 
  reduced2_glmer_model <- update(reduced1_glmer_model, ~ . -BMI.QC, control=glmerControl(op
timizer="bobyqa", optCtrl = list(maxfun = 100000))) 
# Drop each fixed effect from the model and test significance 
  drop1(reduced2_glmer_model, test = "user", sumFun = PBSumFun)
## Single term deletions 
##  
## Model: 
## Total_drivers ~ Age + Vafdepth + Parity.QC + (Age - 1 | PatientID) 
## Method:  
## Parametric bootstrap via pbkrtest package 
##  
##  
##              stat  p.value 
## <none>                     
## Age       10.8621 0.002105 
## Vafdepth   2.4033 0.137539 
## Parity.QC  5.0721 0.037190
Remove next feature with the largest P > 0.05 to make reduced
model 3
# Remove Vafdepth from the above model 
  reduced3_glmer_model <- update(reduced2_glmer_model, ~ . -Vafdepth, control=glmerControl
(optimizer="bobyqa", optCtrl = list(maxfun = 100000))) 
# Drop each fixed effect from model and test significance 
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## Single term deletions 
##  
## Model: 
## Total_drivers ~ Age + Parity.QC + (Age - 1 | PatientID) 
## Method:  
## Parametric bootstrap via pbkrtest package 
##  
##  
##              stat  p.value 
## <none>                     
## Age       10.3793 0.003125 
## Parity.QC  5.8943 0.019348
Define the final model
# Define the final model keeping only the significant features  (P < 0.05) 
   
  final_glmer_model <- reduced3_glmer_model 
 
# Print summary for the final model  
  print(summary(final_glmer_model))
## Generalized linear mixed model fit by maximum likelihood (Laplace 
##   Approximation) [glmerMod] 
##  Family: poisson  ( log ) 
## Formula: Total_drivers ~ Age + Parity.QC + (Age - 1 | PatientID) 
##    Data: endom_burden.qc 
## Control:  
## glmerControl(optimizer = "bobyqa", optCtrl = list(maxfun = 1e+05)) 
##  
##      AIC      BIC   logLik deviance df.resid  
##    477.1    490.9   -234.6    469.1      227  
##  
## Scaled residuals:  
##     Min      1Q  Median      3Q     Max  
## -1.2451 -0.6912 -0.1927  0.6225  2.0057  
##  
## Random effects: 
##  Groups    Name Variance  Std.Dev. 
##  PatientID Age  5.987e-05 0.007738 
## Number of obs: 231, groups:  PatientID, 25 
##  
## Fixed effects: 
##              Estimate Std. Error z value Pr(>|z|)     
## (Intercept) -1.643601   0.391387  -4.199 2.68e-05 *** 
## Age          0.035460   0.009878   3.590 0.000331 *** 
## Parity.QC   -0.253115   0.102227  -2.476 0.013285 *   
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##           (Intr) Age    
## Age       -0.930        
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# Estimate confidence intervals using "likelihood profile" method 
  confint.merMod(final_glmer_model, method = "profile")
## Computing profile confidence intervals ...
##                    2.5 %      97.5 % 
## .sig01       0.002577037  0.01361534 
## (Intercept) -2.493282376 -0.87980304 
## Age          0.015388799  0.05650318 











Modelling the effect of menstrual phase on driver
mutation burden











Load in sample level data for all 28 donors, but exclude post-menopausal women and women with undetermined
menstrual phase.
  endom_burden <- read.csv("Endometrium_for_model_26062019.csv", stringsAsFactors = F, na.s
trings = c("", "NA", "Unknown", "Uncertain")) 
  dim(endom_burden)
## [1] 257  25
# Make BMI and Parity numeric 
  endom_burden %<>%  mutate(BMI.QC = as.numeric(BMI)) 
  endom_burden %<>%  mutate(Parity.QC = as.numeric(Parity)) 
   
# Exclude post-menopausal women  
  endom_burden.qc <- endom_burden %>% filter(Menopause_status_num == 0)  
  dim(endom_burden.qc)
## [1] 218  27
# Exclude cases with undetermined menstrual phase 
  endom_burden.qc <- endom_burden.qc %>% filter(Menstrual_phase_num >0) 
  dim(endom_burden.qc)
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# Remove samples with no Parity information 
  endom_burden.qc %<>% filter(!is.na(BMI.QC), !is.na(Parity.QC)) 
  dim(endom_burden.qc)
## [1] 206  27
 # Samples per patient 
endom_burden.qc %>% group_by(PatientID) %>%  count(PatientID) %>%  rename(`Sample count` =
 n) %>% arrange(desc(`Sample count`)) %>%  kable() %>%  kable_styling(bootstrap_options = c
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# Look at the raw data 
  endom_burden.qc %>% ggplot(aes(Age, Total_drivers, colour = PatientID)) + 
  geom_jitter() + 
  theme(plot.title = element_text(size = 8)) + 
  ggtitle("Driver mutations in normal endometrium (pre-menopausal women only)") + 
  theme(plot.title = element_text(size = 14)) + theme_bw() +theme(plot.title = element_text
(hjust = 0.5))
Does menstrual phase have an effect on the driver mutation burden?
To test the effect of menstrual phase on the driver mutation burden we add Menstrual phase to the final generalized
linear mixed-effects model with Poisson distribution with features that have been shown to be significant in the full
cohort of patients.
The significant features are:
Age
Read depth & VAF (‘Vafdepth’)
Parity
We use backwards elimination to define the final model
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# Combine read depth and median sample depth (Seq_X) as 'Vafdepth' 
  endom_burden.qc %<>%  mutate(Vafdepth = Seq_X*SampleMedianVAF) 
 
# Make BMI and Parity numeric 
  endom_burden.qc %<>%  mutate(BMI.QC = as.numeric(BMI)) 
  endom_burden.qc %<>%  mutate(Parity.QC = as.numeric(Parity)) 
   
# Define the full model containing all features 
  full_glmer_model = glmer(Total_drivers ~ Age + Parity.QC + Menstrual_phase_num +(Age - 1|
PatientID), data=endom_burden.qc, family = poisson(link = "log"), control =   glmerControl
(optimizer="bobyqa", optCtrl = list(maxfun = 100000))) 
   
  print(summary(full_glmer_model))
## Generalized linear mixed model fit by maximum likelihood (Laplace 
##   Approximation) [glmerMod] 
##  Family: poisson  ( log ) 
## Formula: Total_drivers ~ Age + Parity.QC + Menstrual_phase_num + (Age -   
##     1 | PatientID) 
##    Data: endom_burden.qc 
## Control:  
## glmerControl(optimizer = "bobyqa", optCtrl = list(maxfun = 1e+05)) 
##  
##      AIC      BIC   logLik deviance df.resid  
##    403.8    420.4   -196.9    393.8      201  
##  
## Scaled residuals:  
##     Min      1Q  Median      3Q     Max  
## -1.0933 -0.6763 -0.5314  0.6787  2.0963  
##  
## Random effects: 
##  Groups    Name Variance  Std.Dev. 
##  PatientID Age  7.543e-05 0.008685 
## Number of obs: 206, groups:  PatientID, 21 
##  
## Fixed effects: 
##                     Estimate Std. Error z value Pr(>|z|)   
## (Intercept)         -0.97608    0.95243  -1.025   0.3054   
## Age                  0.04002    0.01914   2.091   0.0366 * 
## Parity.QC           -0.24689    0.10749  -2.297   0.0216 * 
## Menstrual_phase_num -0.46049    0.32828  -1.403   0.1607   
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##             (Intr) Age    Prt.QC 
## Age         -0.751               
## Parity.QC   -0.031 -0.101        
## Mnstrl_phs_ -0.649  0.011  0.024 
## convergence code: 0 
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# "user" parametric boot function as defined in drop1.merMod help example 
  PBSumFun <- function(object, objectDrop, ...) { 
    pbnames <- c("stat", "p.value") 
    r <- if (missing(objectDrop)) { 
      setNames(rep(NA, length(pbnames)), pbnames) 
    } else { 
      pbtest <- PBmodcomp(object, objectDrop, nsim = nsim, ref = NULL, seed=12345, details
 = 0) 
      unlist(pbtest$test[2, pbnames]) 
    } 
    attr(r, "method") <- c("Parametric bootstrap via pbkrtest package") 
    r 
  } 
# Drop each fixed effect from model and test significance
# Use 1000 samples to form the reference distribution 
nsim <- 1000 
drop1(full_glmer_model, test = "user", sumFun = PBSumFun)
## Single term deletions 
##  
## Model: 
## Total_drivers ~ Age + Parity.QC + Menstrual_phase_num + (Age -  
##     1 | PatientID) 
## Method:  
## Parametric bootstrap via pbkrtest package 
##  
##  
##                       stat  p.value 
## <none>                              
## Age                 4.2999 0.056701 
## Parity.QC           5.1460 0.048857 
## Menstrual_phase_num 1.7141 0.260549
Remove feature with the largest P > 0.05 to make reduced model
# Remove Menstrual phase from the full model 
  reduced_glmer_model <- update(full_glmer_model, ~ . -Menstrual_phase_num, control=glmerCo
ntrol(optimizer="bobyqa", optCtrl = list(maxfun = 100000))) 
# Drop each fixed effect from the model and test significance 
  drop1(reduced_glmer_model, test = "user", sumFun = PBSumFun)
## Single term deletions 
##  
## Model: 
## Total_drivers ~ Age + Parity.QC + (Age - 1 | PatientID) 
## Method:  
## Parametric bootstrap via pbkrtest package 
##  
##  
##             stat  p.value 
## <none>                    
## Age       3.8150 0.067708 
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Define the final model
# Define the final model keeping only the significant features  (P < 0.05) 
  final_glmer_model <- reduced_glmer_model 
 
# Print summary for the final model  
  print(summary(final_glmer_model))
## Generalized linear mixed model fit by maximum likelihood (Laplace 
##   Approximation) [glmerMod] 
##  Family: poisson  ( log ) 
## Formula: Total_drivers ~ Age + Parity.QC + (Age - 1 | PatientID) 
##    Data: endom_burden.qc 
## Control:  
## glmerControl(optimizer = "bobyqa", optCtrl = list(maxfun = 1e+05)) 
##  
##      AIC      BIC   logLik deviance df.resid  
##    403.5    416.8   -197.8    395.5      202  
##  
## Scaled residuals:  
##     Min      1Q  Median      3Q     Max  
## -1.1113 -0.6955 -0.4384  0.6488  2.1040  
##  
## Random effects: 
##  Groups    Name Variance  Std.Dev. 
##  PatientID Age  9.975e-05 0.009987 
## Number of obs: 206, groups:  PatientID, 21 
##  
## Fixed effects: 
##             Estimate Std. Error z value Pr(>|z|)   
## (Intercept) -1.87925    0.77163  -2.435   0.0149 * 
## Age          0.04092    0.02062   1.985   0.0471 * 
## Parity.QC   -0.24412    0.11431  -2.136   0.0327 * 
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
##  
## Correlation of Fixed Effects: 
##           (Intr) Age    
## Age       -0.978        
## Parity.QC  0.024 -0.145
# Estimate confidence intervals using "likelihood profile" method 
  confint.merMod(final_glmer_model, method = "profile")
## Computing profile confidence intervals ...
##                     2.5 %      97.5 % 
## .sig01       0.0049871530  0.01716773 
## (Intercept) -3.5142119925 -0.37232360 
## Age         -0.0001535045  0.08423708 
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The mutational landscape of normal human 
endometrial epithelium
Luiza Moore1,2, Daniel Leongamornlert1, Tim H. H. Coorens1, Mathijs A. Sanders1,3, Peter Ellis1,4, 
Stefan C. Dentro1,5, Kevin J. Dawson1, Tim Butler1, Raheleh Rahbari1, Thomas J. Mitchell1, 
Francesco Maura1,6, Jyoti Nangalia1, Patrick S. Tarpey1, Simon F. Brunner1, Henry Lee-Six1, 
Yvette Hooks1, Sarah Moody1, Krishnaa T. Mahbubani7,8,9, Mercedes Jimenez-Linan2,  
Jan J. Brosens10, Christine A. Iacobuzio-Donahue11,12, Inigo Martincorena1,  
Kourosh Saeb-Parsy7,8, Peter J. Campbell1 & Michael R. Stratton1 ✉
All normal somatic cells are thought to acquire mutations, but understanding of the 
rates, patterns, causes and consequences of somatic mutations in normal cells is 
limited. The uterine endometrium adopts multiple physiological states over a lifetime 
and is lined by a gland-forming epithelium1,2. Here, using whole-genome sequencing, 
we show that normal human endometrial glands are clonal cell populations with total 
mutation burdens that increase at about 29 base substitutions per year and that are 
many-fold lower than those of endometrial cancers. Normal endometrial glands 
frequently carry ‘driver’ mutations in cancer genes, the burden of which increases 
with age and decreases with parity. Cell clones with drivers often originate during the 
first decades of life and subsequently progressively colonize the epithelial lining of 
the endometrium. Our results show that mutational landscapes differ markedly 
between normal tissues—perhaps shaped by differences in their structure and 
physiology—and indicate that the procession of neoplastic change that leads to 
endometrial cancer is initiated early in life.
Acquisition of mutations is a ubiquitous feature of cells in living 
organisms. Although there has been comprehensive characterization 
of the somatic mutation landscape of human cancer3–5, knowledge of 
the patterns of somatic mutation in normal cells is limited. This has 
mainly been due to the challenge of detecting somatic mutations in 
normal tissues. Several strategies have recently been developed to 
address this, including the sequencing of in vitro-derived cell clones 
from normal tissues6–8, the sequencing of small biopsies that contain 
limited numbers of microscopic clones9–12, the sequencing of micro-
scopically distinguishable structural elements that are clonal units13–15, 
highly error-corrected sequencing16,17 and the sequencing of single 
cells18. Together, these approaches have begun to reveal differing 
mutation burdens between cell types, the patterns of acquisition of 
mutation burdens over time and the underlying mutational processes. 
These strategies have also shown that clones of normal cells with driver 
mutations in cancer genes are present in normal tissues. In the glan-
dular epithelium of the colon, these mutations are relatively uncom-
mon14—but in the squamous epithelia of the skin9 and oesophagus10, 
and in the blood19–21, clones that carry drivers can constitute substantial 
proportions of the normal cells present after middle age.
The factors that determine differences in the mutation landscape 
between normal cell types are incompletely understood. However, 
these factors plausibly include the intrinsic structural and physiologi-
cal features of each tissue. The endometrium is a uniquely dynamic 
tissue composed of a stromal cell layer invaginated by a contiguous 
glandular epithelial sheet that covers the luminal surface. Endometrium 
adopts multiple different physiological states during life, including 
in premenarche, menstrual cycling, pregnancy and postmenopause. 
During reproductive years, the endometrium undergoes cyclical break-
down, shedding, repair and remodelling in response to oscillating levels 
of oestrogen and progesterone, which together entail the iterative 
restoration of the contiguity of the interrupted glandular epithelial 
sheet that is effected by stem cells within basal glands retained after 
menstruation1,2,22.
The characterization of the mutational landscapes of normal tis-
sues is advancing our understanding of the succession of intermediate 
neoplastic stages between normal cells and the cancers that originate 
from them. Endometrial cancer is the most common gynaecological 
tumour in high-income countries, with a peak incidence at 75–80 years 
of age23. There are two major histological classes24,25. Type I, endome-
trioid carcinoma, is the more common of the two; the main known 
risk factor is oestrogen exposure, influenced by ages of menarche and 
menopause, and body mass index24,26. Type II, which includes serous 
and clear cell carcinomas, occurs in older women, with smoking and 
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body mass index as risk factors 27. Commonly mutated cancer genes 
include PTEN , TP53 , PIK3CA , KRAS , ARID1A , FBXW7  and PIK3R1 28, and 
subsets of endometrial cancer carry many base substitution and/or 
small insertion and deletion (indel) mutations due to defective DNA 
mismatch repair or polymerase proof-reading mutations, or many 
copy number changes and genome rearrangement 29.
Recent studies using targeted sequencing have revealed driver muta -
tions in known cancer genes in a high proportion of endometrial glands 
in endometriosis 13,30 ,31 and eutopic normal endometrial epithelium 13,32. 
Here, by whole-genome sequencing of individual glands, we compre -
hensively characterize the mutational landscape of normal endometrial 
epithelium, explore the influences of age and parity, and estimate the 
timing of driver mutations.
Samples and sequencing
-
whole-genome sequenced using a protocol that accommodates small 
amounts of input DNA 14. The mean sequencing coverage was 28-fold; 
only samples with >15-fold coverage were included in subsequent analy -
ses ( n
gland were determined by comparison with whole-genome sequences 
from other tissues from the same individuals.
Clonality of endometrial glands
To assess whether endometrial glands comprise clonal cell populations, 
we examined the variant allele fractions (VAFs) of somatic mutations. 
Ninety-one per cent (234 out of 257) of microdissected endometrial 
glands showed distributions of VAFs with peaks between 0.3 and 0.5 
1  
predominantly of a cell population that is descended from a single 
epithelial progenitor stem cell (a formal clonality analysis is described 
 
analyses (described in ‘Driver mutations’) revealed that many  
endometrial glands carry driver mutations in known cancer genes. 
However, endometrial glands exhibited clonality irrespective of the 
-
ants of single endometrial epithelial stem cells is not contingent on a  
selective growth advantage provided by driver mutations, and may 
occur by a process analogous to genetic drift (as previously proposed 
for other tissues 33,34).
Mutation burdens and signatures
Somatic mutation burdens in normal endometrial glands from the 
2a, b ). This variation was 
per gland per year being acquired during adult life (linear mixed-effect 








     An endometrial gland
laser-capture microdissected
VAF V AF VAF V AF
0 0.25 0.50 0.75 1.00 0 0.25 0.50 0.75 1.00 0 0.25 0.50 0.75 1.00 0 0.25 0.50 0.75 1.00
PD41868 (n = 6) PD41865 (n = 2) PD41869 (n = 13) PD41871 (n = 17)
PD41857 (n = 14) PD41859 (n = 1) PD41860 (n = 4) PD41861 (n = 8)
PD40535 (n = 7) PD40659 (n = 5) PD42475 (n = 8) PD42746 (n = 2)
PD39952 (n = 11) PD39953 (n = 8) PD39954 (n = 10) PD40107 (n = 10)
PD37594 (n = 17) PD37601 (n = 10) PD38812 (n = 2) PD39444 (n = 10)
PD37605 (n = 9) PD37613 (n = 11) PD37607 (n = 19) PD37595 (n = 9)
PD36804 (n = 13) PD36805 (n = 7) PD37506 (n = 10) PD37507 (n = 14)
Fig. 1 | Clonality of normal endometrial glands.  Individual normal 
endometrial glands were laser-capture microdissected and whole-genome 
populations with a median VAF between 0.3 and 0.5 for base substitutions. 
Each density line represents an endometrial gland sample; individual samples 
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43–177, P −3). There was no obvious correlation between parity 
and total somatic mutation burden.
We identified five previously described single-base-substitution 
-
ably due to spontaneous deamination of 5-methylcytosine; SBS5 and 
SBS40, two relatively featureless ‘flat’ signatures of uncertain cause; 
-
sibly due to reactive oxygen species 35; and SBS23, a signature predomi -
SBS5 and SBS40 are relatively featureless, it is challenging to estimate 
their separate contributions 4 and they have therefore been combined  
(designated SBS5/40) (but shown separately in Supplementary 
cancers with high mutation burdens. Given the low mutation burden 
and small contribution of SBS23 in the data reported here, it is unclear 
whether this is the same signature and so SBS23 was included in the 
‘unattributable’ category. The mean signature exposures were 0.23 for 
SBS1, 0.58 for SBS5/40 and 0.12 for SBS18. There were positive linear 
correlations with age for the mutation burdens attributable to each 
2d–f ). To ascertain the periods during  
which different mutational processes operate, we constructed phyloge -
netic trees of endometrial glands for each individual, which indicated 
that the mutational processes that underlie these three signatures  
3, 4  
to small indels, single T insertions at runs of T bases were the most com -
Somatic copy-number changes and structural variants were found 
-
duplications and 9 translocations). One of three glands carrying a TP53  
mutation exhibited nine structural variants, indicating that genomic 
instability caused by defective DNA maintenance occurs in normal cells.
Driver mutations
To identify genes under positive selection, we used a statistical method 
based on the observed:expected ratios of nonsynonymous:synonymous 
mutations 28. Twelve genes showed evidence of positive selection 
PIK3CA , PIK3R1 , ARHGAP35 , 
FBXW7 , ZFHX3 , FOXA2 , ERBB2 , CHD4 , KRAS , SPOP , PPP2R1A  and ERBB3  
previously been shown to be under positive selection in human can -
cer 28. To identify additional drivers in the 257 endometrial glands, we 
sought mutations with the characteristics of drivers in those 369 genes 
-































































































































































































































r = 0.88     P  = 1.91 × 10 –9 r = 0.40     P  = 3.68 × 10 –11
r = 0.77     P  = 2.34 × 10 –6 r = 0.89     P  = 6.06 × 10 –10 r = 0.52     P  = 6 × 10 –3
r = 0.55     P  = 2 × 10 –16
r = 0.65     P  = 2 × 10 –4 r = 0.47     P  = 1 × 10 –2 r = 0.68     P  = 7.84 × 10 –5 
Fig. 2 | Mutation burden correlates with age in normal endometrial glands.  
Mutation burdens shown as mean for each donor ( n
correlation ( r) with age and P P) from linear regression (burden–age).  
a–c , Variant burdens. a , Substitution burden. b, Indel burden. c , Copy-number 
variant (CNV) and structural variant (SV) burden. d–f , SBS burdens. d , SBS1 
burden. e, SBS5/40 burden. f , SBS18. g– i , Driver mutation burden per gland.  
g , Fraction of glands with drivers, per individual. h , Mean number of driver 
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carried driver mutations, which suggests that the whole endometrium 
3, Extended Data 
2g), 
2h) and the number of dif -
ferent drivers in each individual (corrected for the number of glands 
2i) all positively correlated with age of the individual. 
However, there were sufficient outliers to suggest that other factors 
influence the colonization of the endometrium by driver-carrying 
clones. Indeed, our generalized linear mixed-effect model showed 
interval 0.01–0.06, P −4
to −0.05, P −2
We found driver mutations in recessive (tumour-suppressor genes) 
and dominant cancer genes, similar to recent publications 13,30 ,32. PIK3CA  
3, Extended Data 
-
sive cancer genes were heterozygous, indicating that haploinsufficiency 
confers a growth advantage in normal cells. Nevertheless, further inac -
tivating mutations in the same genes in other glands show that an addi -
tional advantage is conferred by complete abolition of their activity 
(notably for ZFHX3 3). Driver muta -
tions were found in genes that encode growth factor receptors ( ERBB2 ,  
ERBB3  and FGFR2 ), components of signal transduction pathways 
(HRAS , KRAS , BRAF , PIK3CA , PIK3R1 , ARHGAP35 , RRAS2 , NF1, PPP2R1A  
and PTEN ), pathways that mediate responses to steroid hormones 
(ZFHX3 , FOXA2  and ARHGAP35 ), proteins involved in chromatin func -
tion ( KMT2D  and ARID5B ) and protein-mediated degradation path -
ways ( FBXW7 ) that target oncoproteins, such as mTOR and MYC. Many  
different combinations of mutated cancer genes were found in  
individual glands.
Timing of driver mutations
Constructing phylogenetic trees of individual endometrial glands 
enabled the characterization of the mode of expansion of normal 
cell clones with drivers and the timing of their initiation. Glands with 
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Fig. 3 | Histology images and reconstructed phylogenetic trees for two 
individuals in whom every normal endometrial gland contained at least 
one driver mutation.  a , b, Haematoxylin and eosin images of endometrial 
glands from a 34-year-old woman ( a) and a 60-year-old woman ( b) were taken 
after laser-capture microdissection (20× magnification). c , d , Phylogenetic 
trees were reconstructed for the 34-year-old woman ( c) and 60-year-old woman 
(d ) using SBSs; the length of each branch is proportional to the number of 
variants. A stacked bar plot of the attributed SBS mutational signatures that 
contributed to each branch is then superimposed onto every branch; signature 
The ordering of signatures within each branch is for visualization purposes 
only, as it is not possible to time the different signatures within individual 
same clade (indicated by the colour of the sample identifier label). Glands that 
did not belong to any clades are in white. SBS signatures are colour-coded; 
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3). In phylogenetic clusters 
for which the mutation catalogues were almost identical, this may 
simply reflect multiple sampling of a single tortuous gland that weaves 
in and out of the plane of section, rather than distinct glands with their 
3a, c ).  
For other phylogenetic clusters, the different branches within the clade 
cell populations. In such instances, phylogenetically related glands 
can range over distances of hundreds of micrometres, which suggests 
that their clonal evolution has entailed the capture and colonization of 
extensive zones of the endometrial lining (for example, glands C1, A2, 
3b, d ). Conversely, some glands in close physi -
cal proximity are phylogenetically distant (for example, glands E1 and 
3a, c ), indicating that their cell populations have remained 
isolated from each other.
Driver mutations were positioned on the phylogenetic trees for 
each individual, and times of occurrence were estimated by assuming 
5, Extended Data 
-
pletely correct, the results show that mutations in normal endometrial 
cells are acquired in a more-or-less linear fashion throughout life and 
only modest differences to mutation rates. Furthermore, overall our 
approach is likely to overestimate the ages before which driver muta -
tions have occurred, because it does not account for the time taken for 
a single endometrial stem cell to colonize an individual gland, which—in  
colorectal crypts—has been estimated to take several years 36. Therefore, 
our results indicate that at least some driver mutations occur early in 
life. These included a KRAS G12D
woman, and a PIK3CA
both of which are likely to have arisen during the first decade of life 
3, 4 ZFHX3  and 
PIK3CA
acquired during the first decade of life, indicating that driver-associated 
3, 5). It is possible that 
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Fig. 4  | Phylogenetic trees of endometrial glands for donors aged 1 9  to 
reconstructed using SBSs with branch length proportional to the number of 
variants; the stacked bar plots represent the attributed SBS mutational 
signatures that contributed to each branch. Signature extraction was not 
signatures within each branch is for visualization purposes only, as it is not 
possible to time different signatures within individual branches. SBS 
signatures are colour-coded; substitutions that were not attributed to the 
reference signatures, and those attributed to SBS23, are shown as 
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many more clones with drivers were initiated during the first decade 
of life, but their phylogenetic trees are not informative in this regard 
continued accumulation and clonal expansion of driver mutations into 
5
Comparison between normal tissue and cancer
Endometrial cancers (from the recent Pan Cancer Analysis of Whole 
Genomes (PCAWG) dataset 4) exhibited higher mutation loads than 
normal endometrial cells for base substitutions (about 5-fold higher, 
medians of 1,346 and 7,330 in normal endometrium and endometrial 
cancer, respectively (Mann–Whitney U-test, P −6)) and indels 
endometrial cells with driver mutations. In most endometrial can -
cers, the differences are attributable to higher mutation burdens of 
the ubiquitous base substitution and indel mutational signatures 3,4. 
In addition, however, the very high mutation loads of the subsets of 
endometrial cancer with deficiencies in DNA mismatch repair and 
proof-reading mutations in polymerase-ε or polymerase-δ were not 
seen in normal endometrial cells. Differences between endometrial 
cancers and normal cells were even more marked for structural variants 
and copy-number changes (median number zero in normal endometrial 
37), and this difference again 
pertained to normal endometrial cells with drivers.
There were also differences in the repertoire of cancer genes in 
-
PTEN , CTCF , CTNNB1  
and ARID1A  in endometrioid, and in TP53  in serous carcinoma of the 
endometrium accounted for higher proportions of driver mutations 
than in normal endometrial cells. It is possible that PTEN , ARID1A , TP53  
and CTCF  require biallelic mutation to confer a growth advantage and 
this may account for their lower prevalence in normal cells. However, 
heterozygous mutations in PTEN  and TP53  were found, albeit only in 
around 2% (5 out of 257) of all sampled glands, and this explanation 
would not account for the relative deficit of CTNNB1  mutations. Over -
all, the results suggest that driver mutations in some cancer genes are 
relatively effective at enabling the colonization of normal tissues, but 
confer a limited risk of conversion to invasive cancers. Conversely, 
other drivers may require biallelic mutation and/or confer limited 
advantage in colonizing normal tissues, but are relatively effective at 
the conversion to malignancy.
Discussion
Studies of normal endometrial epithelium and other types of normal 
cell 6,7,9,10,13–15,19,20  are revealing the landscape of somatic mutations in 
normal human cells. Somatic mutations are predominantly gener -
ated by a limited repertoire of ubiquitous mutational processes that 
generate base substitutions, small indels, genome rearrangements and 
whole chromosome copy-number changes, which exhibit more-or-less 
constant mutation rates during life. Additional mutational processes 
present only in some cells, some cell types and/or that are intermittent 
also contribute to the mutation burden—albeit apparently not in the 
endometrial epithelium.
The prevalence of clones with driver mutations is substantially dif -
ferent in different types of normal cell. Numerous cell clones with one 
or more driver mutations colonize much of the normal endometrial 
epithelium (as discussed in this Article, and in previous studies 13,32), in 
contrast to another glandular epithelium, the colon, in which about 1% 
of normal crypts in middle-aged individuals carry a driver 13,14. This is 
unlikely to be due to differences in the somatic mutation rate between 
endometrial and colonic epithelial cells, which are relatively modest; 
in any case, the somatic mutation rate is higher in the colon 6,14,38. How -
ever, it may be attributable to intrinsic differences in structure and 
physiology between the endometrium and colon. In the endometrium, 
the cyclical process of tissue breakdown, shedding and remodelling 
iteratively opens up denuded terrain for pioneering clones of endome -
trial epithelial cells with drivers to preferentially colonize, compared 
to wild-type cells. In the colon, however, the selective advantage of a 
clone with a driver is usually confined to the small, siloed population of 
a single crypt, with only occasional opportunities for further expansion. 
Although the colonization of endometrium by driver clones progresses 
with age, it is already well-advanced in some young women—and parity 
has an inhibitory effect on it. The effect of parity is of particular inter -
est as increased parity reduces the risk of endometrial cancer and it 
is conceivable that this is mediated by its effect on the expansion of 
driver clones 39. Further studies of normal endometrium are required 
to assess how premenarchical and postmenopausal states, hormone 
contraceptive use and hormone replacement therapies influence the 
mutational landscape and its potential effect on pregnancy and fertility.
The burdens of all mutation classes are lower in normal endome -
trial cells (including those with drivers) than in endometrial cancers. 
Therefore, in endometrial epithelial stem cells, and in all other tis -
sues studied thus far (including colon, oesophagus and skin), normal 
mutation rates are sufficient to generate large numbers of clones with 
driver mutations that behave as normal cells, but acquisition of an 
elevated mutation rate and burden is associated with further evolu -
tion to invasive cancer 9,10,14. Because the endometrial epithelium is 
extensively colonized by clones of normal cells with driver mutations 
in middle-aged women, and the lifetime risk of endometrial cancer is 
only 3% (ref. 23), this conversion from a normal cell clone with drivers 
to symptomatic malignancy appears to be extremely rare.
The first driver mutations in normal endometrial clones with drivers 
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Fig. 5 | Timing of driver mutations in normal endometrial glands.  To time 
the driver mutations, we reconstructed phylogenetic trees using SBSs. To 
estimate the time interval in which specific mutations occurred, we used two 
approaches (Methods). We calculated a patient-specific mutation rate by 
taking the ratio of the mean mutation burden per endometrial gland of the 
patient and age of the patient. The mutation number at the start and end of a 
branch in the phylogenetic tree was then converted to a lower and upper age by 
dividing these numbers by the estimated mutation rate. A similar approach was 
used for timing indels. We timed the driver mutations that occurred in the 
‘trunks’ and branches. We display only those driver variants that occurred in 
the ‘trunks’ of the individual trees. We show that many such events occur 
decades before the reported peak incidence of endometrial cancer (variants 
excluded from this plot for illustration purposes). On the basis of our 
calculations, four driver variants ( KRAS G12D, PIK3CA G118D, PIK3CA E542K  and 
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with of many doing so. The modal period of diagnosis of endometrial 
-
ers are progenitors of endometrial cancers (which is plausible given 
the similar driver mutations found), our results suggest that many 
cancers are initiated during childhood and evolution to malignancy 
takes place over the lifetime of an individual. This perspective on the 
long duration of neoplastic evolution of invasive endometrial cancer 
has resonance with previous observations on leukaemia 40 ,41 and, more 
recently, other solid malignancies 42–45, and may be a common feature 
of the development of human cancers.
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